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THE IMMUNE SYSTEM
Throughout natural history, organisms have developed different defense strategies 
to protect them from colonization by invasive microbes and viruses. These are 
generally referred to as immune responses and are part of the immune system of an 
organism. Even simple, unicellular life forms possess these protection mechanisms, 
usually involving antimicrobial peptides and enzyme systems to fight off potential 
pathogens. More complex, multicellular organisms, however, are more vulnerable 
to infections due to increased body mass and lifespan. Hence more sophisticated 
mechanisms developed, creating a layered defense system with increasing levels of 
specificity. 
 The best studied and most refined immune system can be found in Gnasthostomata, 
or jawed vertebrates, which includes humans. In these animals three layers of defense 
can be discerned. The first layer entails the epithelial and mucosal barriers, which 
prevent access of infections agents to the host’s body. Pathogens that have breached 
this barrier encounter the secondary line of defense, the innate immune response. 
The cells and molecules of the innate system are able to clear the infection, or hold it 
in check until the third line of defense, the adaptive immune response, is activated. 
Adaptive immunity is the most specific defense, tailoring effector mechanisms to 
most efficiently clear the present pathogens. Importantly, the adaptive system 
generates immunological memory, preventing reinfection of the same, or similar, 
pathogens.
 Microbes can, however, also engage mutualistic interactions with their host, for 
example in the gut where they aid digestion and prevent colonization of pathogenic 
bacteria. This requires the host to be tolerant for the presence of these microbes, 
and avert their eradication by the immune system. Furthermore, responses directed 
to harmless compounds, or healthy host cells and tissues should also be prevented, 
in order to avoid development of allergies or auto-immune diseases, respectively. 
In contrast, host cells that have been infected by viruses or transformed into tumor 
cells should be detected and cleared by the immune system. Tight control of both the 
innate and the adaptive arm of the immune system is therefore essential for survival 
of the host.
Innate immunity
Discriminating dangerous pathogens and transformed host cells from harmless 
microbes and healthy tissue is the first task of the innate immune system. This 
requires recognition and uptake of microbes and apoptotic cells, which is facilitated 
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by phagocytes such as neutrophils, macrophages and dendritic cells (DCs).1 Pathogen 
recognition is essentially achieved through detection of non-self molecules, termed 
Pathogen Associated Molecular Patterns (PAMPs).2 These structures are conserved 
among microbial species, and are essential for their survival and pathogenicity. 
Immune escape through mutation or deletion of these molecules will therefore 
impair the microbes’ ability to infect and colonize the host. 
 Detection of PAMPs by cells of the innate immune system is facilitated by 
specialized, germ-line encoded receptors termed Pattern Recognition Receptors 
(PRRs). Currently, four classes of PRRs are recognized. The transmembrane Toll-Like 
Receptors (TLRs) and C-type lectin receptors (CLRs) are specialized in detection of 
exogenous- or phagocytosed pathogens, whereas the cytoplasmic Retinoic acid-
inducible gene (RIG)-I-like receptors (RLRs, also known as RIG-I helicases (RLHs)) and 
the NOD-like receptors (NLRs) recognize intracellular microbes and viruses.2,3 Besides 
PRRs, also Scavenger Receptors, Integrins and Fc Receptors have been shown to be 
involved in pathogen detection (for more detail on PRRs and PAMPs see: Chapter 2).
 PRR expression differs among different cell types. Receptors detecting 
extracellular microbes or infected host cells are most commonly found on specialized 
immune cells, whereas PRRs recognizing intracellular pathogens are more broadly 
expressed. Viruses and other intracellular pathogens can potentially infect all host 
cells, causing activation of the intracellular NLRs4 and RLRs5. Intracellular signaling 
induced by these PRRs results in production of Interferons (IFNs) that attract and 
activate innate immune cells, and induce resistance to viral replication.6
 Pathogen recognition by the innate immune system is generally considered to be 
unspecific, discriminating only between broad classes of microbes. However, recent 
insights suggest that PRR cross-talk enables the innate system to discern between 
different microbial species, and tailor the response accordingly (described in: Chapter 
2). For example, the response to the pathogenic yeast Candida	albicans was shown 
to be much stronger than to the nonpathogenic yeast Saccharomyces	cerevisiae, due 
to different PRR combinations involved in recognition of both species.7 In addition, 
next to pathogen recognition, PRRs have also been suggested to bind host-derived 
molecules released from damaged cells, termed Damage Associated Molecular 
Patterns (DAMPs).3 This importantly triggers tissue reparative responses, however, in 
some cases can also evoke immune activation against host cells and tissues, causing 
auto-immunity.6
 Essentially two important innate effector mechanisms can be induced upon 
pathogen detection: (i) the cellular response and (ii) activation of the complement 
system. Innate cellular responses are elicited by neutrophils, macrophages and DCs, 
General	introduction
11
which induce production of reactive oxygen species (ROS) upon microbe phagocytosis, 
and degrade the ingested microbe.8 In addition, pathogen recognition by these cells 
activates intracellular signaling pathways, resulting in the secretion of cytokines 
and chemokines. These molecules cause infiltration of more innate immune cells to 
the infected area, thereby reinforcing and sustaining the innate immune response.9 
Furthermore, release of cytokines and chemokines activates natural killer (NK) cells, 
which play an important role in the eradication of virus infected cells and tumor 
cells.10
 Pathogen infection may also trigger activation of the complement system, a 
group of plasma proteins that can bind the cell surface of microbes, but not of host 
cells. Upon activation, the complement system coats the pathogen with complement 
proteins, aiding phagocytosis. However, complement binding can also directly 
destroy microbes through a cascade of proteolytic reactions that cause lesions in the 
pathogen’s membrane.11
 Finally, activation of the innate system can trigger, direct and regulate adaptive 
responses. This is essential, since most infections cannot be cleared solely by the 
innate system. In addition, the adaptive system further specifies the response and 
creates immunological memory.
Adaptive	immunity
For proper and specific responses the adaptive system needs to be informed on the 
pathogenic target. This happens through presentation of pathogen derived antigens, 
and is facilitated by so called Antigen Presenting Cells (APCs). These cells encompass 
the innate macrophages and DCs, as well as the adaptive B lymphocytes (B-cells).12 
 Antigen presentation occurs via two important molecules termed Major 
Histocompatebility Complex (MHC) I and II. Classically, MHC-I molecules present 
endogenous proteins, whereas MHC class II display exogenous proteins. Virtually 
all nucleated cells are capable of presenting endogenous self- and viral peptides 
via MHC class I presentation, however only APCs can also present exogenous 
peptides using MHC class II molecules.12-14 Besides MHC, also the major 
histocompatibility complex class I related chain (MIC) A and B have been identified 
as antigen presenting molecules. They are expressed by epithelial cells, fibroblasts, 
monocytes, dendritic cells and endothelial cells, in response to stress. MIC do not 
present peptides to T cells via interaction with the T-cell receptor (TCR), but instead 
bind the NKG2D receptor on NK cells and some T cells.15-17
 Presentation of antigens by APCs activates the two effector arms of the adaptive 
immune system: (i) the cellular response and (ii) the humoral response. Importantly, 
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activation occurs only when antigen presentation is accompanied by high expression 
levels of co-stimulatory molecules (figure 1). Co-stimulation is facilitated by the cell 
surface receptors CD40, B7.1 (CD80) and B7.2 (CD86), and the secretion of pro-
inflammatory cytokines.18 Expression of these molecules only occurs when captured 
antigens are accompanied by PAMPs that activate PRRs, thus preventing responses 
to presented self antigens. Indeed, immunodominant antigens generally also have 
PAMP activity, ensuring that the antigen is of microbial origin.6
Figure 1. Stimulation of T-cells by DCs.	Dendritic	cells	present	antigens	to	T-cells	 in	the	presence	of	co-
stimulatory	molecules	such	as	B7-1	and	-2,	CD-40	and	secretion	of	cytokines.	High	levels	of	co-stimulatory	
signals	 results	 in	 T-cell	 activation	 and	 proliferation,	 whereas	 low	 or	 inhibitory	 co-stimulatory	 signals	
induces	T-cell	tolerance	or	anergy.
The cellular response of the adaptive immune system involves activation and 
proliferation of two types of T lymphocytes (T-cells), the CD8+ cytotoxic T-cells (CTLs) 
and the CD4+ T-helper cells (Th). T-cells express a receptor (T-cell receptor, or TCR) 
that specifically binds the MHC molecule in combination with its presented antigen. 
Each T-cell expresses a unique TCR that originates from rearrangement of antigen 
receptor genes during T-cell development. Activated CTLs directly recognize and 
kill infected and/or transformed host cells upon activation.19 Th-cells on the other 
hand, are important in providing ‘help’ to other cells of the immune system via direct 
interaction and cytokine production.20
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One important cell type that receives help from Th-cells are the B-cells. These cell 
represent the humoral arm of the adaptive immune system, which is very effective 
in eradication of extracellular pathogens. B-cell activation and the generation of 
antibody-producing cells requires sequential phases. Initially, B-cells are activated 
upon capturing antigens with their specialized B-cell receptor (BCR). As with the TCR, 
also the BCR differs among B-cells, with each B-cell expressing a unique BCR. B-cells 
process and present the endocytosed antigens on MHC-II molecules, and migrate to 
the T-cell zones. Here, B-cells interact with activated Th-cells, which triggers B-cell 
proliferation and differentiation. Finally, interaction with antigen presenting follicular 
DCs (FDCs) in the germinal centers of the lymph nodes prevents apoptosis of the 
activated B-cells. The surviving B-cells differentiate into plasma cells, producing 
high amounts of antibodies that bind specific microbial antigens. Antibody binding 
prevents infections by intracellular microbes, and aids their elimination through 
facilitating phagocytosis and complement activation.21
 Both T- and B-cell activation generates long-lived memory cells, which are much 
more efficient in generating immune responses upon reinfection of the same or 
similar pathogens, compared to naïve T- and B-cells.21,22
DENDRITIC CELLS
Dendritic cells are the most efficient APCs of the immune system, and importantly 
function as a bridge between innate and adaptive immunity. The first observation 
of DCs dates back to 1868, when the medical student Paul Langerhans discovered a 
new cell population in the human skin. These cells were termed ‘Langerhans Cells’ 
(LC). However, due to their dendritic nature and typical ‘neuronal’ gold chloride 
stain, he mistakenly characterized them as nerve cells.23 It was not until 1973 that 
Steinman and Cohn first used the term ‘dendritic cell’, and identified DCs as part of 
our immune system.24 DC characterization has been ongoing ever since, increasing 
our understanding on the origin and function of these cells. In time, DCs have been 
increasingly appreciated for their central role in the immune system, initiating and 
modulating immune responses. 
 
Origin	of	Dendritic	Cells
DCs form, together with monocytes and macrophages, a distinct leukocytic subgroup 
termed the mononuclear phagocyte system. Most subsets that are currently known 
originate from bone-marrow precursor cells, and differentiate depending on the 
selection of specific gene expression programs, as well as factors encountered in the 
cells’ microenvironment.25,26
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In the bone marrow, hematopoietic stem cells give rise to myeloid- (MPs) and lymphoid 
precursors (LPs). The MP lineage successively differentiates into macrophage/DC 
precursors which in turn split into monocytes and common DC precursors (CDPs), 
as well as some macrophage populations. The monocytic lineage encompasses two 
subsets, LY-6C+ and LY-6C- cells, which enter the blood stream and populate multiple 
DC and macrophage subsets upon migration into peripheral tissues.26 In	vitro these 
monocytes are commonly used to generate monocyte-derived DCs, since they are 
easily obtained and come in relative high numbers. Differentiation towards DCs 
occurs in the presence of IL-4 and GM-CSF and is complete after 6 days.27
The CDP lineage on the other hand further differentiates into DC precursors (preDCs) 
or plasmacytoid DCs (PDCs) before leaving the bone marrow and entering the blood 
stream. Two subsets of blood circulating preDCs, also referred to as myeloid DCs, 
are currently recognized. Both populations show features of preDCs and immature 
DCs, lacking the characteristic ‘dendrite phenotype’, and effectively mature in	vitro 
upon activation with TLR ligands or cytokine cocktails. Maturation of these DCs is 
accompanied by secreting cytokines and inducing T-cell proliferation.26
 These blood circulating preDCs are therefore considered to be in transit, maturing 
into functional DCs only after entering the tissue. The CD1c+ (BDCA-1+) population 
appears to be the most abundant of the blood DCs, whereas CD141+ (BDCA-3+) 
DCs are known to be very rare. Functional studies have shown specific chemokine 
production by CD1c+ cells, and identified CD141+ cells as major producers of IFN-β. 
CD141+ DCs were also shown to be capable of cross-presenting antigen for CD8+ class 
1 restricted CTL responses after TLR-3/CD283 ligation.25,26
 Plasmacytoid (BDCA-2+/BDCA-4+) DCs and are the third blood DC population, and 
are also present in the bone-marrow and all peripheral tissues. Like the classical DCs, 
they are capable of antigen presentation and control of T-cell responses. What makes 
them unique is their relative long live span, and their specialization in the response 
to viral infections through massive productions of Type I Interferons (IFNs).26,28
Maturation	of	DCs
The DC life-cycle starts with bone marrow progenitors that give rise to DC precursors 
circulating in the blood. These precursors patrol the blood and lympatic system 
for invading pathogens. Differentiation into DCs is completed upon migration into 
peripheral tissues, where they reside in an immature state sampling the environment 
in search for microbes. Pathogen recognition and inflammation triggers the DCs to 
mature, up-regulating the expression of co-stimulatory molecules and inducing 
cytokine secretion. These mature DCs leave the peripheral tissues for migration to 
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lymph nodes where they present the captured antigens to T- and B cells.29
 Upon pathogen detection by PRRs, different intracellular signaling pathways are 
activated, leading to the transcriptional activation of a plethora of genes involved in 
DC maturation. These responses are generally mediated by the transcription factors 
nuclear factor-κB (NF-κB), activator protein 1 (AP-1), nuclear factor of activated 
T-cells (NFAT) and interferon regulatory factor (IRF). In inactive state, these factors 
can be found sequestered in the cytoplasm. Binding of PAMPs by PRRs induces a 
cascade of enzymatic reactions leading to the activation and nuclear translocation of 
these transcription factors, enabling transcription activation (figure 2).30,31
Figure 2. Pathogen recognition and response by DCs.	Dendritic	cells	can	detect	many	different	pathogens	
through	 their	 cytoplasmic	 and	 membrane	 bound	 PRRs	 that	 recognize	 specific	 microbial	 conserved	
signatures.	 Upon	 binding,	 PRRs	 initiate	 intracellular	 signaling	 cascades	 that	 ultimately	 results	 in	 the	
activation	of	multiple	transcription	factors	(TFs)	 in	the	nucleus.	Here,	these	TFs	regulate	the	expression	
of	co-stimulatory	molecule-	and	cytokine	genes	that	are	 involved	 in	T-cell	activation.	Depending	on	the	
pathogen	and	the	PRR,	different	TFs	can	be	activated,	resulting	in	a	differential	cytokine	expression	and	
T-cell	differentiation.
These intracellular signaling events have been shown to differ depending on the 
PAMP and activated PRR, causing differential transcription factor activation. This 
results in expression of different target genes, thereby affecting the DC activation 
and maturation process. Regulation of cytokines IL-12 and IL-23 for instance, requires 
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both common and distinct pathways. Activation of NF-κB and IRF5 is sufficient for 
the expression of IL-23, whereas IL-12 production additionally requires IRF1, -3 and 
-7 activation. IFN signaling, usually triggered by viral infections, stimulates IRF1, -3 
and -7 activation, and therefore favors IL-12 production, which is important in anti-
viral immunity. Conversely, detection of fungal pathogens via CLRs supports IL-23 
secretion, thereby stimulating anti-fungal responses.32,33
 Besides cytokine secretion, other molecules important in DC maturation are 
induced via this process. These include co-stimulatory receptors such as B7.1 (CD80), 
B7.2 (CD86) and CD40, as well as migratory molecules such as CCR7, that direct DC 
migration towards the lymph nodes. In contrast, the expression of adhesive receptors 
that retain the DCs in the peripheral tissues is abrogated via this process.25
Regulation	of	immunity	and	tolerance
Although macrophages and B-cells are also included in the term ‘Professional 
Antigen Presentating Cells’, or Professional APCs, DCs are by far the most efficient 
in presenting antigens to T- and B-lymphocytes. Not only are they at the start of 
immune responses against pathogens and tumors, they also protect the host against 
auto-immune diseases. This dual role is essentially achieved by the way DCs present 
antigens to T-cells, activating them to start an immune response, or to initiate tolerance. 
In essence, the activation state of the DC determines how T-cells are stimulated, and 
whether or not an immune response will be initiated.29 
 To date, four different subsets of Th-cells, generated through alternative co-
stimulation, have been described, each with different specialized functions. Th1-cells 
function in responses targeting endogenous pathogens and tumor cells, whereas 
Th2- and Th17-cells stimulate immunity against extracellular microbes and viruses. 
Th2-responses are known to enhance the humoral immunity, and are involved in 
allergy development. Th17 proliferation is specifically induced during anti-fungal 
responses, and is negatively implicated in auto-immunity. The fourth subset are 
the Regulatory T-cells (Tregs), which regulate immune responses and prevent auto-
immunity by maintaining peripheral tolerance.34
 In DCs, presentation of extracellular derived antigens on MHC-II molecules to 
T-cells induces proliferation of CD4+ Th-cells. Depending on the activated PRR and 
the type of pathogen, DCs secrete IL-12 for Th1-, IL-4 for Th2- or IL-23, IL-21 and 
IL-6 for Th17-responses (figure 2). Importantly, Th-cells activation also requires the 
expression of the co-stimulatory B7.1 and B7.2 molecules. DCs that express low to 
intermediate levels of B7.1 and B7.2, accompanied by IL-10 secretion, induce T-cell 
tolerance and stimulate the expansion of Regulatory T cell (Treg) (figure 1 and 2).34,35 
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Elimination of intracellular pathogens depends on activation of CD8+ CTLs through 
MHC-I presentation of endogenous antigens. DCs are often not infected by 
intracellular pathogens, hence presentation of viral- or tumor derived antigens on 
MHC-I occurs via an alternative pathway, termed cross-presentation. This process 
is unique for DCs, and entails the phagocytic uptake of infected host cells, or tumor 
cells, followed by degradation and alternative routing of antigens to the cytoplasm, 
enabling presentation on MHC-I.36 In addition, DCs also present the thus obtained 
antigens on MHC-II, accompanied by IL-12 secretion, activating anti-viral Th1-cell 
proliferation. 
 Hence, immune regulation greatly depends on DC maturation, which is directed by 
different factors present in the environment of the DCs. Naturally, the type of pathogens 
present is important to DC maturation, however, other factors such as inflammatory 
and immunosuppressive factors produced by other lymphocytes or tissues as well as 
hormones and vitamins also play a major role. 
NUCLEAR RECEPTORS
Cellular responses to hormones and vitamins are mediated by a specialized family 
of receptors termed Nuclear Receptors (NRs). The NR superfamily is a class of 
transcription factors that are crucial for many biological processes, including 
development, homeostasis and immune responses. In Men, 48 members have been 
identified and characterized. NRs are structurally conserved and consist of a variable 
N-terminal activation domain (activation function 1 or AF-1), a DNA-binding Domain 
(DBD) and a C-terminal Ligand Binding Domain (LBD). NRs are commonly divided into 
3 subgroups, depending on their DNA- and ligand-binding characteristics.37-39
Nuclear	Receptor	signaling
The glucocorticoid- (GR), estrogen- (ER), progesterone- (PR), androgen- (AR) and 
the mineralcorticoid receptor (MR) are collectively referred to as steroid receptors, 
hormone receptors or Type I NRs, and are some of the first and most extensively 
studied NRs. Classically, these receptors reside in the cytoplasm complexed with 
chaperone proteins, and are activated upon hormone ligation (figure 3a). Ligand 
binding releases the NRs from the chaperone complex, allowing the receptors to 
homodimerize and translocate to the nucleus where they control expression of 
specific target genes. In addition, type I NRs have also been reported to function in 
the absence of ligand, and outside the nucleus.40
 The Type II NRs, also indicated as vitamin receptors or retinoic x receptor (RXR) 
heterodimers, include the retinoic acid receptor (RAR), thyroid receptor (TR), vitamin 
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D3 receptor (VDR) and peroxisome proliferator-activated receptor (PPAR). In contrast 
to Type I NRs, Type II receptors are commonly present in the nucleus, bound to specific 
response elements in the promoters of their target genes. In the absence of ligand 
these RXR heterodimers bind corepressor complexes, preventing transcription. Upon 
ligand binding the corepressor complex is dissociated, and coactivator proteins are 
recruited, thereby allowing for gene transcription (figure 3a).37-39,41
 The third group comprises NRs without identified cognate ligands, the orphan 
NRs. Well known examples are the estrogen receptor related receptor α (ERRα) 
and the retinoid acid-related receptor (ROR). Orphan receptors function in a ligand 
independent manner, however for some orphans, e.g. ERR ligand 142 and ERR,43 
natural ligands have been identified in subsequent studies.37-39
Figure 3. Nuclear Receptor signaling. (A)	Type	I	NRs	typically	reside	in	the	cytoplasm	bound	to	chaperone	
proteins.	Ligand	binding	triggers	chaperone	release,	homodimerization	and	translocation	to	the	nucleus	
where	the	NR	activate	specific	target	genes.	Type	II	NRs	on	the	other	hand,	are	confined	to	the	nucleus,	
complexed	with	NR	co-repressors	in	the	absence	of	ligand.	Upon	ligand	binding	the	co-repressor	complex	
is	replaced	by	a	co-activator	complex,	initiating	transcription.	(B)	Three	mechanisms	by	which	the	Type	I	
NR	GR	exerts	its	anti-inflammatory	effects.	(i)	GR	directly	induces	expression	of	anti-inflammatory	genes;	
(ii)	 GR	 directly	 inhibits	 expression	 of	 pro-inflammatory	 genes,	 and	 (iii)	 GR	 inhibits	 the	 activity	 of	 pro-
inflammatory	transcription	factors.
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Co-factors	regulate	Nuclear	Receptor	activity
NRs play a role in diverse biological processes, turning different sets of genes on and 
off depending on the situation. However, whether gene transcription is induced or 
inhibited ultimately depends on the coregulator proteins recruited. NR coregulators 
are transcription regulators that do not bind DNA directly, but rather interact with 
NRs to mediate their transcriptional potency.44 Since the cloning of the first NR 
coregulators, the field has expanded dramatically and currently encompasses more 
than 330 identified proteins (www.nursa.org). 
 Originally, co-regulators are categorized by their operational action: co-activators 
necessary for transcriptional activation, and co-repressors facilitating transcription 
repression. Later studies, however, have demonstrated repression by coactivators,45 
and vice versa,46 suggesting that coregulator action depends on the gene, cell, and 
signaling context.44 In general, DNA-bound NRs recruit coregulators depending on 
the presence of NR ligands. The most extensively studied NR corepressors are NCoR 
(Nuclear receptor CoRepressor) and SMRT (Silencing Mediator of Retinoic acid 
and Thyroid hormone receptors).47,48 Recruitment to NR binding sites occurs in the 
absence of ligand, or in the presence of antagonists such as Tamoxifen (ER antagonist) 
or RU-486 (GR antagonist). In this corepressor complex, histon deacetylases (HDACs) 
prevent transcription by catalyzing chromatin condensation.41 
 The first authentic NR coactivator to be identified was SRC-1/ NCOA1,49 which 
forms the SRC coactivator family together with SRC-2/TIF2/GRIP1/NCOA2 and 
SRC-3/AIB1/ACTR/pCIP/RAC3/NCOA3. Agonist binding by NRs leads to attraction 
of coactivators and the assembly of a coactivator complex. HDACs are exchanged 
for histon acetyltransferases (HATs), which facilitate local acetylation, creating a 
transcriptionally permissive environment at the promoter.41 
Nuclear	Receptors	and	Dendritic	Cells
Nuclear Receptors are increasingly recognized as immune-regulatory receptors, 
having positive and negative regulatory activities in immune cells. Anti-inflammatory 
functions of GR, VDR, and LXR, have been documented, whereas ER, PPARγ and RARα 
were shown to have both stimulatory and inhibitory effects on immune cells.50-53 NR 
signaling plays a major role in DCs, which express 20 out of 48 known NRs, affecting 
both differentiation and maturation. In fact, DCs have been demonstrated to actively 
convert hormone precursors into active NR ligands.54
 During DC differentiation from human monocytes, expression of both PPARγ 
and LXRα has been shown to be upregulated.55 Stimulation with the PPARγ ligand 
rosiglitazone during DC differentiation results in DCs with enhanced phagocytic 
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activity, and reduced IL-12 secretion upon maturation with LPS, promoting Th2 over 
Th1-responses. In addition, these cells have enhanced lipid antigen presentation 
capacities, important for activation of invariant natural killer T-cells.56 Activation 
of LXR, a type II NR that binds oxidized forms of cholesterol,57 has been shown to 
reduce the capacity of DCs to activate T-cells.58 Furthermore, exposure to estrogens 
or derivatives of vitamin A (retinoids), stimulates the differentiation and activation of 
monocytes to DCs via IRF459 or activation of RAR and RXR receptors,60 respectively.
  DC maturation can also be modulated by NR stimulation. The majority of the 
currently known consequences of NR activation encompasses impaired DC maturation 
and T-cell stimulation. In some cases, however, stimulation of DCs with NR ligands has 
been shown to enhance DC mediated immune activation. The best known example 
are retinoids, which enhance T-cell stimulation by LCs, promote DC maturation by 
enhancing DNA binding of NF-κB, and stimulate IL6 and TGFβ expression in moDCs, 
inducing a mucosal DC phenotype. In contrast, RA can also induce apoptosis in 
developing DCs, via RARα-RXR activation.61 Studies where DCs were exposed to 
estrogens produced mixed results, demonstrating both immunostimulatory and 
-suppressive effects.50,62,63
 More extensively studied are the suppressive effects of NR signaling on DC 
function. Exposure to GR, VDR or LXR ligands potently suppress the capacity of DCs to 
induce inflammation, and instead trigger tolerance.58,64,65Corticosteroids, the ligands 
for GR, are particularly appreciated for their tolerizing effects, and are widely used 
as immunosuppressive drugs. Three important mechanisms by which GR exerts its 
repressive effects are currently recognized (figure 3b).66-70 First, ligand-bound GR 
homodimers directly induce transcription of immune suppressive genes by binding 
to their promoters. In DCs, GR activation induces the expression of the glucocorticoid 
induced leucine zipper (GILZ), which potently suppresses multiple intracellular 
signaling pathways that aid immune activation.71 Other important GR targets with 
immune suppressive functions include IL-10, lipocortin-1, and DUSP1 (MKP1).66,72 
Second, GR homodimers can potentially inhibit expression of immune stimulatory 
genes via negative GREs (nGREs). The nGRE consensus sequence has recently been 
identified by Surjit et al. (2011), however, the exact role in mediating GR dependent 
immune suppressive effects remains unclear.73 In the third mode of action GR acts 
in monomeric fashion, binding to DNA-bound transcription factors that induce the 
expression of immune stimulatory genes, and repressing their transcriptional activity. 
Well known examples include the NF-κB and AP-1 complexes, as well as IRF3 and 
CREB transcription factors. Together, these responses efficiently inhibit expression 
of pro-inflammatory genes, creating tolerogenic DCs (tolDCs). These tolDCs have 
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impaired MHC class I and II presentation, suppressed costimulatory properties and 
therefore repress T-cell responses and induce Treg proliferation.74-78
 Importantly, DCs can also convert hormone precursors into their active form, a 
process which otherwise occurs in the liver and the kidneys. Secretion of active NR 
ligands by DCs is important for local immune regulation, without affecting immune 
responses in the rest of the body. In the gut, DCs convert vitamin A into RA, which 
is important in the prevention of responses against beneficial microbes. RA, in 
combination with other compounds, blocks IL-6 and TGF-β secretion by Th17-cells 
and stimulates Treg differentiation, inducing gut tolerance. In addition, DC produced 
RA instructs T-cells to migrate to the gut via the upregulation of gut-homing receptors. 
Similarly, DCs in the skin release the active form of vitamin D, instructing local T-cells 
to induce CCR10 expression and migrate to the epidermis.54
NRs	in	tumor	biology
Apart from regulating immune responses, NRs have also been implicated in 
carcinogenesis. Several Type I and Type II NRs have crucial roles in tumor biology, 
and are important targets for drug-based therapies. In particular breast- and prostate 
carcinomas are known for their hormone sensitivity, however, other tumors have 
also been found to be subjected to NR signaling. In fact, NRs are very likely to be 
involved in all known carcinomas, considering their important role in cell cycle and 
differentiation.51,79
 In breast carcinoma cells, the Type I NRs ER and PR are known to stimulate 
cell proliferation and tumor growth, whereas the Type II NRs RAR-RXR and PPAR-
RXR induce differentiation and inhibit proliferation through cell-cycle arrest and 
apoptosis. Breast cancer patients are therefore checked for NRs expression status, 
and treated accordingly. Although RA based therapies have limited efficacy due to 
induced RA resistance in tumor cells, treatment with ER blocking agents has proved 
to be highly effective.80,81
 Prostate cancer is also known as a high incidence, hormone responsive cancer, 
and is dependent on activation of the Type I NR AR. Treatment generally aims to 
suppress AR activity via androgen deprivation and administration of AR antagonists.82 
In addition, the Type II NR VDR is implicated in growth inhibition of prostate tumors, 
exerting anti-proliferative effects and inducing differentiation in prostate cancer 
cells.83 
 Besides breast- and prostate carcinoma, many more hormone responsive tumors 
have been described, including different kinds of leukemia, ovarian cancer, pancreatic 
cancer and colon cancer.84-87 Importantly, alongside NRs, also their co-regulators have 
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been implicated in cancer development, and their expression levels are often used to 
predict treatment efficacy and survival.88 
DC-SCRIPT: DC ASSOCIATED MOLECULE AND NR COREGULATOR
A link between regulation of NR function, DC and tumor biology can be found in the 
transcription regulator DC-SCRIPT (DC-Specific transCRIPT), also known as ZNF366. 
Within the immune system, DC-SCRIPT has been described to be specifically expressed 
by DCs. Expression of DC-SCRIPT mRNA was detected in cultured moDCs as well as 
freshly isolated MDCs, PDCs and LCs. Other cells of the immune system, including 
T-cells, B-cells and macrophages, were tested negative for DC-SCRIPT mRNA.89 
Outside the immune system, DC-SCRIPT expression was demonstrated in healthy 
and malignant epithelial cells from the breast and prostate, albeit expression was 
severely reduced in carcinoma cells. Within these cells, DC-SCRIPT was demonstrated 
to interact with NRs, and affect their transcriptional activity. Together these findings 
suggest an important role for DC-SCRIPT in DC and tumor biology, via the regulation 
of NRs.90,91
Structure	and	function
The DC-SCRIPT gene is positioned on chromosome 5q13.2,92 and encodes an 8 
kb long mRNA. Five exons are recognized within the mRNA sequence, encoding a 
single Open Reading Frame (ORF) of 2232 nucleotides in length. Protein translation 
starts from the ATG codon at position 448 in exon 2, and continues untill the TGA 
translational stop codon in exon 5. The resulting protein contains 744 amino acids 
(aa) encoding a proline-rich domain (aa 111-219), 11 C2H2 zinc finger motifs (aa 255-
556) and an acidic region (aa 586-690). In addition, a N-terminal Nuclear Localization 
Signal (NLS), as well as acidic-region located CtBP- and NR interaction motifs have 
been recognized within the DC-SCRIPT protein. Post-translational modifications 
(PTMs) have been suggested for DC-SCRIPT, based on the presence of possible 
phosphorylation-, SUMOylation and N -glycosylation sites.89 
 DC-SCRIPT expression was demonstrated in human and mouse, and predicted 
in many other species including rat, chimpanzee, chicken and pufferfish. Sequence 
homologies demonstrate that DC-SCRIPT is a well conserved gene, with the protein 
sequence being >80% identical between men and mice. In particular the zinc-finger 
domain shows high levels of resemblance between human- and mouse-, and human- 
and pufferfish proteins, showing respectively 93% and 98,5% homology.89,93
 The presumed transcription factor function of DC-SCRIPT is deduced from the 
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presence of its 11 zinc-fingers. These structures are known to mediate protein-DNA, 
protein-RNA or protein-protein interactions, and are found in many transcription 
factors. The classical Cys-Cys:His-His zinc fingers that are present in DC-SCRIPT, 
mostly aid protein-DNA interactions, suggesting a direct role in regulating target 
gene expression. The conserved character of the zinc finger region suggests that 
DC-SCRIPT binds similar DNA sequences in different species, thereby regulating the 
same genes.89,93
 Furthermore, a direct interaction between the transcriptional corepressor 
CtBP1 (C-terminal Binding Protein 1) has been demonstrated, concomitant with 
the presence of CtBP-binding sites within the acidic domain of DC-SCRIPT. CtBP1 
acts as corepressor through the recruitment of HDACs to the site of transcription, 
thereby catalyzing chromatin condensation. Hence DC-SCRIPT can have a repressive 
effect on gene transcription, through interaction with CtBP1.89,93 Finally, DC-SCRIPT 
suggestively functions as NR coregulator, as it contains the NR interaction LXXLL 
motif, which is regularly found in NR co-activators.94
Figure 4. DC-SCRIPT gene and protein. The DC-SCRIPT	gene	contains	5	exons	which	encode	for;	the	5’-UTR	
(1);	 the	proline	domain	and	zinc-fingers	1-7	 (2);	 zinc-fingers	8-11	 (3	and	4);	 the	acidic	domain	 (5).	The	
DC-SCRIPT	protein	contains	744	amino	acids,	and	contains	two	CtBP1-,	and	a	LxxLL	NR	interaction	motifs.
Function	in	DCs	and	coregulator	of	NRs
Expression of DC-SCRIPT has been demonstrated in all DC subsets tested to date, in 
contrast to other DC associated molecules. In moDCs, DC-SCRIPT mRNA was readily 
detected during differentiation of monocytes to DCs with IL-4 and GM-CSF, and found 
to be consistently expressed throughout moDC life. Stimulation of monocytes with 
GM-CSF alone on the other hand, did not result in DC-SCRIPT mRNA expression.89
 Interestingly, DC-SCRIPT expression is potentially regulated by different 
transcription factors that have a profound role in hematopoiesis and DC biology. 
These factors include growth factor independence (Gfi), GATA-1, AP-1, Spi-B, NF-κB 
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and c-Rel, and their binding sites can be found clustered in the 300 bp preceding the 
first exon of DC-SCRIPT.93 
 DC-SCRIPT protein expression in DCs was found to be confined to the nucleus, in 
agreement with its presumed role as transcription factor. Furthermore, DC-SCRIPT 
was suggested to functionally interact with CtBP1 in DCs, as both proteins were 
found to colocalize within the nucleus of moDCs. Hence repression of DC-SCRIPT 
target genes in DCs is possibly mediated through interaction with CtBP1.89
 Recently, DC-SCRIPT expression was demonstrated in breast- and prostate 
epithelial cells, where it importantly functions as NR co-regulator. Interaction with 
multiple NRs, including Type 1 ERα, PR, AR and GR and Type II RARα, VDR and 
PPARγ has been demonstrated, resulting in either repression or stimulation of the 
NR transcriptional activity. Hereby, DC-SCRIPT balances NR activity, preventing 
carcinogenesis.90,91
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SCOPE OF THIS THESIS
In this thesis we have further elucidated the role of DC-SCRIPT in both human dendritic 
cells and breast carcinoma cells. DCs are at the centre of the immune system and play 
an essential role in the initiation and regulation of immune responses. Advanced 
molecular understanding of the processes in these cells can provide important 
insights into their nature and functionality, knowledge that can potentially be used in 
the development of effective immunotherapy with DC-vaccinations. 
DCs can discriminate between many different types of pathogens via their PRRs. 
Crosstalk between these PRRs is essential for tailoring responses to provide the most 
effective immune response. This process is explained in more detail in chapter 2, 
which describes the crosstalk between PRRs that are involved in the detection, and 
response to fungal pathogens. 
In chapter 3 we studied the role of DC-SCRIPT in the regulation of TLR induced 
cytokine production during dendritic cell maturation. DC-SCRIPT expression was 
investigated in different DC subsets, and knock-down of DC-SCRIPT expression 
resulted in an increased IL-10-, and a consequent decreased IL-12 secretion upon 
TLR-4 or -7/8 mediated maturation. 
Chapter 4 further elucidates the function of DC-SCRIPT in DCs by focusing on 
another important factor in DC maturation, the glucocorticoid receptor. Activation 
of GR prior to DC maturation leads to the generation of tolerogenic DCs, which is 
importantly mediated by the GR target gene GILZ. In this chapter, we show that DC-
SCRIPT functions as co-repressor on GR mediated transcription. Moreover, we found 
that DC-SCRIPT silencing resulted in enhanced GILZ expression, strengthening the 
suggesting for an important role for DC-SCRIPT in DC maturation.
A function for DC-SCRIPT as nuclear receptor co-regulator was also investigated in 
breast carcinoma cells, described in chapter 5. In these cells, DC-SCRIPT was found to 
co-repress the proliferation stimulating NRs ER and PR, while exerting a co-activator 
function on the anti-proliferative NRs RAR-RXR and PPAR. Concomitant with these 
findings, DC-SCRIPT expression was found to be a prognostic marker for disease-free 
survival.
NRs play an important role in both dendritic cell- and breast cancer biology, and 
cross-talk between these receptors is an important aspect of their function. Chapter 
6 reviews the current knowledge on NRs crosstalk in breast carcinoma cells, and 
anticipates on a role for DC-SCRIPT in this process, regulating both Type I and Type 
II NRs.
 Chapter 7 summarizes the findings of this thesis, and discusses their implications 
and future perspectives in DC-, NR-, and cancer biology.
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ABSTRACT
The identification of a major class of innate immune receptors, termed Pattern 
Recognition Receptors (PRRs), has boosted research on innate pathogen recognition. 
The immune response to a specific pathogen is not restricted to the recognition by 
one type of PRR or activation of a single cell type, but instead comprises complex 
collaborations between different receptors, cells, and signal mediators. Here we will 
discuss the crosstalk between PRRs involved in fungal recognition, focusing on the 
molecular interactions occurring at the plasma membrane. 
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INTRODUCTION
In multicellular organisms, the innate immune system is the first line of defence 
against invading pathogens. Recognition and uptake of these microbes is crucial 
for an effective host defence, and is facilitated by phagocytes such as neutrophils, 
macrophages and dendritic cells (DC). Phagocytosis of microorganisms by 
neutrophils triggers direct cellular antimicrobial immunity such as production of 
reactive oxygen species (ROS) and the fusion of cytoplasmic granules with pathogen 
containing vacuoles.1 This mechanism is highly effective in killing most bacteria and 
fungi. Furthermore, recognition of pathogens by phagocytes activates intracellular 
signalling pathways that result in production of numerous cytokines and chemokines. 
These mediators attract more phagocytes and activate antigen presenting cells (APC) 
such as DC, creating an essential foundation for the initiation of adaptive immunity, 
that protects us from re-infection. 
 Despite its importance, in the past the innate immune system has received 
relatively little attention. The identification of the innate immune receptors termed 
Pattern Recognition Receptors (PRRs) provided a boost for research on innate 
pathogen recognition. Indeed, proper pathogen recognition is key to adequate 
immune defence, and is facilitated by PRRs expressed on phagocytes. By definition, 
these germline-encoded receptors detect Pathogen Associated Molecular Patterns 
(PAMPs), structures conserved among microbial species. Well known PAMPs include 
the bacterial components lipopolysaccharide, peptidoglycans and flagelin, viral 
nucleic acids and fungal polysaccharides such as mannan and β-glucans. Currently, 
PRRs are categorised into four classes: i) Toll-Like Receptors (TLRs), ii) C-type lectin 
receptors (CLRs), iii) Retinoic acid-inducible gene (RIG)-I-like receptors (RLRs) known 
also as RIG-I helicases (RLHs) and iv) the NOD-like receptors (NLRs) (see: BOX 1). 
 In the past, the majority of in	vitro studies aiming to unravel the mechanism of 
pathogen recognition by PRRs used an isolated cell type or a single PAMP. In recent 
years it has become increasingly apparent that the immune response to a specific 
pathogen is not restricted to the recognition by one type of PRR or activation of 
a single cell type, but instead comprises complex collaborations between different 
receptors, cells, and signal mediators. Indeed, in	vivo invading pathogens generally 
contain multiple PAMPs that are recognized by various PRRs on multiple cell types. 
Additionally, there is redundancy in the recognition of PAMPs between different 
classes of PRRs. The simultaneous or sequential binding of multiple PRRs to different 
PAMPs resulting in coordinated activation or inhibition of signal transduction is 
referred to as ‘receptor crosstalk’. It is anticipated that the presence of PRRs in multi-
receptor complexes in the plasma membrane facilitates this crosstalk. 
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BOX 1. Four classes of pattern recognition receptors
TLRs are the best characterized PRRs. These type I transmembrane proteins are 
present on the plasma membrane or within the endosomal compartment. The 
extracellular domain is involved in the recognition of PAMPs, while the intracellular 
TIR domain activates signalling pathways leading to the activation of NF-κB. So far, 
10 functional TLRs have been identified in man versus 12 in mice. Each TLR detects 
different PAMPs from viruses, bacteria, fungi, and parasites.2 Some TLR, such as 
TLR2 form functional heterodimers, thus further broadening PAMP recognition. 
CLRs represent the second class of PRRs, mainly recognizing carbohydrate ligands. 
The CLR family comprises transmembrane- and soluble receptors that share a 
carbohydrate-recognition domain (CRD).3 Not all CLRs effectively function as 
PRRs. Those which do, can be divided into two classes: “self-sufficient” CLRs that 
autonomously recognize PAMPs initiating downstream signalling, and CLRs that 
do recognize PAMPs but are dependent on partnering proteins for intracellular 
signalling. 
RLRs are present in the cytosol and involved in sensing intracellular pathogens. 
RLRs bind mainly viral nucleic acids. So far, three members of the RLR family have 
been identified: RIG-I, MDA-5 and LGP2. RIG-I and MDA-5 recognize a wide range 
of viruses and initiate IFN responses, whereas LGP2 is considered to regulate 
responses initiated by RIG-I and MDA-5.4
NLRs are also expressed intracellularly. Members of the NLR family have a common 
domain architecture that includes a nucleotide-binding domain (NBD) and a leucine-
rich repeat (LRR) domain. The best characterized NLRs are NOD1 and NOD2. They 
sense different building blocks of peptidoglycans (PGN). Some NLRs can function as 
crucial components in multiprotein complexes termed “inflammasomes” that are 
important for activation of inflammatory caspases and cytokines of the IL-1 family.5
As a consequence, separate or shared signalling pathways are activated that 
ultimately determine the type and magnitude of the immune responses directed 
against the pathogen.
 The outcome of PRR crosstalk may be quantitative when receptors act 
synergistically or antagonistically. Synergistic responses may be particularly 
important under conditions of low ligand concentrations, when recognition by more 
than one receptor can enhance the immune response. A classical example of the 
synergistic response is the production of IL-12p70 cytokine by DCs, which increases 
greatly when multiple PRRs are triggered.6 On the other hand, collaboration of PRRs 
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is also important to dampen unwarranted host responses. For example triggering of 
the C-type lectin receptor, DCIR, selectively inhibits TLR8-meditated IL-12 and TNF-α 
production.7
Crosstalk between distinct PRRs can also have a qualitative effect. For instance, 
recognition of Salmonella typhimurium by TLR4 and TLR5 activates transcription 
of proinflammatory cytokines including IL-1β. Subsequent release of functional IL-
1β from the cells, however, requires processing of pro-IL-1β by Caspase-1, which is 
critically dependent on activation of NLRP3 and NLRC4 in the inflammasome.8 
 Hence, collaboration between PRRs enhances the specificity of recognition, 
broadens their signalling capacity and enables the host to detect and respond to 
almost any type of infection. In this review we will focus on the molecular basis of 
PRR crosstalk important in detection of the fungal pathogen Candida	albicans.
FUNGAL RECOGNITION BY THE INNATE IMMUNE SYSTEM
The last decade has yielded significant advances in the identification and functional 
characterization of a variety of PRRs that sense fungi. Candida	albicans represents an 
opportunistic fungus that asymptomatically colonizes the mucosa of most healthy 
individuals. However, mucosal and/or systemic infections caused by	C.	albicans are 
regularly observed in immunocompromised patients, emphasizing the importance 
of the immune system in clearing fungal pathogens. The severity of such infections 
is exemplified by the high mortality rate amongst patients with invasive candidiasis, 
despite the availability of novel effective antifungal drug classes such as the azoles 
and echinocandins.
 The cell wall of C.	 albicans	 is comprised of different sugar polymers (chitin, 
β-glucans, mannan) and proteins that can function as PAMPs for CLRs, TLRs, and 
NLRs.9,10 In addition, members of the scavenger receptor (SR) family and certain 
integrins also possess intrinsic fungal recognition capacity although these are not 
classified as classical PRRs. Many PRRs that are involved in C.	albicans recognition 
belong to the CLR family, (reviewed in 11) and can directly activate signalling pathways, 
or indirectly through interaction with other signalling adaptors or receptors, such as 
the FcRγ chain or TLRs.12 The importance of CLR in anti-fungal immune responses has 
been validated in different murine knock-out models (reviewed in 10,11).
 The recent finding that human Dectin-1 deficiency causes an increased 
susceptibility to mucocutaneous fungal infections emphasizes the importance of 
specific CLR in	 vivo.13 Furthermore, individuals with mutations in the CLR adaptor 
molecule CARD9 are more susceptible to both mucosal and systemic fungal 
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infections.14 Dectin-1 is expressed by DCs, macrophages and monocytes, where 
ligation with its ligand β-1,3 glucan induces phagocytosis and an oxidative burst, 
as well as the production of eicosanoids, inflammatory cytokines and chemokines. 
Albeit β-1,3 glucans in de cell wall of C.	albicans are only exposed in bud scars or 
after heat inactivation of the yeast, Dectin-1-knockout mice were documented to 
have increased susceptibility for C.	albicans infections.15 However, it must be noted 
that different results were obtained between the mice models Balb/cA and 129/
C57BL/6, most likely due to background differences in inherent T-cell polarisation.16,17 
In addition, differences can arise between systemic versus mucosal C.	 albicans 
infections. Dectin-1 is mainly involved in mucosal candidiasis, which is evidenced by 
the study of Ferwerda et al (2010). Interestingly, Dectin-1 molecules in myeloid cells 
have recently been reported to cluster in a ‘phagocytic synapse’ crucial for triggering 
phagocytosis and full antifungal activity.18 Responses following Dectin-1 ligation are 
variable depending on cell type and microenvironment, however, prevailing evidence 
suggest that Dectin-1 signalling preferential directs Th17 polarization.19 Similar Th17-
polarizing effects have been described for other CLRs such as dectin-2 and MR.20,21
 Fungal recognition by the TLR family can be mediated by TLR2/6, TLR4, and TLR9 
sensing phospholipomannan (PLM), O-linked mannan, and phagocytosed fungal 
DNA, respectively.10 The latter, however, seem to have a redundant role, since 
TLR9-deficient mice do not show increased susceptibility to C.	albicans infection.22 
The role of the individual receptors has not been fully elucidated and divergent 
results have been published, however, it is generally accepted that TLR-mediated 
antifungal immunity acts through the induction of inflammatory cytokines. Deletion 
of the intracellular TLR-adaptor protein MyD88 clearly increases susceptibility to 
fungal infections (reviewed in 10). Moreover, TLR4	polymorphisms in humans have 
been found to associate with an increased risk of invasive fungal infections.23,24 
In contrast, TLR2-deficient mice are more resistant to disseminated candidiasis, 
showing enhanced Th1 responses and decreased Treg proliferation.25,26 A similar, 
although weaker effect, was shown in TLR6-deficient mice, suggesting both TLR2 
and TLR6 are involved in C.	albicans	detection.27
 Recent studies have demonstrated an important role for the NLRP3 inflammasome 
in anti-fungal immunity.28 C.	albicans can induce caspase-1-mediated IL-1β secretion 
in a NLRP3 dependent-manner in APC, most likely through Dectin-1/Syk kinase/
CARD9 signalling.29,30 Interestingly, a critical role for the inflammasome in regulating 
Th17/Th1 responses during C.	 albicans infection was recently reported.31 Other 
receptors involved in C.	albicans detection include the family of scavenger receptors 
(SR), Integrins and Fc Receptors (FcR). SR represent structurally unrelated proteins 
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that recognize multiple ligands including lipoproteins, β-glucan motifs, microbial 
antigens, and modified or endogenous molecules derived from the host.32 Integrins 
on the other hand can act as opsonic receptors that recognize fungal particles coated 
with complement factors, or possess intrinsic microbial recognition. Fc receptors 
(FcR) recognize antibody-opsonised C.	 albicans and can also efficiently induce 
phagocytosis, cytotoxicity and/or antigen presentation.33,34
 Recognition of C.	 albicans	by these many different PRRs expressed by innate 
immune cells is a highly complex and dynamic process. Evidence is accumulating 
that the clustering of receptors, including PRR, into organized membrane 
complexes, such as lipid rafts or tetraspanin microdomains, is important to regulate 
ligand binding and subsequent signal transduction.35-37 This may allow for cross-talk 
between the different PRRs that facilitates integration of different incoming signals 
leading to a potent antifungal response.
MOLECULAR VIEW ON PRR CROSSTALK IN FUNGAL RECOGNITION
Collaboration between different classes of PRRs is important for the innate immune 
responses to C.	albicans. The underlying molecular mechanisms, however, are still 
largely unknown. Interaction studies have been performed for some of these PRRs, 
and suggest physical contact between some of the receptors at the plasma membrane. 
True insight into the molecular interaction platforms involved in PRR collaboration 
requires more detailed characterization of these interactions, and should distinguish 
between direct and indirect binding. Here we will review the current understanding 
of the molecular interactions among PRRs at the plasma membrane that are involved 
in fungal recognition. 
TLR-2/TLR-6
TLR2 is known to form heterodimers with TLR6 in the recognition of fungal PAMPs. 
This interaction is well characterized at the molecular level with known crystal 
structure and binding domains. Dimerization of TLR molecules occurs at both the 
extracellular Leucin-rich repeat domain (LRR) and the intracellular TIR-domain. The 
LRR domain forms the characteristic TLR horseshoe structure, consisting of the 24 
amino acids conserved motif XLXXLXXLXLXXNXLXXLPXXXFX. Interestingly, TLR2 has 
an aberrant LRR domain that lacks the conserved Asparagine ladder important for 
structure stability. It has been suggested that this modification allows for variations 
in structural conformation, permitting the binding of different ligands and receptors. 
Intracellularly, TIR-TIR interactions depend on the BB-loop, DD-loop and αC-helix, 
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domains that are essential for recruitment of adaptor proteins and domain stability. 
Indeed, mutations within the BB-loop region have been shown to abrogate TLR 
signalling. For TLR2/6 complexes, the adaptor proteins MyD88 and Mal directly 
interact with the TIR domains, mediating downstream signalling leading to NF-κB 
activation and cytokine production.38 In addition, TLR2 can also functionally cooperate 
with the CD14 receptor, whereby CD14 enhances TLR2-mediated NF-κB activation in 
response to zymosan.39 Whether a direct interaction of the TLR2 heterodimers with 
CD14 is essential for this collaboration is unknown.
Dectin-1
A molecule well known to functionally synergize with TLR2 is Dectin-1. This CLR family 
member is composed of an extracellular carbohydrate recognition domain (CRD), a 
short stalk region, a transmembrane domain and a 40 amino acid long intracellular 
tail. Alternative splicing generates respectively two and eight isoforms in mice and 
men, with both species preferentially expressing the ‘stalkless’ Dectin-1 isoform. The 
extracellular C-type lectin domain is used for β-glucan binding. Ligation of β-glucans 
triggers phosphorylation of the Dectin-1 intracellular tail, containing an unconventional 
immunoreceptor tyrosine-based activation motif (ITAM). Conventional ITAM motifs 
contain two tyrosine phosphorylation sites that are phosphorylated upon receptor 
activation. Syk family kinases bind to these phosphorylated sites via two Src homology 
2 (SH2) domains, forming the basis of the intracellular signalling route. In the Dectin-1 
ITAM-like motif, the membrane-distal phosphorylation site is not available for binding 
to an SH2 domain due to an additional amino acid. However, Syk recruitment and 
activation requires both SH2 domains to bind phosphorylated tyrosine residues. 
For Dectin-1 this is only possible by receptor dimerization, providing a binding site 
for Syk on adjacent clustered Dectin-1 ITAM motifs. Syk subsequently recruits the 
CARD9⁄Bcl10⁄Malt1 complex, leading to cytokine secretion via the activation of Erk, 
p38 and Jnk MAP kinases, and NF-κB and NFAT transcription factors.19 Dectin-1 is 
known to form homodimers and larger clusters in the plasma membrane in order 
to induce signalling, and has been shown to synergistically collaborate with different 
TLRs, including TLR2. Despite many attempts, no direct interactions between Dectin-1 
and TLR2 have been reported to date.
Galectin-3
A molecule possibly linking Dectin-1 and TLR2 molecules is Galectin-3. This S-type 
lectin receptor belongs to the Galectin family, defined by their conserved elements in 
the CRD domain. In mammals, 15 members of the Galectin family have been identified, 
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all of which are synthesized and stored in the cytoplasm, separated from their glycan 
ligands. Upon infection these molecules are released, and function as soluble PRRs 
or immunomodulators. Galectin-3 contains one CRD and an additional non-CRD 
domain, which functions in oligomerization. The unbound soluble Galectin-3 is found 
in monovalent form. Ligand binding induces oligomerization through self-assembly 
of the N-terminal non-CRD domain, generating pentameric Galectin-3 molecules 
with multivalent CRDs. Galectins lack a transmembrane domain or signalling motif, 
but are implicated in direct binding of host glycoproteins, crosslinking receptors 
and ligands at the cell surface. Indeed, the formation of so-called Galectin-3 lattices 
has been shown to promote cell-surface retention of cytokine and growth factor 
receptors, by interfering with endocytosis. This potentially results in prolonged 
signalling and facilitates receptor collaboration. Importantly, since Galectin-3 binds 
β-1,2 oligomannans of C.	 albicans, it can also directly crosslink pathogens to this 
receptor complex.40 
 Interestingly, Esteban et. al (2011) recently discovered a physical association 
between Dectin-1 and Galactin-3 in the cell membrane of murine macrophages 
using co-immunoprecipitation studies. Stimulation with zymosan particles 
increased the amount of Dectin-1 in the immunoprecipitate.41 In line with this work, 
crosstalk between TLR2 and Galectin-3 has been reported, which enhanced TLR2-
induced TNFα production. Again, co-immunoprecipitation studies demonstrated an 
interaction between endogenously expressed TLR2 and Galectin-3 in THP-1 cells, 
which was critically dependent on prior stimulation with C.	albicans.42 Unfortunately, 
secretion of other relevant cytokines such as IL-6, IL-23, IL-10 and IL-12 were not 
assessed, despite clear effects on TNFα. This could provide a more complete view 
on the functional role of Dectin-1-Galectin-3 and TLR/2-Galectin-3 collaboration in 
C.	albicans detection.
 Further insight into the molecular make-up of putative Dectin-1, Galactin-3 and 
TLR2 complexes requires the identification of the domains involved in the molecular 
interactions. Both studies use stringent co-immunoprecipitation conditions, 
suggesting direct interactions. Taken together, these results suggest that Galectin-3 
represents an important mediator in the recognition of C.	albicans by molecular 
assembly of TLR2 and Dectin-1 in the plasma membrane at the site of fungal 
recognition. An important question that remains to be answered is how clustering 
of these receptors during C.	 albicans	 detection occurs in time. Possibly, initial 
binding could be facilitated by coating of fungal material with Galectin-3. This could 
facilitate ligand binding by Dectin-1 and TLR2/6, as well as recruitment of other 
cell surface receptors, which will induce intracellular signalling and will stabilize 
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the interaction. Finally, phagocytosis and intracellular degradation may release 
ligands for intracellular PRRs such as TLR9. Hence, an interesting challenge lies in 
assessment of the sequential events leading to receptor activation and clustering 
during C.	albicans detection.
Tetraspanins 
Another phenomenon contributing to crosstalk between different PRRs in fungal 
detection is the occurrence of specialized membrane microdomains controlling 
signal transduction and cell function. The tetraspanin family of transmembrane-
four proteins have the ability to interact in	 cis with specific (immune-) receptors, 
with each other, and with signalling molecules, whereby they form multi-molecular 
complexes, or ‘tetraspanin microdomains’.43,44 There is now convincing evidence 
that tetraspanins in immune cells control proliferation, antibody production and 
antigen presentation (reviewed in 45,46). Moreover, tetraspanins are involved in the 
pathogenesis of infectious diseases.47,48 Two independent studies have shown that the 
tetraspanins CD37 and CD63 interact with Dectin-1 in the cell membrane of human 
and murine APC.49,50 Although the exact binding domains have not been identified, 
the stalk region present in the larger isoform A of Dectin-1 was not required for the 
interaction with CD37 since co-immunoprecipitations were successfully performed 
with isoform B of Dectin-1. CD37 was demonstrated to stabilize Dectin-1 expression 
at the plasma membrane of macrophages and to inhibit Dectin-mediated signalling 
leading to IL-6 production. This effect was specific for Dectin-1, because signalling via 
other PRR (including TLRs) was not affected by CD37-deficiency.50 Thus, tetraspanins 
can modulate the organization and subsequent downstream signalling of specific PRR 
by their recruitment into tetraspanin microdomains leading to immune activation or 
tolerance.36 It will be intriguing to investigate how the Dectin-1-tetraspanin interaction 
relates to the reported collaboration between Dectin-1 and TLR2, and moreover 
whether tetraspanins modulate Syk- or Raf-1-dependent signalling pathways which 
are known to be active downstream of Dectin-1 
Crosstalk	between	other	PRRs	involved	in	C.	albicans	detection
Different studies have demonstrated that also other CLR, including the mannose 
receptor (MR), DC-SIGN (SIGNR1 in mouse) and Dectin-2 can collaborate with other 
fungal sensors during antifungal responses. For example, Dectin-2 was reported to 
interact with the FcγR chain, which was essential for the detection of C.	 albicans 
hyphae and the subsequent induction of TNFα and IL-1 receptor antagonist (IL-
1Ra).51 The intracellular domain of Dectin-2 (amino acids 8–14) proximal to the 
Molecular	view	on	PRR	crosstalk
41
transmembrane domain was required for the association with the FcγR chain. 
Other studies report functional interactions between Dectin-1 and DC-SIGN/SIGNR1 
during C.	albicans	recognition although the underlying molecular mechanisms are 
ill-defined.52,53 Similarly, TLR4 collaborates with Dectin-1 in APC as has been shown 
for TLR2.54 Finally, CR3 and also the recently discovered CLR Mincle interacts with Fc 
receptors in the plasma membrane of APC during C.	albicans detection.55 
 Together, clustering of PRRs importantly aids to the formation of the ‘phagocytic 
synapse’, providing a platform for efficient phagocytosis of the captured antigen.18,56 
However, the amount and type of PRR ligands that are available to immune cells 
can differ between initial interactions, full blown infections and the type of fungus. 
Initially, only surface expressed PAMPs on the intact pathogens trigger PRR detection. 
During ongoing infections, however, more ligands become available through the 
degradation of fungal material. The quality and quantity of PRRs triggered on 
immune cells may therefore differ during the development of a fungal infection, 
possibly resulting in tuning of responses.
Figure 1. Model of the molecular interactions and collaborations between PRRs and other molecules 
on immune cells detecting C. albicans.	Dectin-1	 is	sequestered	from	active	PRR	domains	by	CD37,	and	
clusters	with	TLR2/6,	and	Galectin-3	upon	C.	albicans	detection,	facilitating	receptor	collaboration	(large	
arrows).	Crosstalk	with	other	molecules	detecting	C.	albicans	 is	suggested	(dashed	arrows).	 Interaction	
domains	are	hypothesized	to	be	highly	dynamic,	varying	in	composition	depending	on	the	pathogen,	cell	
type	and	activation	status.
Concluding	remarks	on	the	molecular	network	of	fungal	recognition
Based on these studies, one can envisage a dynamic 3D-interaction-model, in which 
multiple receptors involved in sensing fungal pathogens can cluster together at 
the cell surface of innate immune cells (figure 1). Receptor compartmentalization 
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provides immune cells with an efficient mechanism for regulated membrane-
proximal signalling upon fungal detection. In the context of C.	albicans recognition, 
extensive crosstalk between various PRRs has been shown, including the synergistic 
effects of Dectin-1, TLR2/6 and Galectin-3 on enhancing NF-κB mediated responses. 
In addition, negative regulatory circuits are in place, e.g. Dectin-1 interaction with 
tetraspanin CD37 was demonstrated to inhibit Dectin-1 signalling, possibly by 
sequestering Dectin-1 molecules away from activating PRR complexes.50 Thus, 
receptor compartmentalization can act in both stimulatory and inhibitory manners to 
regulate PRR complexes. Furthermore, we anticipate that PRR complexes are highly 
dynamic and variable in composition, containing different PRRs and their adapter 
molecules, as well as non-PRR proteins. Depending on the fungal pathogen, the 
immune cell type and its activation status, the composition, dynamics and activity of 
the PRR complexes will be modulated. For example, Dectin-1 ligation with β-glucans 
reportedly induced NF-κB activation in bone marrow-derived DC, but not in bone 
marrow-derived macrophages. Furthermore, the Dectin-1/CARD9 signalling pathway 
is differentially activated in macrophages and DC. In conclusion, PRR crosstalk 
represents an important regulatory mechanism for the immunological response to 
pathogens in	 vivo. Future studies on PRR interactions are therefore necessary to 
increase further insight in this important process. 
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ABSTRACT
Dendritic cells (DCs) are the professional antigen presenting cells of the immune system 
that dictate the type and course of an immune response. Molecular understanding 
of DC biology is important for the design of DC based immunotherapies and optimal 
clinical applications in vaccination settings. Previously, we isolated and characterized 
the cDNA encoding DC-SCRIPT (dendritic cell–specific transcript, also known as 
ZNF366). DC-SCRIPT mRNA expression in the immune system was confined to DCs 
and was reported to be an early hallmark of DC differentiation. Here, we demonstrate 
IL-4 to be the dominant factor for DC-SCRIPT expression in human monocyte derived 
DCs (moDCs). In addition we show, for the first time, endogenous DC-SCRIPT protein 
expression in human DCs both in	vitro and in	situ. DC-SCRIPT protein is detected early 
upon differentiation of monocytes into DCs and is also present in multiple freshly 
isolated DC subsets. Maturation of DCs with TLR ligands further increased DC-SCRIPT 
mRNA expression, suggesting a role in DC maturation. Indeed, siRNA mediated knock-
down of DC-SCRIPT affected the cytokine response upon TLR stimulation. These 
DCs displayed enhanced IL-10 and decreased IL-12 production, compared to wild-
type DCs. Silencing of IL-10 in DC-SCRIPT knock-down DCs rescued IL-12 expression, 
suggesting a primary role for DC-SCRIPT in the regulation of IL-10 production.
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INTRODUCTION
Dendritic cells (DCs) are the professional antigen presenting cells of the immune 
system and play an essential role in the initiation and modulation of immune 
responses. DCs reside in the tissue in an immature state, and are capable of 
recognizing and capturing microbial antigens through specific receptors. Upon 
infection or inflammation, they undergo a complex process of maturation, where 
they change from antigen-capturing cells into antigen-presenting cells.1 With the 
expression of co-stimulatory or co-inhibitory molecules and the secretion of pro- or 
anti-inflammatory cytokines, DCs generate either immunity or tolerance through 
T-lymphocyte stimulation.2 The type of molecules that are expressed greatly depends 
on the activation status of the DC, and is affected by environmental stimuli.3-5 
 A broad range of DC subsets have been described, including the in	vitro monocyte 
derived DCs (moDCs) and the in	vivo	blood derived myeloid and plasmacytoid DCs 
(mDCs and pDCs, respectively). Myeloid DCs act as sentinels in the periphery and 
have a specialized function depending on their location and Pattern Recognition 
Receptors (PRRs) expression profile. The cellular cues present at different locations, 
e.g. gut, skin or other organs, inflicted by local invading pathogens direct the mDCs 
towards a specific response. Plasmacytoid DCs are considered the front line of 
defense in anti-viral immunity as they rapidly produce massive amounts of type I 
interferon in response to viral infection and prime T cells against viral antigens.6-8 
In	vitro, DCs can be generated from monocytes through stimulation with IL-4 and 
GM-CSF.9 These cytokines trigger DC differentiation while inhibiting macrophage and 
osteoclast differentiation.10-12 
 The differentiation of the DC subsets from their precursors is a highly complex 
process. Genetic analyses have identified different transcription factors, including 
IRF4, RelB and PU.1, to be crucial in the development of specific DC subsets in 
lymphoid organs.13-17 DC differentiation and maturation requires a complete change 
in the DC gene expression profile, mediated by the combinatorial effect of a few key 
transcription factors and chromatin re-organization.18 
 In 2006 we identified and characterized a new DC expressed transcription factor, 
termed dendritic cell–specific transcript (DC-SCRIPT; also known as ZNF366). DC-
SCRIPT mRNA is present in all DC subsets tested so far, including moDCs, mDCs, 
pDCs and LCs (Langerhans cells). Interestingly, expression was not detected 
among other leukocyte populations,19 suggesting an essential role of DC-SCRIPT 
in DC biology. Outside the immune system, DC-SCRIPT has also been detected in 
epithelial cells in the breast and in tumors derived thereof.20,21 DC-SCRIPT is located 
on human chromosomes 5q13.222 and is encoded by an 8 kb messenger RNA. It 
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is well conserved in evolution, with the human and mouse genes both located in 
syntenic chromosomal regions, sharing 80% amino acid sequence homology.23 The 
protein consists of a proline rich region, 11 C2H2-type zinc fingers and an acidic 
region. In addition, it bears a functional CtBP1 motif and an LxxLL Nuclear Receptor 
(NR) interaction motif.19,24 NRs are ligand-inducible transcription factors that bind 
specific DNA-regulatory response elements. NRs and their co-regulators have been 
described to play an important role in a wide variety of biological processes including 
immunobiology and cancer biology.25-30 Moreover, we demonstrated that DC-SCRIPT 
is a unique modulator of NR function and a strong and independent prognostic 
marker in breast carcinoma.20
 Thus far, the expression and function of DC-SCRIPT in DCs remains largely 
unknown. Here, we characterized the endogenous DC-SCRIPT protein expression 
dynamics in the in	vitro monocyte derived DCs as well as in primary blood derived 
DCs and studied its functional role in DC maturation.
MATERIALS & METHODS
Generation	of	human	DCs
Human monocyte derived Dendritic Cells (moDCs) were generated from PBMCs as described previously.31 
Monocytes were derived from buffy coats. Plastic-adherent monocytes were cultured for 6 days in 
Phenol red free RPMI-1640 medium (Life Technologies, Breda, The Netherlands) supplemented with 1% 
ultra-glutamine (Cambrex, Wiesbaden, Germany), 0,5% antibiotic-antimycotic (Invitrogen, Breda, The 
Netherlands), 10% (v/v) FCS (Greiner, Kremsmuenster, Austria), IL-4 (300 U/ml), and GM-CSF (450 U/ml) 
both from cellgenix. During day 3 moDCs were supplemented with new IL-4 (300 U/ml) and GM-CSF (450 
U/ml). Mature moDCs were generated from day 6 immature moDCs through 48 hour stimulation with 200 
ng/ml LPS (InvivoGen, Toulouse, France). Human Myeloid Dendritic Cells (mDCs) were isolated from PBMCs 
using the CD1c (BDCA-1)+ Dendritic Cell Isolation Kit (Miltenyi Biotec, Leiden, The Netherlands). Human 
Plasmacytoid Dendritic Cells (pDCs) were isolated from PBMCs using the CD304 (BDCA-4/Neuropilin-1)+ 
MicroBead Kit (Miltenyi Biotec, Leiden, The Netherlands). Purity (>90%) of the freshly isolated mDCs and 
pDCs were ensured by FACS staining.
RNA	isolation	and	quantitative	PCR
Total RNA was isolated from cells using an RNA isolation kit (Zymo research). RNA quantity and purity 
were determined on a NanoDrop spectrophotometer. RNA was treated with DNase I (amplification 
grade; Invitrogen) and reverse-transcribed into cDNA by using random hexamers and Moloney 
murine leukemia virus reverse transcriptase (Invitrogen). mRNA levels for the genes of interest were 
determined with a CFX96 sequence detection system (Bio-Rad, Veenendaal, The Netherlands) with 
SYBR Green (Roche, Woerden, The Netherlands) as the fluorophore and gene specific oligonucleotide 
primers. The primers for DC-SCRIPT and PBGD were described previously.20 Other used primers 
(forward, reverse): IL-12 (5’-ATGGCCCTGTGCCTTAGTAGT-3’, 5’-CGGTTCTTCAAGGGAGGATTTT-3’), 
IL-6 (5’-GCTATGAACTCCTTCTCCACAAGCG-3’, 5’-ATCCATCTTTTTCAGCCATCTTTGG-3’), 
TNF (5’-ATGAGCACTGAAAGCATGATCC-3’, 5’-GAGGGCTGATTAGAGAGAGGTC-3’), IL10 
(5’-TCAAGGCGCATGTGAACTCC-3’, 5’-GATGTCAAACTCACTCATGGCT-3’). Reaction mixtures and program 
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conditions were used that were recommended by the manufacturer (Bio-Rad). Quantitative PCR data were 
analyzed with the CFX Manager V1.6.541.1028 software (Bio-Rad) and checked for correct amplification 
and dissociation of the products. mRNA levels of the genes of interest were normalized to mRNA levels 
of the housekeeping gene porphobilinogen deaminase (PBGD) and were calculated according to the cycle 
threshold method.32
Immunohistochemistry
Snap-frozen tonsil specimens were obtained from the Department of Pathology, RUNMC St, Radboud 
and approved by the institutional ethics committee of the RUNMC. The specimens were embedded in 
OCT embedding matrix (CellPath, Newtown, UK) and sectioned in 5 μM thick tissue sections. The sections 
were placed on Superfrost slides (Thermo Scientific, Etten-Leur , the Netherlands), fixed with acetone, 
and incubated with 4 μg/mL goat anti-human DC-SCRIPT antibody (R&D Systems, Abingdon, UK), 4 μg/mL 
mouse anti-human DC-SIGN (AZN-D1), followed by incubation with a biotinylated horse anti-goat IgG or 
horse anti-mouse (Vector Laboratories), and signal development was performed using a Vectastain ABC-
HRP Kit (Vector Laboratories, Burlingame, CA) and DAB (Sigma Aldrich, Zwijndrecht, the Netherlands). 
Isotype-matched goat IgG (R&D Systems) and mouse IgG1 (BD Bioscience) were used as controls. Sections 
were counterstained with hematoxylin to visualize the cell nuclei and analyzed by using a Leica DM LB 
microscope (Leica Microsystems B.V., Rijswijk, the Netherlands).
Western	blotting
Cells were lysed in 1% SDS and 62,5mM Tris pH 6.8 and the protease inhibitors 2 μg/mL leupeptin 
(Sigma Aldrich), 2 μg/mL aprotinin (Roche), and 1 mM phenylmethylsulfonyl fluoride (Sigma Aldrich). 
Cell lysates were mixed with sample buffer containing 5% glycerol, 6% sodium dodecyl sulfate, 125 mM 
Tris–HCl (pH 6.8), 0.1 mg/mL bromophenol blue (Gebr . Schmid GmbH + Co, Freudenstadt, Germany), 
and 10%-mercaptoethanol (Sigma Aldrich); heated at 95°C for 5 minutes; and then cooled on ice. 
The proteins were resolved by electrophoresis on an 8% polyacrylamide gel (ratio of acrylamide to 
bisacrylamide, 37.5:1) and transferred overnight to Protran nitrocellulose transfer membranes (Schleicher 
and Schuell, ‘s-Hertogenbosch, the Netherlands) at 30 mA and 4°C. To block nonspecific protein binding, 
the membranes were incubated in 1% skimmed milk powder and 3% bovine serum albumin in PBST. The 
membranes were then incubated for 1 hr with 2,5 μg/ml goat anti-human DC-SCRIPT antibody (R&D 
Systems, Abingdon, UK), washed three times in PBST, and subsequently incubated for 1 hour with the 
secondary antibody IRDye 800CW donkey anti goat IgG (1:5000 dilution; Li-cor Biosciences, Bad Homburg, 
Germany ) to detect DC-SCRIPT. To detect actin, the membranes were incubated with a mouse anti-actin 
(1:20.000 dilution, Sigma clone AC-40), washed three times in PBST, and incubated for 1 hour with the 
secondary antibody Alexa Fluor 680 – conjugated Donkey-anti-mouse IgG (1:5000 dilution; Invitrogen). All 
membranes were then washed three times in PBST. After staining, the membranes were scanned by using 
an Odyssey Infrared Imaging System (Li-cor Biosciences) to visualize the proteins.
Confocal	Laser	Scanning	Microscopy
Round ø 12 mm cover slides (Thermo Scientific, Braunschweig, Germany) were coated with Poly-L-Lysine 
(Sigma Aldrich). Immature and mature moDCs (day 6), mDCs and pDCs were seeded on cover slides 
(50.000 cell/slide) and adhered for 2 hours in serum free, phenol red free RPMI-1640 supplemented with 
1% ultra-glutamine, 0,5% antibiotic-antimycotic, IL-4 (300 U/ml) and GM-CSF (450 U/ml). DCs were fixed 
using 1% paraformaldehyde extra pure DAC 1 (Merck, Haarlem, The Netherlands) in PBS for 15 min at RT. 
DCs were permeabilized with 100% ice cold Methanol (Boom, Meppel, The Netherlands) for 5 minutes 
at 4oC, washed with PBS, blocked for 1 hour with 3% BSA (Roche) and 1% Normal Donkey Serum (Sigma 
Aldrich) in PBS, stained 1 hour with 2,5 μg/ml Goat-anti-human DC-SCRIPT (R&D Systems, Abingdon, UK) 
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and 1 hour with 1/400 Alexa Fluor 488 Donkey anti-Goat IgG (Invitrogen). The nucleus was stained for 5 
minutes with 0,3 μg/ml DAPI (Sigma Aldrich) or 1 μg/μl Propidium Iodide (ITK, Uithoorn, The Netherlands), 
washed with PBS and mounted on 76 x 26 mm microscope slide (Thermo Scientific) with mowiol + 2,5% 
azide (Calbiochem, San Diego, US). Confocal laser scanning microscopy (CLSM) was carried out with an 
Olympus FV1000 Confocal Laser Scanning Microscope with an Argon (457, 488, 515nm), and 405, 559 and 
635 diode lasers at the Microscopic Imaging Facility of the Department of Cell Biology, Nijmegen Centre for 
Molecular Life Sciences, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. The 
N/C ratio (mean Nuclear values/mean Cytoplasmic values) of DC-SCRIPT expression was calculated using a 
custom written quantitative image analysis algorithm in Fiji/ImageJ software (http://fiji.sc/).
Goat-anti-DC-SCRIPT	validation
Immature moDCs were stained with 2,5 μg/ml goat-anti-human DC-SCRIPT or mouse-anti-human GR 
(Abcam, Cambridge, UK) for 40 minutes and 1 hour with 1/400 Alexa Fluor 488 Donkey-anti-goat or Goat-
anti-mouse. Prior to staining the primary antibodies were supplemented with vehicle (2,9 μl 10 mM HCl + 
2,9 μl 10mM NaOH) or 9,96 μg/ml recombinant human DC-SCRIPT (R&D Systems, Abingdon, UK). 
siRNA	mediated	knock-down
For DC-SCRIPT silencing a 23 nucleotide Custom ZNF366 siRNA termed SC38 targeting the DC-SCRIPT 
gene at position 2349-2369 was used (Dharmacon, Lafayette, Colorado, US). For IL-10 silencing the ON-
TARGETplus SMARTpool IL10 (Dharmacon) containing 4 different IL-10 targeting siRNA oligos each 21 
nucleotides long was used. The irrelevant siRNA ON-TARGETplus Non-Targeting siRNA#1 (Dharmacon) was 
used as control. Cells were washed twice in PBS and once in OptiMEM without phenol red (Invitrogen). 
A total of 10 μg of siRNA was transferred to a 4-mm cuvette (Bio-Rad), and 10 × 106 DCs were added in 
200 μL of OptiMEM and incubated for 3 minutes before being pulsed with an exponential decay pulse at 
300 V, 150 μF in a Genepulser Xcell (Bio-Rad) as described previously.33 Immediately after electroporation, 
the cells were transferred to warm (37°C) DC culture medium without AA and supplemented with 1% 
ultra-glutamine, 0,5% antibiotic-antimycotic, 10% (v/v) FCS, IL-4 (300 U/ml), and GM-CSF (450 U/ml). Day 
6 (72 hours after transfection) DCs were stimulated with vehicle, 200 ng/ml LPS, 4 μg/ml R848 (Axxora, 
Raamsdonkveer, The Netherlands) or 20 μg/ml PolyI:C (Sigma Aldrich) for 24 hours. RNA was isolated with 
the Quick-RNA MiniPrep kit (Zymoresearch). Total lysates were prepared 72 hours after transfection, lysing 
50.000 cells in 50 μl 1% SDS lysis buffer containing 1% SDS and 62,5 mM TRIS pH 6,8 plus the protease 
inhibitors 2 μ g/mL leupeptin, 2 μg/mL aprotinin, and 1 mM phenylmethylsulfonyl fluoride. 
ELISA
Cytokines were measured in the supernatants 24 hours after induction of maturation. IL-12p70 
production was measured using a standard sandwich enzyme-linked immunosorbent assay (ELISA; Pierce 
Biotechnology, Etten-Leur, The Netherlands). IL-6 was measured using PeliPair human IL-6 ELISA kit 
(Sanquin, Amsterdam, The Netherlands), TNF was measured using Human TNF ELISA Set (BD Biosciences, 
Breda, The Netherlands), IL-10 was measured using Human IL-10 Module Set (Bender MedSystems, 
Vienna, Austria). Differences in cytokine production were assessed using t tests. Two-sided P	values less 
than .05 were a priori considered to be statistically significant.
Mixed	Leukocyte	Reaction
DCs were electroporated at day 4 of differentiation with siSC or control siRNA and seeded in a 96-well 
plate (50000 cells/well). At day 7 DCs were stimulated with vehicle or 4 μg/ml R848 for 8 hours, after 
which the medium was replaced with fresh DC-medium. At day 8, 24 hours after R848 stimulation, PBLs 
were added to the DCs, in a ratio of 1:1, and co-cultured for 120 hours. After 4 days of co-culture cells were 
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pulsed with [3H]-thymidine for 15 hours, harvested, and [3H]-thymidine incorporation was determined as 
a measure for T-cell proliferation. To analyze the T helper cell profile, supernatants were collected after 2 
days of DC-PBLs coculture. Cytokine production  in the supernatant were analyzed with a human Th1/Th2 
Multiplex kit (eBioscience, Vienna, Austria) according to manufacturer’s instructions.
 
RESULTS
IL-4	induces	DC-SCRIPT	mRNA	expression	in	monocytes
Within the immune system, human DC-SCRIPT mRNA has been found to be preferentially 
expressed by DCs.19 To obtain more insight into the expression characteristics of 
DC-SCRIPT, we investigated DC-SCRIPT mRNA expression during differentiation of 
monocytes into DCs. Hereto, adherent monocytes were cultured in the presence of 
IL-4,34,35 GM-CSF or the combination of both cytokines. Cells were analyzed at different 
time points after start of differentiation. In the absence of cytokines (vehicle) essentially 
no DC-SCRIPT mRNA expression could be detected. In the presence of GM-CSF alone, 
only small amounts of DC-SCRIPT mRNA were discerned. Incubation with IL-4 and 
GM-CSF or IL-4 alone resulted in DC-SCRIPT mRNA expression within 2 hours after the 
start of stimulation, indicating IL-4 as the dominant factor for DC-SCRIPT induction. An 
increase in DC-SCRIPT mRNA levels was observed up to 8 hours after stimulation (figure 
1A). At later time points, DC-SCRIPT mRNA levels decreased somewhat but remained 
stable from day 3 to day 8. DCs matured with LPS demonstrated an increase in mRNA 
expression levels (figure 1B), suggesting a role for DC-SCRIPT in DC maturation.
Figure 1. DC-SCRIPT mRNA expression in moDCs 
(A	and	B)	DC-SCRIPT	mRNA	expression	relative	to	PBGD	mRNA	in	monocytes	as	determined	by	quantitative	
polymerase	chain	reaction.	Monocytes	were	cultured	 in	the	presence	of	vehicle	 (white	bars),	 IL-4	 (light	
grey	bars),	GM-CSF	(dark	grey	bars)	or	IL-4	and	GM-CSF	(black	bars)	and	harvested	at	the	indicated	time	
points.	Day	6	DCs	were	stimulated	with	vehicle	or	LPS	for	48	hours	to	obtain	immature	and	mature	day	8	
DCs,	respectively.	Representative	data	from	1	out	of	3	donors.
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DC-SCRIPT	protein	is	expressed	in	different	DC	subsets	
To confirm endogenous DC-SCRIPT protein expression, cell lysates were prepared 
from monocytes at different time points after the onset of differentiation towards 
DCs. Within 4 hours, DC-SCRIPT protein expression could be observed. Protein levels 
steadily increased during differentiation to DCs and remained constant from day 6 
onwards (Figure 2A). In line with its mRNA expression, DC-SCRIPT protein expression 
is also dependent on IL-4 (data not shown).
 To prove that DC-SCRIPT protein is also present in freshly isolated blood mDCs and 
pDCs, cell lysates were prepared from purified mDCs and compared to total PBMC 
(peripheral blood mononuclear cells). DC-SCRIPT protein could not be detected in 
total PBMCs (figure 2B, lane 1), nor could it be detected in the mDC negative fraction 
(figure 2B, lane 2). However, in the mDC fraction DC-SCRIPT protein expression was 
readily observed (figure 2B, lane 3). Similarly, DC-SCRIPT protein was present in pDCs, 
albeit at lower levels compared to moDCs and mDCs (figure 2C, lane 3). No DC-SCRIPT 
expression could be detected in the total PBL (peripheral blood leukocyte) fraction 
(figure 2C, lane 1) and the pDC negative fraction (figure 2C, lane 2). These data show 
for the first time that DC-SCRIPT is endogenously expressed at protein level in freshly 
isolated mDCs and pDCs.
DC-SCRIPT	sub-cellular	distribution	varies	among	DC	subsets
The localization of endogenous DC-SCRIPT protein in the different subsets of DCs 
was investigated with confocal laser scanning microscopy (CLSM). Hereto, DCs 
were stained with anti-DC-SCRIPT antibodies recognizing the C-terminal part of DC-
SCRIPT. The specificity of the antibody was validated by DC-SCRIPT peptide blocking 
experiments (supplemental figure S1). 
Figure 2. DC-SCRIPT protein expression in moDCs, 
mDCs and pDCs
Proteins	 from	 cell	 lysates	 of	 the	 indicated	 cell	
fractions	 were	 subjected	 to	 immunoblotting	 with	
anti-DC-SCRIPT	antibodies	and	anti-actin	as	loading	
control.	 (A)	Cell	 lysates	of	moDCs	harvested	at	 the	
indicated	 time	 points.	 Day	 6	 DCs	 were	 stimulated	
with	vehicle	or	LPS	for	48	hours	resulting	in	immature	
and	mature	day	8	DCs,	 respectively.	 (B	and	C)	Cell	
lysates	of	the	indicated	fractions	of	an	mDC	(B)	and	
pDC	(C)	isolation	procedure.
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Our data show that DC-SCRIPT is predominantly localized in the nucleus of moDCs, 
and reveal that localization does not change upon maturation of the cells with LPS 
(figure 3A). Some DC-SCRIPT expression could be discerned in the cytoplasm. In fresh 
mDCs, DC-SCRIPT localization is also most pronounced in the nucleus of the cells. 
In pDCs, expression levels of DC-SCRIPT were apparently lower compared to mDC 
and moDC subsets. DC-SCRIPT staining could be found in both the cytoplasm and 
nucleus of pDCs, depending on the donor. Quantification of DC-SCRIPT expression in 
the nucleus and the cytoplasm was used to confirm localization differences between 
pDC donors, and between mDCs and pDCs. Between pDC donors the nucleus to 
cytoplasm (N/C) ratio varied between 1,1 and 2,4 (mean: 1,5 +/- 0,59) In contrast, 
mDCs displayed a N/C ratio of 2,5, whereas moDCs showed an average ratio of 3. The 
variation in N/C ratio within pDCs and mDCs from a single donor was minimal. These 
data show that the DC-SCRIPT localization is predominantly nuclear in moDCs and 
mDCs, while in pDCs a more pronounced cytoplasmic DC-SCRIPT staining is observed 
that varies between different pDC donors. 
 To further confirm DC-SCRIPT protein expression in DCs in immunological tissue, 
frozen tonsil sections were analyzed for DC-SCRIPT expression. The presence of DCs 
was confirmed by staining the consecutive section with the DC marker DC-SIGN (figure 
3B). As expected, DCs with myeloid appearance were mainly present in the T-cell 
area in between the germinal centers, as shown by the DC-SIGN staining. The area 
in which DC-SCRIPT positive cells were found overlapped with the area containing 
DC-SIGN, a previously defined marker for myeloid DCs.36 Furthermore, also DC-
SCRIPT expression was observed in cells with myeloid DC morphology located in the 
T-cell area, further substantiating its protein expression in mDCs. In situ, DC-SCRIPT 
expression in the observed myeloid DCs appeared to be mostly confined to the 
nucleus. The low expression levels of DC-SCRIPT in pDCs, and their low abundance in 
lymph nodes, did not allow proper assessment of pDCs with this approach. 
Figure S1. Validation of the goat-anti-DC-
SCRIPT antibody
CLSM	validation	of	the	anti-DC-SCRIPT	antibody	
using	a	recombinant	human	DC-SCRIPT	peptide	
(rh-DC-SCRIPT).	 This	 peptide	 represents	 the	
epitope	 for	 the	 anti-DC-SCRIPT	 antibody.	
Mouse-anti-GR	 antibody	 was	 used	 as	 control.	
Cells	were	stained	with	goat-anti-DC-SCRIPT	or	
mouse-anti-GR	 pre-incubated	 with	 vehicle	 or	
rh-DC-SCRIPT.
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Figure 3. DC-SCRIPT localization in different DC subsets
CLSM	analysis	of	DC-SCRIPT	expression	in	different	DC	subsets.	DC-SCRIPT	in	immature	and	mature	DCs	
(A)	or	pDCs	was	stained	with	a	goat-anti-DC-SCRIPT	(green),	the	nucleus	was	visualized	by	staining	with	
DAPI	(blue).	DC-SCRIPT	in	myeloid	DCs	was	stained	with	a	goat-anti-DC-SCRIPT	(green),	the	nucleus	was	
visualized	by	staining	with	PI	(red)	The	scale	bar	represents	10	µm.	(B)	Immunohistochemistry	staining	of	
DC-SIGN	and	DC-SCRIPT	in	frozen	tonsil	sections.	Cells	were	counterstained	with	hematoxiline	to	visualize	
the nuclei.
DC-SCRIPT:	DC	marker	and	regulator	of	TLR	induced	cytokine	production
57
DC-SCRIPT	knock-down	affects	IL-10	secretion	by	moDCs
DC-SCRIPT mRNA and protein is expressed during the complete lifecycle of moDCs, 
including in mature DCs. To investigate its function in DC maturation, DC-SCRIPT was 
silenced using a siRNA oligo (siSC) targeting the acidic region of the DC-SCRIPT gene 
at position 2349-2369. DCs treated with non-targeting siRNA oligos as well as non-
treated DCs were used for comparison. Subsequently, immature DCs were stimulated 
for 24 hours with ligands for TLR4, -7/8 and -3, respectively LPS, R848 and PolyI:C. 
Our data demonstrate an efficient knock-down of DC-SCRIPT protein expression 
in siSC treated DCs at day 6 of differentiation prior to stimulation, but not control 
siRNA-treated and non-treated DCs (figure 4A). 
The effect of DC-SCRIPT knock-down on DC maturation was examined by 
investigating cell surface maturation marker expression and cytokine secretion in the 
supernatant, at respectively 48 hours and 24 hours after stimulation. As expected, 
non-electroporated DCs markedly increased expression of both maturation markers 
CD80 and CD83 upon TLR stimulation (figure 4B). DCs electroporated with siSC or 
irrelevant siRNA (control) also enhanced CD80 and CD83 expression upon activation, 
at equal intensities. Relative to untreated DCs, electroporated DCs showed some 
disparity in CD83 expression upon LPS stimulation, possibly due to the variable 
maturation effects by LPS. 
 DC maturation was also qualified by analyzing cytokine secretion (figure 4C). 
Secretion of the pro-inflammatory cytokines IL-6 and TNF by non-stimulated DCs 
electroporated or not, could not be detected, in agreement with their immature 
status. Stimulation with TLR ligands differentially induced IL-6 and TNF secretion, 
with highest levels found upon R848 treatment, and lowest levels after PolyI:C 
stimulation. Both electroporated and not electroporated DCs secreted equal amounts 
of IL-6 and TNF. No significant effect of DC-SCRIPT silencing was detected relative to 
control siRNA treated and non-treated DCs. Variation after LPS treatment, was again 
detected between donors. In line with the absence of pro-inflammatory cytokine 
expression, also secretion of the anti-inflammatory cytokine IL-10 was minimal in all 
conditions in immature DCs. As expected, TLR mediated maturation did induce only a 
minimal amount of IL-10 expression in both siRNA control DCs and non-treated DCs. 
Surprisingly, DCs electroporated with siSC displayed a significant increase in IL-10 
secretion after treatment with LPS or R848. Little or no effect of DC-SCRIPT silencing 
could be detected upon PolyI:C stimulation. Hence, these data demonstrate that DC-
SCRIPT expression in DCs is important for repression of IL-10 secretion during TLR4 
and -7/8 induced maturation. 
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Figure 4. Cytokine secretion by DC-SCRIPT knock-down moDCs
Day	4	moDCs	were	not	electroporated	(non-treated),	or	electroporated	with	control	siRNA	or	siSC	oligos.	
At	day	6,	vehicle,	LPS,	R848	or	PolyI:C	were	used	to	mature	the	DCs.	(A)	DC-SCRIPT	expression	at	day	6,	prior	
to	stimulation,	was	analyzed	by	western	blot	analysis.	DC-SCRIPT	was	visualized	by	immunoblotting	with	
anti-DC-SCRIPT	and	anti-actin	as	a	loading	control.	Maturation	of	non-treated	DCs	(white	bars),	control	
siRNA	treated	DCs	(grey	bars)	and	siSC	treated	DCs	(black	bars)	was	analyzed	by	measuring	maturation	
markers	CD80	and	CD83	by	means	of	FACS	(B)	and	secretion	of	IL-6,	TNF	and	IL-10	in	the	supernatant	by	
means	of	ELISA	(C),	respectively	48	hours	and	24	hours	after	stimulation.	Data	from	at	least	3	donors.	Error	
bars	correspond	to	+/-	SEM.
Increased	IL-10	secretion	in	siSC	DCs	impairs	IL-12	secretion
The anti-inflammatory cytokine IL-10 is known to impair DC maturation, including 
IL-12production.2 To gain more insight into the kinetics of cytokine production in 
siRNA control and DC-SCRIPT knock-down DCs, cytokine mRNA and protein levels 
were monitored in time. To this end, IL-6, TNF, IL-12 and IL-10 mRNA and protein 
expression of control siRNA or siSC electroporated DCs was measured at 0-, 2-, 4-, 
8-, 16- and 24 hours after R848 stimulation (figure 5). Both siSC and control siRNA 
treated cells demonstrated maximum mRNA expression between 2 and 16 hours 
for all cytokines, which decreased at later time points. Maximum levels of IL-6 and 
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TNF expression were detected 4 hours after stimulation, whereas IL-12p35 and IL-
10 mRNA expression peaked at 8 hours. The protein expression of IL-6, TNF and IL-
10 followed the mRNA expression kinetics, reaching maximum levels at later time 
points, after which expression remained relatively stable. When comparing control 
siRNA and siSC treated DCs, no effect was found for IL-6 or TNF secretion. In contrast, 
siSC and control siRNA DCs differed greatly in the expression of IL-10 and IL-12. 
In addition to the increase in IL-10 production, IL-12 production was significantly 
impaired at both the mRNA and the protein level in siSC DCs. The impaired IL-12 
expression observed in siSC DCs was preceded by the increased IL-10 secretion, 
suggesting a role for IL-10 in reducing IL-12 levels in siSC DCs. 
IL-10	silencing	rescues	IL-12	secretion	in	DC-SCRIPT	knock-down	DCs
In order to confirm the role of enhanced IL-10 secretion on the expression of IL-
12, both DC-SCRIPT and IL-10 expression were silenced. To this end, DCs were 
electroporated with either control siRNA, siSC with control siRNA or siSC with IL-10 
targeting siRNA (siIL-10). 
Figure 5. Kinetics of cytokine 
expression 
Day	4	moDCs	were	electroporated	with	
control	 siRNA	 (black)	 or	 siSC	 oligos	
(grey).	 At	 day	 6	 DCs	 were	 stimulated	
with	 vehicle	 or	 R848.	Messenger	 RNA	
and	 protein	 were	 measured	 at	 the	
indicated	 time	 points	 for	 IL-10,	 IL-12,	
IL-6	 and	 TNF	 expression	 by	 means	
of	 Q-PCR	 and	 ELISA,	 respectively.	
Representative	 data	 from	 1	 out	 of	 3	
donors.
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Day 6 DCs were stimulated with R848 for 24h after which cytokine production was 
measured in the supernatant. As an additional control, untreated DCs stimulated 
with R848 received 106 U/ml IL-10 or vehicle 4 hours after R848 stimulation, in order 
to mimic the enhanced IL-10 secretion in siSC DCs.
 Again, efficient knock-down of DC-SCRIPT protein expression was detected in all 
conditions electroporated with siSC prior to stimulation (figure 6A). IL-10 protein 
expression in the supernatant was measured at both 8 hours (data not shown) and 
24 hours after stimulation and demonstrated efficient IL-10 silencing at both time 
points. DC-SCRIPT knock-down DC again showed decreased IL-12 secretion upon 
R848 simulation. Likewise, addition of recombinant IL-10 to untreated DCs stimulated 
with R848 resulted in a significant (p=.011) reduction in IL-12 secretion (figure 6B). 
Silencing of both DC-SCRIPT and IL-10, however, resulted in normal IL-12 protein 
levels, confirming that IL-10 signaling mediates down-regulation of IL-12 secretion 
in siSC DCs (figure 6C). In line with previous results, no effect was detected on IL-6 
and TNF secretion, suggesting that the enhanced IL-10 production specifically affects 
IL-12 expression in these cells. 
DC-SCRIPT	knock-down	impairs	T-cell	responses
Next, we investigated the biological consequences of DC-SCRIPT silencing on DC-
mediated T-cell responses in an allogeneic Mixed Leukocyte Reaction (MLR). 
Figure 6. Cytokine secretion by moDCs with silenced DC-SCRIPT and IL-10 expression
Day	4	moDCs	were	electroporated	with	control	siRNA,	siSC	+	control	siRNA	or	siSC	+	siIL-10	oligos.	At	day	
6	DCs	were	stimulated	with	vehicle	or	R848.	(A)	Western	blot	analysis	of	DC-SCRIPT	expression	at	day	6,	
prior	to	stimulation.	DC-SCRIPT	was	visualized	by	immunoblotting	with	anti-DC-SCRIPT	and	anti-actin	as	
a	loading	control.	(B)	Day	6	immature	DCs	were	stimulated	with	R848,	or	not,	and	treated	with	vehicle	or	
IL-10	4	hours	after	R848.	IL-12,	IL-6	and	TNF	secretion	in	the	supernatant	was	measured	24	hours	after	
R848	by	means	of	ELISA.	Data	from	5	donors.	Error	bars	correspond	to	+/-	SEM.	(C)	Analysis	of	IL-10,	IL-12,	
IL-6	and	TNF	secretion	in	the	supernatant	of	control	siRNA	DCs	(white	bars),	siSC	+	control	siRNA	DCs	(grey	
bars)	and	siSC	+	siIL-10	DCs	(black	bars),	24	hours	after	stimulation,	by	means	of	ELISA.	Data	from	at	least	
3	donors.	Error	bars	correspond	to	+/-	SEM.
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SiSC or control siRNA electroporated DCs were stimulated at day 7 with vehicle or 
R848 for 8 hours, after which the medium was replaced with fresh DC-medium. 
Twenty-four hours after stimulation, PBLs were added and both T-cell proliferation 
and cytokine secretion were determined as a measure of T-cell activation. As shown 
(figure 7A), T-cell proliferation was readily detected upon stimulation with control 
siRNA treated DCs and was significantly impaired after stimulation with siSC treated 
DCs. The effect of R848 stimulation on T cell proliferation was limited, possibly 
reflecting the overall immune activation at these allogeneic conditions. 
Figure 7. DC-SCRIPT knock-down affects T-cell activation
Effect	 of	 DC-SCRIPT	 silencing	 on	 T-cell	 proliferation	 (A)	 and	 IFNγ	 secretion	 (B)	 in	 an	 allogeneic	 mixed	
leukocyte	reaction	(MLR).	Day	4	moDCs	were	electroporated	with	control	siRNA	or	siSC	oligos.	At	day	7	
DCs	were	stimulated	with	vehicle	or	R848	for	8	hours.	Day	8	DCs	were	co-cultured	with	PBLs	in	a	ratio	of	
1:1.	Data	from	at	least	3	donors.	Error	bars	correspond	to	+/-	SEM.	Data	indicated	with	N.D.	(not	detected)	
were	below	the	detection	limit.
In contrast to T cell proliferation, IFNγ secretion by T-cells in these co-cultures was 
largely dependent on the presence of R848 (figure 7B). Strikingly, DC-SCRIPT silenced 
DCs showed an impaired capacity to induce IFNγ secretion by T-cells relative to 
control siRNA silenced DCs. No significant differences were detected for the pro-
inflammatory cytokine levels of IL-6 and TNF between control and siSC treated DCs 
in these co-cultures (supplemental figure S2). Collectively, these data strengthen 
the finding that DC-SCRIPT plays an important role during DC maturation and the 
induction of T cell responses.
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Figure S2. DC-SCRIPT knock-down does 
not affect IL-6 and TNF secretion in a 
MLR
Effect	 of	 DC-SCRIPT	 silencing	 on	 IL-6	
and	 TNF	 secretion	 in	 an	 allogeneic	
mixed	 leukocyte	 reaction	 (MLR).	 Day	 4	
moDCs	were	electroporated	with	control	
siRNA	or	 siSC	oligos.	At	day	7	DCs	were	
stimulated	 with	 vehicle	 (not	 shown)	 or	
R848	 for	 8	 hours.	 Day	 8	 DCs	 were	 co-
cultured	with	PBLs	in	a	ratio	of	1:1.	Data	from	3	donors.	Error	bars	correspond	to	+/-	SEM.	Data	indicated	
with	N.S.	(not	significant)	did	not	meet	the	criteria	in	the	t	test	to	be	considered	statistically	significant.
DISCUSSION
Previously, we have isolated and characterized the cDNA encoding the transcription 
regulator DC-SCRIPT19,23 that is preferentially expressed in DCs within the immune 
system. In the present study, DC-SCRIPT mRNA and protein expression were found to 
be induced early in DC differentiation and were dependent on IL-4. 
 Silencing of DC-SCRIPT expression affected DC maturation and induced IL-10 
secretion in mature DCs, whichconsequently impaired IL-12 secretion by these cells. 
Furthermore, DC-SCRIPT silenced DCs were shown to have a significantly impaired 
capacity to induce T-cell proliferation and IFNγ responses. Hence, DC-SCRIPT appears 
to be an important factor in regulating DC maturation.
 In human moDCs, DC-SCRIPT expression was dependent on the presence of 
IL-4. Control experiments demonstrated no DC-SCRIPT expression in PBLs upon 
IL-4 stimulation (data not shown). In addition, although in	 vivo studies previously 
demonstrated DC-SCRIPT expression in breast epithelial cells,20 IL-4 stimulation of 
the DC-SCRIPT negative MCF-7 breast carcinoma cells did not induce DC-SCRIPT 
expression (data not shown). These data therefore suggest that the IL-4 mediated 
induction of DC-SCRIPT is related to the differentiation of monocytes to DCs. It is 
therefore important to further deduce the expression and function of DC-SCRIPT in 
the DC differentiation process itself.
 Next to moDCs, DC-SCRIPT expression was readily detected in mDCs and pDCs. 
Previous reports demonstrated DC-SCRIPT mRNA expression in all DC subsets tested, 
including LCs, mDCs and pDCs.19 Here we show, for the first time, endogenous DC-
SCRIPT protein expression in both mDCs and pDCs. Moreover, in	 vivo	DC-SCRIPT 
expression was observed in DCs present in T-cell areas of tonsil tissue. In IHC- and 
CLSM slides DC-SCRIPT is predominantly localized in the nucleus of moDCs and mDCs, 
concomitant with the presence of a nuclear localization motif. Interestingly, some 
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expression was also detected in the cytoplasm of moDCs and mDCs. This was even 
more pronounced in pDCs, however, it must be noted that expression is lower and 
that variations between donors were observed for this subset. In addition, our recent 
work demonstrated a predominant cytoplasmic expression of DC-SCRIPT in breast 
epithelial cells.20 This suggests that DC-SCRIPT might also have important functions 
outside the nucleus.
 Further insight into the cytoplasmic expression of DC-SCRIPT might be gained 
from the NR biology. In a previous publication we have characterized DC-SCRIPT 
as a NR co-regulator.20 NRs and many of their co-regulators are found both in the 
nucleus as well as in the cytoplasm. The type I NRs are classically sequestered in 
the cytoplasm, and translocate to the nucleus upon ligand binding, where they 
bind to specific DNA sequences.26,37-40 NR function is controlled by NR co-regulators, 
such as N-CoR and SMRT. Recent evidence suggests shuttling of these co-regulators 
between the nucleus and cytoplasm, triggered by changes in signaling at the cell 
surface.41 Further research is necessary to fully elucidate the pattern and dynamics 
of DC-SCRIPT expression in different DC subsets. Investigating the effects of various 
extracellular signals, such as NR ligands, will provide more insight into the DC-SCRIPT 
localization characteristics in DCs.
 In addition, our data uncovered an important role for DC-SCRIPT in DC maturation. 
DCs with silenced DC-SCRIPT expression displayed enhanced IL-10 and decreased 
IL-12 cytokine production upon maturation. Silencing IL-10 expression rescued the 
IL-12 secretion in DC-SCRIPT knock-down DCs, suggesting that DC-SCRIPT primarily 
affects the expression of IL-10. No effect was detected on IL-6 and TNF secretion, or 
after PolyI:C maturation. Interestingly, TLR4 and -7/8 signal via the adaptor protein 
MyD88, whereas TLR3 activates TRIF mediated signaling,42 suggesting that DC-SCRIPT 
primarily functions in the MyD88 pathway. Functionally, DC-SCRIPT silenced DCs are 
less capable of inducing T-cell proliferation and IFNγ secretion in a co-culture with 
allogeneic PBLs. 
Unraveling the underlying molecular mechanisms by which DC-SCRIPT can regulate 
IL-10 expression in DCs will be an important next step. In DCs, IL-10 transcription 
is induced through NF-κB activation.43 One way of enhanced and prolonged IL-10 
transcription is NF-κB acetylation.44 It would therefore be of great interest to see 
whether, and how DC-SCRIPT is involved in NF-κB acytylation. Furthermore, besides 
immunostimulatory DCs, future studies on DC-SCRIPT expression and function 
should also include tolerogenic DCs (tolDCs). These immunosuppressive DCs are 
known to secrete elevated levels of IL-10, while having diminished IL-12 secretion, 
thereby preventing T-cell proliferation.45 Studying tolDCs is even more interesting as 
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we have recently found that DC-SCRIPT also affects the function of the Glucocorticoid 
Receptor (GR) (Hontelez et al., submitted). GR is well known for its central role in the 
generation of tolerogenic DCs, and known to induce IL-10 production. Moreover, the 
IL-10 promoter contains a Glucocorticoid Responsive Element (GRE), that could serve 
as a binding site for GR to stimulate IL-10 transcription.46,47 
DCs are in the centre of the immune system, controlling the type and course of an 
immune response. They regulate both innate and adaptive immunity and serve as a 
bridge between both systems. Therefore, DCs are regularly used in immunotherapy. 
Detailed understanding of DC differentiation and maturation will allow for the 
generation of the best suitable DC for these therapies. Collectively, our data provide 
important insight in the DC biology, highlighting DC-SCRIPT as an essential factor in 
DC maturation.
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ABSTRACT
Dendritic cells (DCs) play a central role in the immune system; they can induce immunity 
or tolerance depending on diverse factors in the DC environment. Pathogens, but 
also tissue damage, hormones and vitamins affect DC activation and maturation. In 
particular glucocorticoids (GCs) are known for their immunosuppressive effect on 
DCs, creating tolerogenic DCs (tolDCs). GCs activate the Type I Nuclear Receptor (NR) 
Glucocorticoid Receptor (GR), followed by induced expression of the transcription 
factor GILZ (Glucocorticoid Inducible Leucine Zipper). GILZ has been shown to be 
necessary and sufficient for GC induced tolDC generation. Recently, we have identified 
the dendritic cell specific transcript (DC-SCRIPT) as a NR co-regulator, suppressing 
type I steroid NRs ER (estrogen receptor) and PR (progesterone receptor). Here, we 
analyzed the effect of DC-SCRIPT on GR activity. We demonstrate that DC-SCRIPT co-
exists with GR in protein complexes, and functions as a co-repressor of GR mediated 
transcription. Co-expression of DC-SCRIPT and GR is shown in human monocyte 
derived DCs, and DC-SCRIPT knock-down enhances GR dependent up-regulation of 
GILZ mRNA expression in DCs. This demonstrates that DC-SCRIPT serves an important 
role in regulating GR function in DCs, corepressing GR dependent up-regulation of 
the tolerance inducing transcription factor GILZ. These data imply that by controlling 
GR function and GILZ expression, DC-SCRIPT is potentially involved in the balance 
between tolerance and immunity.
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INTRODUCTION
Dendritic cell (DC) maturation occurs upon pathogen recognition and inflammation 
in the peripheral tissue, and involves up-regulation of co-stimulatory molecules and 
inflammatory cytokine secretion. Fully matured DCs migrate to T-cell areas in the 
lymph nodes, inducing T-cell activation.1 In addition, DCs can also be activated to 
become tolerogenic, suppressing inflammation. Both human and murine studies 
demonstrated that this process involves impaired DC activation, which can be 
triggered by ligand dependent activation of the Glucocorticoid Receptor (GR) prior 
to pathogen recognition. Glucocorticoid (GC) treated DCs displayed suppressed 
MHC-I restricted antigen presentation,2,3 impaired up-regulation of co-stimulatory 
molecules4,5 and reduced secretion of pro-inflammatory cytokines. Secretion of 
immunosuppressive cytokines was enhanced in these cells.5-7 Collectively, these 
effects result in altered DC mediated T-cell activation, with reduced Th1 responses 
and selective expansion of T regulatory cells.8,9 This does not only apply to monocyte 
derived DCs (moDCs), also myeloid DCs (MDCs)10 and plasmacytoid DCs (PDCs)11 have 
been shown to become tolerogenic following GC exposure. 
 The immunosuppressive effects of GCs are typically mediated by GR, a Type I 
Nuclear Receptor. The ligand-free form of GR predominantly resides in the cytoplasm, 
complexed to chaperone proteins. Conformational changes through ligand binding 
release GR from the chaperone complex, allowing for nuclear translocation and 
transcription initiation.12
 The human GR is encoded by a single gene, and is expressed in virtually all cell 
types. Various GR isoforms have been described, and tissue specific effects are 
currently attributed to variation in GR isoform expression.13-15 GR pre-mRNA can be 
alternatively spliced generating the transcriptional active GRα and the repressor 
GRβ, differing in sequence only at the C-terminus ligand binding domain (LBD). In 
contrast to GRα, GRβ expression is confined to the nucleus, where it antagonizes GRα 
dependent gene transcription.16 Additionally, translation reinitiation occurs at seven 
AUG-start sites at the mRNA 5’-end, generating 8 different GR polypeptides. These 
isoforms, termed GR-A, -B, -C1, -C2, -C3, -D1, -D2 and -D3, differ in length at the 
N-terminus and in glucocorticoid responsiveness, differentially affecting target gene 
expression. The GR-A, -B and -C isoforms are localized in the cytoplasm, translocating 
to the nucleus upon ligand binding where they initiate target gene transcription. In 
contrast, GR-D isoforms are, independent of ligand binding, confined to the nucleus, 
and have markedly lower transcriptional activity.14 
 Recently, we have identified DC-SCRIPT (DC-Specific transcript) as a transcription 
factor and a NR co-regulator in human breast and prostate carcinoma tissue. DC-
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SCRIPT was found to be present in Type I and Type II NR protein complexes, repressing 
Type I NRs ER, PR or AR (androgen receptor) mediated transcription, while enhancing 
Type II NRs RARα/RXR, VDR/RXR or PPARγ/RXR function.17-20 In the immune system 
DC-SCRIPT is specifically expressed in DCs, and in contrast to other DC markers, 
identifies all DC-subsets tested to date.21,22 Interestingly, we have demonstrated 
an important role for DC-SCRIPT in TLR4 and TLR7/8 mediated DC maturation. DC-
SCRIPT knock-down in moDCs increased secretion of the anti-inflammatory cytokine 
IL-10, which subsequently impaired both the production of the pro-inflammatory 
cytokine IL-12, as well as T-cell proliferation.23 Here, we investigated the putative role 
of DC-SCRIPT in controlling the anti-inflammatory function of GR in moDCs. Our data 
show the presence of DC-SCRIPT in GR protein complexes, and demonstrate altered 
GR mediated transcription in the presence and absence of DC-SCRIPT. Our findings 
therefore suggest active regulation of GR function by DC-SCRIPT in DCs.
MATERIAL & METHODS
Cell	lines
Human embryonic kidney 293 (HEK293) cells were cultured in DMEM containing GlutaMAX (Invitrogen, 
Breda, the Netherlands) supplemented with 10% heat-inactivated FCS (Greiner Bio-one, Alphen a/d Rijn, 
the Netherlands), 1% nonessential amino acids (Invitrogen), and 0.5% antibiotic–antimycotic (Invitrogen). 
Human hepatocellular carcinoma Hep3B cells were cultured in IMDM (Invitrogen) supplemented with 10% 
heat-inactivated FCS and 0,5% antibiotic-antimycotic (Invitrogen).
Generation	of	human	Dendritic	Cells
Human moDCs were generated from PBMCs as described previously.24 Monocytes were derived from 
buffy coats. Plastic-adherent monocytes were cultured for 6 days in DCs culture medium (Phenolred free 
RPMI-1640 medium (Life Technologies, Breda, The Netherlands) supplemented with 1% ultra-glutamine 
(Cambrex, Wiesbaden, Germany), 0,5% antibiotic-antimycotic (Invitrogen, Breda, The Netherlands), 10% 
(v/v) FCS (Greiner, Kremsmuenster, Austria), IL-4 (300 U/ml), and GM-CSF (450 U/ml) both from cellgenix). 
During day 3 moDCs were supplemented with new IL-4 (300 U/ml) and GM-CSF (450 U/ml). Mature 
moDCs were generated from day 6 immature moDCs through 24 hr stimulation with vehicle followed by 
24 hour stimulation with 200 ng/ml LPS (InvivoGen, Toulouse, France). Tolerogenic moDCs were generated 
from day 6 immature moDCs through 24 hour stimulation with 100 nM Dexamethasone and subsequent 
24 hours with 200 ng/ml LPS. DC maturation was ensured by FACS staining.
Confocal	Laser	Scanning	Microscopy
Round ø 12 mm cover slides (Thermo Scientific, Braunschweig, Germany) were coated with Poly-L-Lysine 
(Sigma Aldrich, Zwijndrecht, the Netherlands). Immature, mature and tolerogenic moDCs were seeded 
on cover slides (50.000 cell/slide) and adhered for 2 hours in serum free, phenolred free RPMI-1640 
supplemented with 1% ultra-glutamine, 0,5% antibiotic-antimycotic, IL-4 (300 U/ml) and GM-CSF (450 
U/ml). DCs were stimulated for 1 hour with 100 nM Dexamethasone or vehicle. DCs were fixed using 
1% paraformaldehyde extra pure DAC 1 (Merck, Haarlem, The Netherlands) in phosphate-buffered 
saline (PBS) for 15 min at RT. DCs were permeabilized with 100% ice cold Methanol (Boom, Meppel, The 
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Netherlands) for 5 minutes at 4oC, washed with PBS, blocked for 1 hour with 3% BSA (Roche, Woerden, 
The Netherlands) and 1% Normal Donkey Serum (Sigma Aldrich) in PBS, stained 1 hour with 2,5 μg/ml 
(moDCs) Goat-anti-human DC-SCRIPT (R&D Systems, Abingdon, UK) and 2,5 μg/ml (moDCs) Mouse-anti-
human GR (Abcam, Cambridge, UK) and 1 hour with 1/400 Alexa Fluor 488 Donkey-anti-Goat IgG and 
1/400 Alexa Fluor 647 Rabbit-anti-Mouse IgG (Invitrogen). The nucleus was stained 5 minutes with 0,3 
μg/ml DAPI (Sigma Aldrich), washed with PBS and mounted on 76 x 26 mm microscope slide (Thermo 
Scientific) with mowiol + 2,5% azide (Calbiochem, San Diego, US). Confocal laser scanning microscopy 
(CLSM) was carried out with an Olympus FV1000 Confocal Laser Scanning Microscope with an Argon (457, 
488, 515nm), and 405, 559 and 635 diode lasers at the Microscopic Imaging Facility of the Department of 
Cell Biology, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, 
Nijmegen, The Netherlands.
Plasmids
The nuclear receptor isoforms GR, GR-C3 and GR-D3 (National Center for Biotechnology Information 
accession number) (NM_001018077) were isolated and cloned into pHA-n3 (described previously in,18 
generating pHA-n3/GR, pHA-n3/GR-C3, pHA-n3/GR-D3). The vectors pCATCH and pCATCH-DCSCRIPT were 
described previously.22 pCATCH-DCSCRIPT was used to generate pCATCH-DCSCRIPTΔCtBPdm and pCATCH-
DCSCRIPTΔLxxLL. The transcription reporter plasmid pMMTV-luc containing the mouse mammary tumor 
virus (MMTV) promoter was kindly provided by Prof. Dr. H. Stunnenberg (Department of Molecular Biology, 
Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen, Nijmegen, the Netherlands). 
pMMTV-luc was used to generate pMMTVΔ-luc and pMMTVΔNF-I/Oct1-luc. pGRE-luc (Stratagene, La 
Jolla, United States) was used to generate pHRE1-luc, pHRE2-luc, pHRE3-luc and pHRE4-luc.
Co-Immunoprecipitation	assay
Hek293 cells were seeded in 10 cm culture dish (6.106 cells per dish) 24 prior to transfection. Cells were 
cotransfected with 5 μg pCATCH-DC-SCRIPT or pCATCH (control) and 5μg pHA-n3/GRα or pHA-n3 (control) 
by using Metafectene transfection reagent (Biontex, Martinsried/Planegg, Germany) according to the 
manufacturer’s protocol. Cells were lysed 24 hours after transfection, in immunoprecipitation assay buffer 
(50 mM NaCl, 1% Triton X-100, 0.1% sodium dodecyl sulfate, 50 mM Tris – HCl [pH 7.5], 5 mM EDTA, and 
0.5% sodium-deoxycholate) containing the protease inhibitors 2 μg/mL leupeptin (Sigma Aldrich), 2 μg/mL 
aprotinin (Roche, Woerden, the Netherlands), and 1 mM phenylmethylsulfonyl fluoride (Sigma Aldrich). 
Cell lysates were used for immunoprecipitation (IP) of DC-SCRIPT using anti-DC-SCRIPT-coupled dynabeads 
(GE Healthcare, Hoevelaken, The Netherlands) according to the manufacturer’s protocol. Isotype-coupled-
dyna-beads were used as a control.
Western	Blotting
Proteins were subjected to electrophoresis on an 8% 37.5:1 acryl/Bisacrylamide gel and transferred onto 
Protan nitrocellulose transfer membranes (Schleicher and Schuell) for 1 hour at 100 V at 4°C. Blots were 
blocked in 1%Elk/3%BSA in Phosphate-buffered saline with 0.01% Tween (PBST). DC-SCRIPT was detected 
with anti-DC-SCRIPT (R&D, 1,2 μg/ml) and IRDye 680CW donkey-anti-goat IgG (1:5000 Li-cor biosciences) 
as secondary antibody. GR was detected with a rat anti-HA (1:1000, 3F10, Roche) and IRDye 800CW goat-
anti-rat IgG (1:5000 Li-cor biosciences), or Anti-Glucocorticoid Receptor antibody [3D5] (Abcam, 200 μg/μl, 
1:80) and IRDye 680CW goat-anti-mouse IgG (1:5000 Li-cor biosciences)as secondary antibody. Blots were 
probed with a mouse-anti-β-actin (1:20.000, Roche Applied Science) or rabbit-anti-actin (Sigma Aldrich) 
and IRDye 680CW donkey-anti-mouse IgG or goat-anti-rabbit (1:5000 Li-cor biosciences) as secondary 
antibody, as loading control. After staining, the membranes were scanned using the Odyssey™ Infrared 
Imaging system visualize the labeled proteins.
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Luciferase	transcription	assay
Hep3b cells were plated (6.104) in 24-wells plates 8 hours before transfection and transfected using the 
Calcium Phosphate precipitation method (Invitrogen). HEK293 cells were plated at (1.105) in 24-wells 
plates 24 hours before transfection and transfected using metafectene. Transfected cells were stimulated 
with 100 nM dexamethasone, 100 nM Prednisolone or vehicle for 24 h. Cells were harvested 24 hours 
after stimulation and cell lysates were analyzed for luminescence according to manufacturer’s protocol 
(Dual-Luciferase® Reporter assay, Promega) using a Victor3 luminometer (PerkinElmer). Relative light 
units (RLU) were calculated after correction for transfection efficiency based on the activity of the co-
transfected pRL-SV40 (Promega). The data are expressed as the mean activity of at least four independent 
experiments +/-s.e.
DC-SCRIPT	knock-down
Human moDCs day 4 were electroporated with a 23 nucleotide Custom ZNF366 siRNA termed siSC 
targeting the DC-SCRIPT gene at position 2349-2369 (Dharmacon, Lafayette, Colorado, US) or the irrelevant 
siRNA ON-TARGETplus Non-Targeting siRNA#1 (Dharmacon) termed control. Cells were washed twice in 
PBS and once in OptiMEM without phenol red (Invitrogen). A total of 10 μg of siRNA was transferred to a 
4-mm cuvette (Bio-Rad), and 10 × 106 DCs were added in 200 μL of OptiMEM and incubated for 3 minutes 
before being pulsed with an exponential decay pulse at 300 V, 150 μF in a Genepulser Xcell (Bio-Rad) 
as described previously.25 Immediately after electroporation, the cells were transferred to warm (37°C) 
DC culture medium without AA and supplemented with 1% ultra-glutamine, 0,5% antibiotic-antimycotic, 
10% (v/v) FCS, IL-4 (300 U/ml), and GM-CSF (450 U/ml). Day 6 (72 hours after transfection) DCs were 
stimulated with vehicle or 100 nM RU-486 (Sigma Aldrich), for 1 hour and subsequently with vehicle or 
100 nM Prednisolone for 24 hours. RNA was isolated with the Quick-RNA MiniPrep kit (Zymoresearch). 
Total lysates were prepared 72 hours after transfection, lysing 50000 cells in 50 μl 1% SDS lysis buffer 
containing 1% SDS and 62,5 mM TRIS pH 6,8 plus the protease inhibitors 2 μ g/mL leupeptin, 2 μ g/mL 
aprotinin, and 1 mM phenylmethylsulfonyl fluoride.
RNA	isolation	and	quantitative	PCR
Total RNA was isolated from cells using an RNA isolation kit (Zymo research).RNA quantity and purity 
were determined on a NanoDrop spectrophotometer. Total RNA was DNase-I (amplification grade; 
Invitrogen) treated and cDNA was synthesized using random hexamers and Moloney murine leukemia 
virus reverse transcriptase (Invitrogen). mRNA levels for the genes of interest were determined 
with a CFX96 sequence detection system (Bio-Rad, Veenendaal, The Netherlands) with SYBR Green 
(Roche, Woerden, The Netherlands) as the fluorophore and gene specific oligonucleotide primers. 
The primers for DC-SCRIPT and PBGD were described previously.18 Other used primers (forward, 
reverse): GR (5’- CCATTGTCAAGAGGGAAGGAAAC-’3, 5’- ATGATTTCAGCTAACATCTCGGG-’3), GILZ 
(5’-AGAACCTCAATACCGACAAG-’3, 5’- CATCAGATGATTCTTCACCA-’3). Reaction mixtures and program 
conditions were used that were recommended by the manufacturer (Bio-rad). Quantitative PCR data were 
analyzed with CFX Manager V1.6.541.1028 software (Biorad) and checked for correct amplification and 
dissociation of the products. As a reference gene the housekeeping gene porphobilinogen deaminase 
(PBGD) was used. DC-SCRIPT and GILZ levels relative to PBGD were calculated calculated according to the 
cycle threshold method.26 Differences in mRNA expression were assessed using t tests. Two-sided P	values 
less than .05 were a priori for samples to be considered statistically significant.
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RESULTS
DC-SCRIPT	co-immunoprecipitates	GR
DC-SCRIPT was previously shown to be present in protein complexes containing type I 
and/or type II NRs using co-immunoprecipitation (co-IP) assays.18 Whether DC-SCRIPT 
is also present in GR containing protein complexes is unknown. To investigate this, 
whole cell lysates were prepared from HEK293 cells co-transfected with expression 
vectors encoding DC-SCRIPT and GR or their controls. Immunoprecipitations (IPs) were 
performed on these lysates using goat-anti-DC-SCRIPT-coated beads or control goat-
IgG-coated beads. Both the immunoprecipitated fractions and the total lysates were 
subjected to immunoblotting. The data show an effective IP of DC-SCRIPT using goat-
anti-DC-SCRIPT antibody-coated beads, whereas unspecific binding to the control 
beads is minimal (figure 1). In addition, GR was effectively co-immunoprecipitated 
with goat-anti-DC-SCRIPT-coated beads from lysates of HEK-293 cells that were co-
transfected with DC-SCRIPT and GR. No GR co-IP was observed when DC-SCRIPT was 
co-transfected with control HA only. These data demonstrate that DC-SCRIPT and 
GR can exist in the same protein complex. This occurs most likely through indirect 
interaction, as the co-IP of GR with DC-SCRIPT could only be demonstrated when 
using mild lysis conditions (data not shown). 
DC-SCRIPT	represses	GR	function	on	MMTV
Next, we investigated whether DC-SCRIPT affects transcriptional activity of GR by 
using luciferase reporter assays. Hep3B cells were co-transfected with DC-SCRIPT, GR 
or their controls and a reporter construct containing the MMTV promoter controlling 
luciferase expression (MMTV-luc). 
Figure 1. Co-immunoprecipitation of GR with DC-SCRIPT
Association	 of	 DC-SCRIPT	 with	 the	 Glucocorticoid	 Receptor.	 Lysates	 prepared	 from	 HEK293	 cells	 co-
transfected	with	flag	or	flag-DC-SCRIPT	and	HA	or	HA-GR	were	subjected	to	immunoprecipitation	using	
goat-IgG	or	goat-anti-DC-SCRIPT	antibody-coated	beads.	Immunoblotting	was	performed	on	the	IP	proteins	
with	goat-anti-DC-SCRIPT	to	detect	DC-SCRIPT	and	rat-anti-HA	to	detect	the	Glucocorticoid	Receptor.	Data	
shown	are	from	one	of	three	experiments	that	produced	the	same	result.	*	Indicates	background	band.
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In the MMTV promoter, four hormone responsive elements (HRE) have been identified 
that bind ligand activated GR, thereby inducing transcription of the luciferase gene.27 
Eighteen hours after transfection the cells were treated with vehicle, or the GR ligands 
Dexamethasone (Dex) or Prednisolone (Pred). Luciferase production was analyzed 24 
h after stimulation. 
 Hep3B cells lack endogenous GR expression, therefore only background luciferase 
activity was detected after GR-ligand stimulation in the absence of ectopically 
expressed GR. Cells that were co-transfected with the GR expression vector did 
show luciferase activity in a GR ligand dependent manner. Both dexamethasone and 
prednisolone were able to induce luciferase production (figure 2A). Interestingly, 
increasing expression levels of DC-SCRIPT resulted in a dose- and ligand dependent 
repression of GR activity. Previously, DC-SCRIPT has been shown to directly interact 
with the global transcription co-repressor CtBP1 via its CtBP1 interaction motif.22 In 
addition, DC-SCRIPT harbors a LxxLL motif, a motif known to facilitate interactions 
with NRs.3 Next, we examined whether the CtBP1 and the NR binding (LxxLL) motifs 
within DC-SCRIPT were important for its repressive function on GR. We therefore 
mutated both CtBP domains or deleted the LxxLL motif. Figure 2B shows that both 
mutants are still able to strongly repress GR dependent luciferase production. Thus, 
DC-SCRIPT functions as a co-repressor of GR induced transcription on the MMTV 
promoter, independent of its CtBP1 binding- and LxxLL motif. 
 Efficient transcription initiation via the MMTV promoter requires the presence of 
the most distal HRE site (HRE1), the regulatory element AA upstream of HRE128 and 
binding of the transcription factors NF-I and Oct1.27,29,30 To assess the requirement 
of these regulatory elements for DC-SCRIPT mediated co-repression, we deleted 
these sequence elements from the MMTV-luc reporter. In the MMTVΔ1-luc and 
MMTVΔ2-luc reporters the AA element alone, or both the HRE1 and the AA element 
are deleted, respectively, whereas the MMTVΔNF-I/Oct1-luc reporter lacks the NF-I 
and Oct1 binding sites31 (figure 2C). The wild-type MMTV-luc reporter was used as 
positive control. Deletion of the AA element or the NF-I/Oct1 binding sites reduced 
GR dependent luciferase expression compared to the wt reporter, which was even 
further decreased upon deletion of both AA	and HRE1 (figure 2D). On all MMTV 
reporters/mutants, DC-SCRIPT expression effectively repressed luciferase production. 
These data imply that that the repressive function of DC-SCRIPT does not depend on 
the HRE1 and the AA element, nor the NF-I and Oct1 binding sites. 
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Figure 2. Effect of DC-SCRIPT on GR mediated transcription
Luciferase	reporter	assay	for	GR	mediated	transcription.	Hep3B	cells	were	co-transfected	with	the	firefly	
luciferase	 reporter	 plasmid	MMTV-luc,	 the	 expression	 plasmid	 for	 GR	 and	 increasing	 amounts	 of	 the	
expression	plasmid	for	wild-type	DC-SCRIPT	(A)	or	with	mutated	CtBP-	or	deleted	LxxLL	binding	sites	(B).	Cells	
were	stimulated	with	vehicle,	100	nM	Dexamethasone	or	100	nM	Prednisolone	for	24	h.	Luciferase	activity	
is	displayed	relative	to	luciferase	production	upon	Dexamethasone	stimulation	in	the	presence	of	GR	and	
absence	of	DC-SCRIPT.	(C)	Schematic	representation	of	firefly	luciferase	reporters.	Reporters	consist	of	the	
MMTV	promoter	with	4	hormone	responsive	elements	(HRE)	in	front	of	a	TATA-box	controlling	luciferase	
gene	expression.	Three	MMTV	mutants	have	been	created	from	the	wild	type	(MMTVwt),	deleting	the	
upstream	3’-end	including	the	AA	domain	(MMTVΔ1),	the	3’-end	and	the	most	distal	HRE	(MMTVΔ2),	or	
the	binding	sites	for	nuclear	factor	1	(NF-I)	and	octamer	transcription	factor	1	(Oct1)	(MMTVΔNF-I/Oct1).	
(D)	 Luciferase	 reporter	 assay	 for	GR	mediated	 transcription.	Hep3B	 cells	were	 co-transfected	with	 the	
firefly	luciferase	reporter	plasmids	MMTVwt-luc,	MMTVΔ1,	MMTVΔ2	or	MMTVΔNF-I/Oct1,	the	expression	
plasmid	for	GR	and	 increasing	amounts	of	the	expression	plasmid	for	DC-SCRIPT.	Cells	were	stimulated	
with	vehicle	(white	bars)	or	100	nM	Dexamethasone	(black	bars)	for	24	h.	Luciferase	activity	is	displayed	
relative	to	luciferase	production	upon	Dexamethasone	stimulation	in	the	presence	of	MMTVwt	and	in	the	
absence	of	DC-SCRIPT.	Data	from	at	least	3	independent	experiments.	Error	bars	correspond	to	+/-	SEM.
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DC-SCRIPT	represses	transcriptional	activity	of	GR	isoforms
GR has been shown to be translated into 8 different isoforms using alternative 
translational start sites (figure 3A, adapted from 15). The GR expression vector includes 
all translational start sites, thus could express all GR isoforms. Indeed transfection of 
GR in HEK293 cells demonstrates expression of the full length GR-A, as well as the 
GR-B, -C, and, albeit at markedly lower levels, GR-D isoforms (figure 3A). To examine 
DC-SCRIPT function on different GR isoforms, we also cloned GR-C3 and GR-D3. Of 
note, the GR-C3 vector includes downstream ATGs, hence in addition to GR-C3, this 
vector could theoretically also express GR-D1, -D2, and -D3. However, only GR-C3 
and GR-D1 could be detected (data not shown). 
 The effect of DC-SCRIPT on transcription initiation of the reporter construct MMTV-
luc by these isoforms was tested using luciferase transcription assays. GR isoforms 
expressed by both GR and GR-C3 expression vectors equally induced luciferase 
production in a ligand dependent manner. Cells expressing the GR-D3 isoform, 
however, were less potent in inducing luciferase expression, displaying a more than 
4-fold reduction in luciferase production. Increasing expression levels of DC-SCRIPT 
resulted in a dose- and ligand dependent repression of the transcriptional activity of 
all GR isoforms figure 3B). This indicates that the 1-336 amino acid N-terminal part of 
GR that was deleted in the GR-D3 expression vector is not required for the effect of 
DC-SCRIPT on GR dependent transcription.
DC-SCRIPT	and	GR	expression	in	immature,	mature	and	tolerogenic	DCs	
Next, we investigated DC-SCRIPT and GR protein expression by western blotting and 
confocal laser scanning microscopy (CLSM) in immature- (iDCs), mature- (mDCs) and 
tolerogenic DCs (tolDCs). Immature and mature DCs were obtained by stimulating 
immature moDCs with vehicle or 24 hours of LPS, respectively. Tolerogenic DCs were 
generated from immature moDCs through 24 hour stimulation with Dexamethasone 
and subsequent 24 hours with LPS. Western blot analysis of DC-SCRIPT and GR 
protein levels showed equal expression of both proteins in iDCs, mDCs and tolDCs 
(figure 4A). The translational isoforms GR-A, -B and -C, but not GR-D which lacks the 
epitope for the anti-GR antibody, could be detected in all conditions. 
CLSM analysis revealed co-expression of DC-SCRIPT and GR protein in all three 
DC types tested. Expression of both proteins was observed predominantly in the 
nucleus, no major changes were detected between iDCs, mDCs and tolDCs (figure 4B). 
Co-localization between DC-SCRIPT and GR could be discerned but areas containing 
either GR or DC-SCRIPT were at least as abundant. As expected, nuclear expression 
of GR protein was increased upon 1 hour dexamethasone stimulation. In contrast, 
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DC-SCRIPT localization was unaffected by dexamethasone treatment. Hence these 
data clearly demonstrate nuclear- and, to a lesser extent, cytoplasmic co-expression 
and partial co-localization of DC-SCRIPT and GR in moDCs.
Figure 3. Effect of DC-SCRIPT on translational isoforms of GR
(A)	Translational	isoforms	of	GR.	One	GR	mRNA	generates	9	isoforms	by	means	of	alternative	translation	
initiation.	Numbers	indicate	N-	and	C-terminal	residue	of	each	GR	isoform.	Different	domains	are	indicated:	
the	 modulation	 domain	 contains	 the	 transactivation	 sequence,	 and	 is	 subject	 to	 phosphorylation	 and	
SUMOylation	affecting	protein	interactions;	the	DNA	binding	domain	(DBD);	the	hinge	region	and	the	ligand	
binding	domain	(LBD)	(adapted	from	15).	Expression	plasmids	have	been	created	for	underscored	isoforms.	
The	western	blot	shows	the	GR-A,	-B,	-C	and	-D	isoforms	visualized	with	rat-anti-HA	in	GR-HA	transfected	
HEK293	cells	.	(B)	Luciferase	reporter	assay	for	GR-A,	GR-C	and	GR-D	mediated	transcription.	Hep3B	cells	
were	co-transfected	with	the	firefly	luciferase	reporter	plasmid	MMTV-luc,	expression	plasmids	for	GR-A,	
GR-C	or	GR-D	and	increasing	amounts	of	the	expression	plasmid	for	DC-SCRIPT.	Cells	were	stimulated	with	
vehicle	(white	bars)	or	100	nM	Dexamethasone	(black	bars)	for	24	h.	Luciferase	activity	is	displayed	relative	
to	luciferase	production	upon	Dexamethasone	stimulation	in	the	presence	of	GR-A	and	in	the	absence	of	
DC-SCRIPT.	Data	from	at	least	3	independent	experiments.	Error	bars	correspond	to	+/-	SEM.
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Figure 4. DC-SCRIPT and GR expression in iDCs, mDCs and tolDCs
(A)	Proteins	from	iDC,	mDC	and	tolDC	lysates	were	subjected	to	immunoblotting	with	anti-DC-SCRIPT	or	
anti-GR	antibodies	and	anti-actin	as	loading	control.	(B)	CLSM	analysis	of	DC-SCRIPT	and	GR	expression	in	
iDCs,	mDCs	and	tolDCs.	DC-SCRIPT	was	visualized	with	goat-anti-DC-SCRIPT	(green),	GR	with	mouse-anti-
GR	(red)	and	the	nucleus	with	DAPI	(not	in	merge).	Immature	and	mature	DCs	were	stimulated	with	vehicle	
or	100	nM	Dexamethasone	for	1	hour.	Representative	data	from	1	out	of	3	donors.
Knock-down	of	DC-SCRIPT	enhances	GILZ	expression	in	moDCs
To determine the physiological relevance of the interaction between DC-SCRIPT and 
GR, DC-SCRIPT expression was silenced in moDCs using siRNA electroporation. As 
DC-SCRIPT was demonstrated to repress GR mediated transcription on the MMTV 
promoter, we hypothesized a similar effect on the endogenous GR target GILZ in 
moDCs. DC-SCRIPT knock-down was therefore expected to enhance GR dependent 
transcription, which could be detected by an increase in GILZ expression. 
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Figure S1. DC-SCRIPT knock-down does not affect GR 
expression in moDCs
Day	 4	 human	 monocyte	 derived	 DCs	 were	
electorporated	 with	 control	 non-targeting	 siRNA	
(control,	white	bars)	or	DC-SCRIPT	siRNA	(siSC,	black	
bars)	 and	 differentiated	 to	 day	 6	 immature	 DCs.	 At	
day	6	DCs	were	stimulated	with	vehicle	or	100	nM	RU-
486	for	1hr	prior	to	24	h	stimulation	with	vehicle	or	
100	nM	Prednisolone.	GR	mRNA	expression	is	shown	
relative	 to	 PBGD	 in	 mRNA	 lysates	 from	 day	 7	 DCs.	
Data	from	3	donors.	Error	bars	correspond	to	+/-	SEM.
Human moDCs were electroporated at day 4 with an DC-SCRIPT specific siRNA 
oligo (siSC) or an irrelevant control siRNA oligo. DC-SCRIPT protein expression was 
markedly reduced in siSC treated DCs 48- and 72 hours after electroporation (figure 
5A), whereas GR expression remained unaltered (supplemental data S1). At day 
6 moDCs were treated with vehicle or the GR antagonist RU-486 for 1 hour and 
subsequently stimulated with vehicle or the GR agonist prednisolone for 24 hours. 
After stimulation GILZ mRNA levels were measured. As expected, little or no GILZ 
mRNA expression was detected in vehicle treated control DCs. Stimulation with 
prednisolone resulted in an upregulation of GILZ expression levels in control DCs 
(figure 5B) which could be effectively blocked by inhibiting GR activation with the 
GR antagonist RU-486. Strikingly, vehicle treated siSC DCs already demonstrated a 
significant (p=.05) increase in GILZ expression compared to control DCs. 
Figure 5. DC-SCRIPT knock-down in moDCs
Day	 4	 human	 monocyte	 derived	 DCs	 were	 electorporated	 with	 control	 non-targeting	 siRNA	 (control,	
white	bars)	or	DC-SCRIPT	siRNA	(siSC,	black	bars)	and	differentiated	to	day	6	immature	DCs.	At	day	6	DCs	
were	stimulated	with	vehicle	or	100	nM	RU-486	for	1hr	prior	to	24	h	stimulation	with	vehicle	or	100	nM	
Prednisolone.	(A)	DC-SCRIPT	protein	expression	in	protein	lysates	from	day	6	and	day	7	DCs.	(B)	GILZ	mRNA	
expression	relative	to	PBGD	in	mRNA	lysates	from	day	7	DCs.	Data	from	6	donors.	Error	bars	correspond	
to	+/-	SEM.
Chapter 4
80
This upregulation appears to be GR independent, as it is also detected in the presence 
of the GR antagonist RU-486. In the absence of the GR antagonist, treatment with 
prednisolone further increased GILZ expression in DC-SCRIPT knock down DC, with 
relative GILZ mRNA levels being significantly higher than in control siRNA treated 
DCs (p=.01). These data thus indicate DC-SCRIPT to function as co-repressor of GR 
mediated transcription of GILZ in DCs. Blocking GR activation with the GR antagonist 
abolished GILZ up-regulation in DC-SCRIPT knock-down DCs, confirming that this was 
indeed dependent on GR activation. These results indicate that DC-SCRIPT affects GR 
activity in DCs, and represses expression of the endogenous GR target gene GILZ, a 
transcription factor that has been associated with the generation of tolerogenic DCs.
DISCUSSION
The present study demonstrates that the NR co-regulator DC-SCRIPT modulates GR 
function in human moDCs. In cell-lines, DC-SCRIPT was present in GR containing 
protein complexes, and GR mediated transcription was found to be repressed by DC-
SCRIPT. Human moDCs co-express DC-SCRIPT and GR in the nucleus and cytoplasm, 
and DC-SCRIPT silencing resulted in enhanced expression of the GR target gene GILZ, 
a transcription factor that is instrumental for the generation of tolDCs. 
 Co-presence of DC-SCRIPT and GR in protein complexes could be demonstrated, 
and is in line with our previous findings, suggesting that DC-SCRIPT interacts with 
NRs via other proteins present in NR protein complexes. DC-SCRIPT has been shown 
to bind the transcription co-repressors RIP140 (receptor-interacting protein 140) and 
CtBP1, as well as histone de-acetylase (HDAC) 1, -3 and -6, all known to be present in 
NR protein complexes.3,31,32 The absence of a direct contact between DC-SCRIPT and 
GR is also consistent with the finding that deletion of the NR interaction motif LxxLL 
and the CtBP1 interaction motif in the acidic domain of DC-SCRIPT did not affect its 
repressive function on GR transcription. This implies that interaction with CtBP1 and 
the presence of the LxxLL motif is not required for the repressive effect of DC-SCRIPT. 
 Co-expression of DC-SCRIPT and GR in DCs was demonstrated with CLSM, albeit 
areas containing either DC-SCRIPT or GR were equally abundant. Ligand dependent 
GR translocation was observed in iDCs. However, in the absence of its ligand, GR was 
also detected in the nucleus of iDCs. The nuclear GR expression most likely reflects 
the expression of GRβ isoforms, known to have restricted nuclear localization.16 DC-
SCRIPT expression was found to be mostly nuclear, in line with previous localization 
studies and its function as a transcriptional (co)factor.32-34
Within DCs, DC-SCRIPT was shown to co-regulate GR function affecting expression of 
the well known GR target gene GILZ. Knock-down of DC-SCRIPT expression markedly 
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increased GILZ expression upon GR activation, implicating co-repression of GR by 
DC-SCRIPT on the GILZ promoter in DCs. GILZ functions as an effector protein of GR 
activation in DCs, mediating the anti-inflammatory action of GR. It has previously been 
shown that the immunosuppressive effect of GR can be reproduced in the absence 
of GR ligand by GILZ overexpression, whereas GILZ silencing abrogates the GR ligand 
effect.34 GILZ has been shown to interact with STAT, NF-κB, AP-1, 14-3-3, Raf-1 and 
Ras proteins, all of which lead to inhibition of inflammation.35 Hence, by regulating 
GR activity and GILZ expression, DC-SCRIPT may represent an important factor in DC 
biology, programming DCs towards immunity or tolerance. In line with this, we have 
recently demonstrated an important role for DC-SCRIPT in the repression of IL-10 
secretion,33 an anti-inflammatory cytokine known to be produced in large amounts 
by tolDCs.36 In this study, DC-SCRIPT knock-down in immature moDCs significantly 
increased IL-10 expression levels upon TLR4 and -7/8 mediated maturation. Elevated 
IL-10 levels subsequently impaired IL-12 secretion and T-cell proliferation, suggesting 
that DC-SCRIPT knock-down skews DCs towards tolerance.
In addition to GILZ, we also investigated the expression of other genes known to 
be induced by ligand dependent GR activation in other cells. However, identification 
of these other GR targets in DC and whether they are affected by DC-SCRIPT proved 
to be difficult (data not shown). For eight out of ten tested target genes no GR-ligand 
dependent upregulation in moDCs could be detected. This could be due to cell-type 
specific differences between DCs and other cells, like differences in the expression 
and function of the repressive GRα-D and GRβ isoforms. Increased expression upon 
GR activation was only detected for FKBP5 (51 kDa FK506-binding protein 5) and 
PTX3 (pentraxin 3), however, induction levels were low and DC-SCRIPT silencing did 
not affect expression of these genes (data not shown). One major reason could be 
the HRE sequence or the context of this sequence in the promoter of these genes. 
Meijsing et. al (2009) recently demonstrated that a single nucleotide change in the 
GRE sequence influences GR binding affinity and conformation, affecting co-factor 
recruitment and transcription activation.37 Similarly, the binding properties of DC-
SCRIPT might differ depending on GR conformation and affect the binding of other 
co-factors. Furthermore, adjacent binding sites of other transcription factors can 
also affect GR mediated transcription and possibly DC-SCRIPT function.17 In line with 
this, we have preliminary data that suggests that DC-SCRIPT can also activate GR 
dependent transcription, depending on the promoter context (data not shown). As 
soon as a suitable DC-SCRIPT antibodies for Chromatin-ImmunoPrecipitation (ChIP) 
become available, it would be extremely interesting to perform ChIP-sequencing 
studies and expression arrays, to further investigate gene regulation specifically in 
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DCs with respect to DC-SCRIPT and GR activation and expression. 
 Finally, besides GR, also other NRs are known to function in DC biology, affecting 
either differentiation, maturation, or both. The human NR superfamily contains 
48 members, of which 20 NRs have been described to be expressed in monocyte 
derived DCs.38 Since we have recently indentified DC-SCRIPT as a NR co-regulator in 
breast-18 and prostate carcinoma,20 affecting both type I and type II NR function, it is 
tempting to speculate about a role for DC-SCRIPT as NR co-regulator in DC biology. It 
would therefore be interesting to study target gene expression of various NRs after 
DC-SCRIPT knock-down in DCs.
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ABSTRACT 
Background Nuclear receptors, including estrogen receptor (ER), progesterone 
receptor (PR-B), peroxisome proliferator-activated receptor gamma (PPARγ), and 
retinoic acid receptor alpha (RARα), have been implicated in breast cancer etiology 
and progression. We investigated the role of dendritic cell-specific transcript (DC-
SCRIPT) as coregulator of these nuclear receptors and as a prognostic factor in breast 
cancer.
Methods The effect of DC-SCRIPT on the transcriptional activity of nuclear receptors 
was assessed by luciferase reporter assays. DC-SCRIPT expression in normal and tumor 
breast tissue was analyzed by PCR assays and immunohistochemistry. The prognostic 
value of tumor DC-SCRIPT mRNA expression was assessed in three independent 
cohorts of breast cancer patients: a discovery group (n = 47) and a validation group 
(n = 97) (neither of which had received systemic adjuvant therapy), and a second 
tamoxifen-treated validation group (n = 68). Univariate and multivariable Cox 
proportional hazards model analyses were performed. 
Results DC-SCRIPT suppressed ER- and PR-mediated transcription in a ligand-
dependent fashion, whereas it enhanced the RARα- and PPARγ-mediated 
transcription. In breast tissue samples, DC-SCRIPT mRNA was expressed at lower 
levels in tumor than in corresponding normal tissues (P	= .010). Patients with high 
tumor DC-SCRIPT mRNA levels (66%) had a longer disease-free interval than those 
with a low DC-SCRIPT mRNA level (34%) (hazard ratio [HR] of recurrence for high vs 
low DC-SCRIPT level = 0.23, 95% confidence interval [CI] = 0.06 to 0.93, P = .039), 
which was confirmed in the validation group (HR of recurrence = 0.50, 95% CI = 0.26 
to 0.95, P	= .034). This prognostic value was confined to patients with ER- and/or PR-
positive tumors (discovery group: HR of recurrence = 0.16, 95% CI = 0.03 to 0.89, P = 
.030; validation group: HR of recurrence = 0.42, 95% CI = 0.19 to 0.91, P	= .028), and 
was also observed in the second validation group (HR = 0.46, 95% CI = 0.22 to 0.97, P	
= .040). DC-SCRIPT was an independent prognostic factor after correction for tumor 
size, lymph node status, and adjuvant therapy (n = 145; HR = 0.50, 95% CI = 0.29 to 
0.85, P	= .010). 
Conclusions DC-SCRIPT is a key regulator of nuclear receptor activity that has 
prognostic value in breast cancer.
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INTRODUCTION
Nuclear receptors form a unique class of phylogenetically conserved transcriptional 
regulators.1 They execute a transcriptional program upon binding to a ligand. Ligands 
for the nuclear receptor family of proteins vary from hormones to vitamins and 
metabolic products. In accordance with the wide variety of ligands, nuclear receptors 
are key regulators in a diversity of physiological functions, including development, 
metabolism, cell differentiation, and immune responses.2 Malfunction of nuclear 
receptors has been associated with diseases such as diabetes, chronic inflammatory 
diseases, and cancer.2-4 Clinically, a connection between hormone-dependent 
nuclear receptor function and breast cancer development has long been recognized. 
Most research has focused on the expression and function of two nuclear receptors, 
estrogen receptor-α (ER) and progesterone receptor (PR), which are preserved or 
increased in approximately 70% of breast tumors.5 Estrogens, the ligands for the 
ER, are often associated with the initiation and progression of breast cancer,6 and 
are well known for their proliferative effect on breast cancer cells.7-9 Anti-estrogen 
therapy with tamoxifen has been applied successfully in the treatment of breast 
cancer patients.5 In line with the importance of the ER and PR in breast cancer, 
the expression of transcriptional co-regulators of ER and PR are also of prognostic 
significance in breast cancer.10,11 For example, the genes encoding nuclear receptor 
coactivator 3 (NCOA3; also known as AIB1) and nuclear receptor co-repressor 2 
(NCOR2; also known as SMRT) have been shown to serve as a tumor suppressor gene 
and an oncogene for breast cancer, respectively.12-17
 Another class of nuclear receptors, the retinoid X receptor alpha (RXRα) 
heterodimers (ie, RXRα–retinoic acid receptor alpha [RARα] and RXRα–peroxisome 
proliferator-activated receptor gamma [PPARγ]), have recently been implicated in 
breast cancer. For example, whereas the presence of ER and PR is associated with 
breast tumor development and breast tumor cell proliferation, RARα and PPARγ 
play a predominantly antitumorigenic role in human breast cancer by inhibiting cell 
growth and inducing apoptosis.7,18 These properties imply that an imbalance in the 
activity of nuclear receptors may contribute to the development and progression of 
breast cancer. How the activity of the nuclear receptor repertoire in cells is regulated 
and which factors determine the response of the nuclear receptor repertoire to 
environments in which multiple nuclear receptor ligands are present are still open 
questions. 
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CONTEXT AND CAVEATS
Prior knowledge An imbalance in the transcriptional activities of estrogen receptor 
(ER), progesterone receptor (PR-B), peroxisome proliferator-activated receptor 
gamma (PPARγ), and retinoic acid receptor alpha (RARα) may contribute to the 
development and progression of breast cancer, but how the activities of these 
nuclear receptors are regulated is unclear.
Study design Luciferase reporter assays were used to examine the role of the 
novel transcriptional repressor dendritic cell-specific transcript (DC-SCRIPT) as 
a coregulator of ER, PR-B, PPARγ, and RARα in human cancer cells. DC-SCRIPT 
expression in normal and tumor tissue from breast cancer patients was analyzed by 
polymerase chain reaction assays and immunohistochemistry, and the prognostic 
value of tumor DC-SCRIPT mRNA expression was assessed in three independent 
cohorts of breast cancer patients.
Contribution In vitro, DC-SCRIPT suppressed ER- and PR-mediated transcription 
in a ligand-dependent fashion, whereas it enhanced RARα- and PPARγ-mediated 
transcription. Breast tumors expressed lower levels of DC-SCRIPT than normal 
breast tissue from the same patient. Quantification of DC-SCRIPT mRNA expression 
in three cohorts of breast cancer patients revealed that DC-SCRIPT mRNA expression 
is an independent prognostic factor for breast cancer patients with ER- and/or PR-
positive tumors.
Implications DC-SCRIPT is a key regulator of nuclear receptor activity that has 
prognostic value in breast cancer.
Limitations The clinical conclusions about DC-SCRIPT mRNA expression as a 
prognostic marker in breast cancer were based on nonrandomized retrospective 
analyses and could not be independently validated in publicly available databases.
From	the	editors
We previously identified and characterized a novel protein, dendritic cell-specific 
transcript (DC-SCRIPT; also known as ZNF366), that is preferentially expressed by 
dendritic cells in the immune system.19,20 DC-SCRIPT contains an amino-terminal 
proline-rich domain, 11 Cys2His2-type zinc fingers, and a carboxyl-terminal acidic 
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region. The acidic region of DC-SCRIPT contains a functional binding motif for the 
corepressor protein CtBP19,21 and an LXXLL nuclear receptor interaction motif, which 
is thought to be involved in ER function.22 Herein, we investigate the effect of DC-
SCRIPT on the function of multiple members of the nuclear receptor family as well as 
the prognostic relevance of DC-SCRIPT expression in breast cancer patients.
MATERIALS & METHODS
Cells
Human embryonic kidney 293 (HEK293) cells were cultured in Dulbecco’s modified Eagle (DMEM) medium 
containing GlutaMAX (Invitrogen, Breda, the Netherlands) supplemented with 10% heat-inactivated 
fetal calf serum (FCS; Greiner Bio-one, Alphen a/d Rijn, the Netherlands), 1% non-essential amino acids 
(Invitrogen), and 0.5% antibiotic–antimycotic (Invitrogen). Human hepatocellular carcinoma Hep3b cells 
were cultured in Iscove’s modified Dulbecco’s medium (Invitrogen), 10% heat-inactivated FCS, and 0.5% 
antibiotic–antimycotic. Human breast adenocarcinoma MCF-7 cells were cultured in RPMI-1640 medium 
(Invitrogen), 10% heat-inactivated FCS, and 0.5% antibiotic–antimycotic. Schneider’s Drosophila Line 
2 (SL2) cells were grown in Schneider’s drosophila medium (Invitrogen) and 10% heat-inactivated FCS. 
All cell lines were originally obtained from American Type Culture Collection (Manassas, VA). Cells were 
regularly checked morphologically to verify the identity of each cell line.
Co-immunoprecipitation	Assay
The nuclear receptors (National Center for Biotechnology Information [NCBI] accession number) ERα 
(NM_000125), PR-B (NM_000926), RARα (NM_000964), RXRα (NM_002957), and PPARγ (NM_138712) 
were each cloned into the expression vector pHA-n1 to enable expression of fusion proteins that 
contain a carboxyl-terminal haemagglutinin (HA) epitope tag. pHA-n1 was generated by replacing the 
green fluorescent protein (GFP) DNA sequence from the plasmid pEGFP-n3 (Clontech) with the HA DNA 
sequence. The DNA for DC-SCRIPT (NM_152625) was cloned into the mammalian expression vector pEYFP 
(Clontech) to enable expression of a DC-SCRIPT fusion protein tagged with enhanced yellow fluorescent 
protein (YFP). HEK293 cells were plated in 10-cm dishes (6 × 106 cells per dish) and incubated for 24 hours. 
The cells were cotransfected with 5 μg pDC-SCRIPT-EYFP or pEYFP (control) and 5 μg of a vector expressing 
HA-tagged ERα, PR-B, RARα, or PPARγ by using Metafectene transfection reagent (Biontex, Germany) 
according to the manufacturer’s protocol. The cells were stimulated 8 hours after transfection with the 
following ligands (all from Sigma, Zwijndrecht, the Netherlands): 10 nM β-estradiol for cells expressing HA-
tagged ER; 1 µM all-trans-retinoic acid (AtRA) for cell expressing HA-tagged RAR; 1 µM GW1929 (a PPARγ 
ligand) for cells expressing HA-tagged PPARγ; or the PR ligand 10 nM R5020 (Perkin Elmer, Groningen the 
Netherlands) for cells expressing HA-tagged PR-B. For all ligands, a 1000-times stock dilution in ethanol 
was used. Twenty-four hours after transfection, the cells were lysed in radioimmunoprecipitation assay 
buffer (50 mM NaCl, 1% Triton X-100, 0.1% sodium dodecyl sulfate [SDS], and 50 mM Tris–HCl [pH 7.5]) 
containing the protease inhibitors 2 µg/mL leupeptin (Sigma, Zwijndrecht, the Netherlands), 2 µg/mL 
aprotinin (Roche, Woerden, the Netherlands), and 1 mM phenylmethylsulfonyl fluoride (Sigma, Breda, the 
Netherlands). The cell lysates were used for immunoprecipitation of YFP-tagged proteins with anti-green 
fluorescent protein (GFP) antibody–coupled protein G beads (GE Healthcare) (this antibody recognizes 
YFP-tagged proteins). Cells transfected with YFP and HA-tagged ERα, PR-B, RARα, or PPARγ were used as 
controls for nonspecific binding. Immunoprecipitated proteins were mixed with sample buffer containing 
5% glycerol, 6% SDS, 125 mM Tris-HCl [pH 6.8], 0.1 mg/mL bromophenol blue (Gebr. Schmid GmbH + co, 
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Freudenstad, Germany), and 10% β-mercaptoethanol (Sigma, Breda, the Netherlands), heated at 95°C for 
5 minutes, and then cooled on ice. The proteins were resolved by electrophoresis on an 8% polyacrylamide 
gel (ratio of acrylamide to bisacrylamide, 37.5:1) and transferred overnight to Protan nitrocellulose 
transfer membranes (Schleicher and Schuell, ‘s Hertogenbosch, the Netherlands) at 30 mA and 4 °C. To 
block nonspecific protein binding, the membranes were incubated in 2% skimmed milk powder (Campina, 
Eindhoven, the Netherlands) and 1% bovine serum albumin (BSA) (Roche, Woerden, the Netherlands) in 
phosphate-buffered saline with 0.01% Tween (PBST) for detecting HA-tagged proteins or in 1% skimmed 
milk powder and 3%BSA in PBST for detecting YFP-tagged proteins. The membranes were then incubated 
for 2 hours with a mouse anti-GFP antibody (1:1000 dilution; Roche Applied Science), washed three 
times in PBST, and subsequently incubated for 1 hour with the secondary antibody IRDye 800CW goat 
anti-mouse IgG (1:5000 dilution; Li-cor Biosciences) to detect YFP-tagged proteins. To detect HA-tagged 
proteins, the membranes were incubated with a rat monoclonal anti-HA antibody (1:1000 dilution, clone 
3F10; Roche), washed three times in PBST, and incubated for 1 hour with the secondary antibody Alexa 
Fluor 680–conjugated goat anti-rat IgG (1:5000 dilution; Invitrogen). All membranes were then washed 
three times in PBST. After staining the YFP- or Ha-tagged proteins, the membranes were scanned by using 
an Odyssey Infrared Imaging system (Li-cor Biosciences) to visualize the YFP- or Ha-tagged proteins.
Transcription	Assays
The transcription reporter plasmids pTk-RARE3-luc, which contains three RAR response elements (RAREs) 
upstream of a firefly luciferase reporter, and pTk-luc were described previously.23 pAc5.1 (Invitrogen), 
which contains the Drosophila actin 5C (Ac5) promoter for high-level expression of the gene of interest 
in SL2 cells,24 was used to generate the following plasmids for expression in insect cells: pAc-RAR 
containing RARα, pAc-RXR containing RXRα, and pAc-DCSCRIPT containing DC-SCRIPT. The mammalian 
expression plasmids pCATCH and pCATCH-DCSCRIPT were described previously19 and were used in the 
transcription assays in Hep3b and MCF-7 cells. MMTV-luc, a transcription reporter plasmid containing 
the mouse mammary tumor virus (MMTV) promoter, which is positively regulated by several classes of 
steroid hormones including ligands for the PR,25,26 was kindly provided by Prof. Dr. Stunnenberg (NCMLS, 
Nijmegen, the Netherlands). MMTV-luc was used to generate MMTV-RLuc, a reporter plasmid in which 
Renilla luciferase expression is under the control of the MMTV promoter, which was used in the MCF-7 
transcription assay. The transcription reporter PPRE-luc (Addgene plasmid number 1015) contains the 
PPAR response elements upstream of a firefly luciferase reporter and has been described previously.27 The 
PR expression plasmid pSG5-PR-B28 was kindly provided by Prof. Dr. Horwitz (University of Colorado Health 
Sciences Center) and was used in the transcription assays in Hep3B and MCF-7 cells. The transcription 
reporter ERE3-TATA-luc (Addgene plasmid number 11354), which contains three copies of the vitellogenin 
estrogen response element (ERE), has been described previously29 and was used in the transcription 
assays in Hep3b cells. 
 Hep3b cells were plated in 24-well plates (6 × 104 cells per well) 8 hours before transfection and 
all plasmids were transfected into these cells by using a calcium phosphate precipitation kit (Invitrogen) 
according to the manufacturers protocol. SL2 cells were plated in medium without FCS in 24-well plates 
(1 × 106 cells per well) just before transfection by using a calcium phosphate precipitation kit (Invitrogen). 
MCF-7 cells were plated in 24-well plates (5 × 104 cells per well) 8 hours before transfection and all 
plasmids were transfected into these cells by the use of Metafectene reagent (Biontex, Germany). Twenty-
four hours after transfection, Hep3B, MCF-7, and SL2 cells were stimulated with the RAR ligand AtRA (1 
µM) or vehicle (ethanol) for 16 hours. Transfected Hep3B and MCF7 cells were stimulated 16 hours after 
transfection with the following ligands or vehicle (ethanol) for 24 hours: the ER ligand β-estradiol (10 
nM; Sigma, Zwijndrecht, the Netherlands); the PR ligands progesterone (100 nM; Sigma Zwijndrecht, the 
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Netherlands) or R5020 (10 nM; PerkinElmer, Groningen, the Netherlands); or the PPARγ ligands GW1929 
(1 µM; Sigma, Zwijndrecht, the Netherlands) or troglitazone (10 µM; Sigma, Zwijndrecht, the Netherlands). 
Forty hours after transfection, the cells were lysed in 100 µl Passive Lysis buffer (Promega) and the lysates 
were analyzed for luminescence with the use of the Dual-Luciferase Reporter Assay System (Promega, 
Leiden, the Netherlands) according to manufacturer’s protocol and a Victor 3 luminometer (PerkinElmer, 
Groningen, the Netherlands). Relative light units (RLU) were calculated after correction for transfection 
efficiency based on the activity of a co-transfected reporter plasmid encoding Renilla luciferase under the 
control of the SV40 promoter (pRL-SV40; Promega). The data are expressed as the mean relative luciferase 
activity of at least three independent experiments with 95% confidence intervals (CIs). 
Dissociation	and	Purification	of	Epithelial	Cells	from	Breast	Biopsy	Samples	
Normal breast tissue located distally from the tumor was obtained during surgical resection of the primary 
tumor at the Radboud University Nijmegen Medical Centre (RUNMC) from six anonymous breast tumor 
patients and was macrodissected within 12 hours of surgical removal and dissociated as previously 
described;30 tissue procurement was approved by the institutional ethics committee of the RUNMC. In short, 
the tissue was minced with a scalpel and dissociated in 0.1% DNase (Roche, Woerden, the Netherlands) 
and 0.14% collagenase A (Roche) in RPMI-1640 medium, by incubating the minced tissue three times for 
45 minutes each time in fresh DNase–collegenase-containing medium. The cell suspension was passed 
through a 30-µM MACS preseparation filter (Miltenyi Biotec, Utrecht, the Netherlands) washed to remove 
tissue debris, and stored overnight at 4 °C. The cell suspension was incubated with allophycocyanin 
(APC)-conjugated anti-human CD326 antibody (Miltenyi Biotec), which recongnizes the epithelial cell 
surface marker Epithelial Cell Adhesion Molecule (Epcam) followed by incubation with anti-APC MACS 
beads (Miltenyi Biotect), and the CD326-positive and CD326-negative cells were fractionated by magnetic 
separation. The CD326-positive and CD326-negative cell fractions were lysed for RNA isolation, and 
analyzed for the expression of the leukocyte marker CD45, the dendritic cell marker CD11c, the epithelial 
cell marker CD326, and DC-SCRIPT by means of quantitative polymerase chain reaction (PCR) analysis. 
Complementary	DNA	(cDNA)	Synthesis	and	Quantitative	Polymerase	Chain	Reaction	(PCR)	Analysis	
For quantitative PCR analysis of DC-SCRIPT, PBGD, CD45, CD11c, and CD326 mRNA levels, total RNA was 
isolated from fresh normal breast tissue or cell lines with the use of Trizol reagent (Gibco BRL) according to 
the manufacturer’s protocol. RNA was treated with DNase I (amplification grade, Invitrogen) and reverse-
transcribed into cDNA by using random hexamers and Moloney murine leukemia virus reverse transcriptase 
(Invitrogen). mRNA levels for the genes of interest were determined with a PRISM 7000 sequence detection 
system (Applied biosystems, Foster City, CA) with SYBR Green (Applied Biosystems) as the fluorophore 
and the following oligonucleotide primers (forward, reverse): DC-SCRIPT (5’-AAGCATGGAGTCATGGAG-3’, 
5’-TTCTGAGAGAGGTCAAAGG-3’); PBGD (5’-GGCAATGCGGCTGCAA-3’, 5’-GGGTACCCACGCGAATCAC-3’); 
CD326 (5’-TGTCTGTGAAAACTACAAGCTGG-3’, 5’-AGCCATTCATTTCTGCCTTCATC-3’); CD45 
(5’-ACCACAAGTTTACTAACGCAAGT-3’, 5’-TTTGAGGGGGATTCCAGGTAAT-3’); and CD11c 
(5’-ATCACCTTCTTGGCTACCT-3’, 5’-TGAGGTATTTGGTGAATTGT-3’). We used reaction mixtures and program 
conditions that were recommended by the manufacturer (Applied Biosystems).
 Quantitative PCR data were analyzed with 7000 Systems SDS Software v1.2.3 (Applied Biosystems) 
and checked for correct amplification and dissociation of the products. mRNA levels of the genes of 
interest were normalized to mRNA levels of the housekeeping gene porphobilinogen deaminase (PBGD),31 
and were calculated according to the cycle threshold method.32
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Immunohistochemistry
Snap-frozen breast cancer specimens from eight anonymous breast cancer patients were obtained from 
the Rijnstate Hospital (Arnhem, the Netherlands; approved by the institutional ethics committee of 
the Radboud University Nijmegen Medical Centre) and embedded in OCT embedding matrix (CellPath, 
Newtown, UK) and sectioned (5-µM thick tissue sections). The sections were placed on Superfrost slides 
(Thermo Scientific, Ettenleur, the Netherlands), fixed with acetone, and incubated with 4 µg/mL goat anti-
human DC-SCRIPT antibody (R&D Systems) followed by incubation with a biotinylated horse anti-goat IgG 
(Vector Laboratories) and signal development was performed using a Vectastain ABC-AP kit (Vector Labs, 
Brunswig, Amsterdam) and fast red (Sigma). The epithelial cell surface marker epithelial cell adhesion 
molecule (Epcam) was detected with a mouse monoclonal anti-CD326 antibody (Miltenyi Biotec) and a 
biotinylated horse anti-mouse IgG (Vector Laboratories). Isotype-matched goat IgG (R&D Systems) and 
mouse IgG1 (BD Bioscience) were used as controls. Sections were counterstained with hematoxylin to 
visualize the cell nuclei and analyzed by using a Leica DM LB microscope (Leica Microsystems B.V., Rijswijk, 
the Netherlands). 
Patients
Our use of coded tumor tissues in this study was performed in accordance with the Code of Conduct of the 
Federation of Medical Scientific Societies in the Netherlands (http://www.federa.org/ [a link to the English 
version is available at this site]) and was approved by the institutional ethics committee of the Radboud 
University Nijmegen Medical Centre. All steps in tissue processing and marker assaying were performed 
by individuals who blinded to the clinical outcomes, and, as much as possible, in accordance with the 
guidelines for biomarker characterization described by Pepe et al.33
 From nine anonymous patients who underwent surgery in the early 1990s, both breast tumor and 
distally located normal breast tissue was macrodissected, and stored in liquid nitrogen until RNA isolation 
as described below. No other information on these patients or tissues is available.
 Other tumor tissues were from patients who had operable unilateral breast cancer and had 
undergone resection of their primary tumor between November 1987 and December 1997. We included 
patients who had no previous carcinoma diagnosis, no distant metastases at diagnosis, and no evidence 
of disease within 1 month after primary surgery. We excluded patients who had received neoadjuvant 
systemic therapy or who were diagnosed with carcinoma in situ only. 
 The discovery group (n = 47) was selected from among a previously described cohort of patients34 
based on the availability of tumor RNA and consisted of stage pT1 or pT235 ductal (n = 42) or lobular (n = 5) 
node-negative breast tumors that had received no adjuvant systemic therapy. The tumors were collected, 
snap frozen, and embedded in OCT compound (Tissue-Tek) as soon as possible after surgical resection 
(breast conserving lumpectomy: n = 34; modified radical mastectomy: n = 13) at the Rijnstate Hospital 
(Arnhem, the Netherlands). 
 Tumors in the validation (n = 97) and tamoxifen-treated (n = 68) groups were also selected based 
on tumor RNA availability and receipt of adjuvant treatment (no adjuvant systemic treatment [validation 
group] or adjuvant systemic treatment with tamoxifen) from among a different cohort of patients that 
was also described earlier 36. The tumors from this cohort of patients were obtained from a tumor bank in 
the Department of Chemical Endocrinology (Radboud University Nijmegen Medical Centre) that contains 
frozen tumor tissue collected from breast cancer patients who were treated at the nine hospitals that form 
the Comprehensive Cancer Center East in the Netherlands. The tumor tissues were collected by these 
hospitals for the central measurement of estrogen receptor (ER) and progesterone receptor (PR) levels by 
ligand binding assay. Patients were defined as ER- and/or PR-positive (level of either or both receptors ≥10 
fmol/mg protein) or as ER- and PR-negative (levels of both receptors < 10 fmol/mg protein). 
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All patients were followed up once every 3 months during the first 2 years after surgery once every 6 months 
for the next 5 years, and once a year thereafter by means of a medical history, physical examination, and 
routine laboratory investigations. Each patient received once yearly x-ray mammography, and for those 
with suspicious results, magnetic resonance imaging of the breast. 
Tumor	Tissue	RNA	isolation
Aliquots of frozen tissue were pulverized using a microdismembrator (Braun, Melsungen, Germany) 
and the resulting tissue powder was stored in liquid nitrogen. Total RNA was isolated from 20 mg of 
tissue powder with the use of an RNeasy Mini kit (Qiagen, Hilden, Germany) with on-column DNase I 
treatment. Aliquots of RNA were stored at −80 °C. RNA quality was verified by examining the ribosomal 
RNA bands after agarose gel electrophoresis of each RNA sample and by PCR amplifying PBGD mRNA. 
RNA concentrations were determined from the spectrophotometric absorption at 260 nm by using 
a Genequant spectrophotometer (Amersham, Eindhoven, the Netherlands). We observed no effect of 
storage time in liquid nitrogen on the quality of the RNA.
Statistical	Analyses
Statistical analyses were carried out using SPSS software (version 16.0; SPSS, Benelux BV). The normality 
of distributions was tested by the method of Kolmogorov–Smirnov.37 A normal distribution for DC-SCRIPT 
mRNA expression values was achieved after taking the 10log of each value. Differences in the proportions 
of clinicopathological characteristics among the three patient groups were assessed with Pearson chi-
square tests. Differences in PBGD-normalized DC-SCRIPT mRNA expression levels between normal breast 
tissue and tumor tissue from the same patient were assessed using paired t tests, and between tumor 
tissues and cell lines by unpaired Student t tests. Differences in DC-SCRIPT mRNA levels for variables with 
more than two groups were assessed by analysis of variance. Because data on histological grading were 
missing for a substantial number of patients, patients with missing data were included in all analyses as a 
separate group. The disease-free interval (defined as the time from surgery until the diagnosis of recurrent 
disease) was used as follow-up end point. Contralateral breast cancer or second malignancies were not 
considered to be recurrent disease. Overall survival was not evaluated because data on breast cancer–
specific causes of death were difficult to retrieve from the patient records and, thus, the number of events 
was too small for reliable statistical analysis. Survival curves were generated by using the Kaplan–Meier 
method. Cox proportional hazards modeling was used to assess the prognostic value of DC-SCRIPT mRNA 
expression after dichotomization of the patient group. The proportional hazard assumption was confirmed 
by examination of the Schoenfeld residuals. An optimal cutpoint was selected in a discovery group at the 
lowest possible P	value at such cutpoint, thus representing the best dichotimization of the patient group. 
The cutpoint was selected by multiple testing and validated in the two other independent patient cohorts. 
Multivariable Cox proportional hazards modeling was then used to assess the independent prognostic 
value of DC-SCRIPT mRNA expression in the combined validation and tamoxifen-treated patient cohorts. 
All clinicopathological variables were entered into the Cox regression model. Subsequently variables 
that did not contribute to the model (P > .1) according to the likelihood ratio statistic were removed 
in a stepwise fashion until only statistically significant variables remained in the model. Interactions 
between DC-SCRIPT mRNA expression and ER and PR status and between DC-SCRIPT mRNA expression 
and tamoxifen treatment were assessed by entering an interaction variable into the model. Two-sided P 
values less than .05 were a priori considered to be statistically significant.
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RESULTS
Interaction	Between	DC-SCRIPT	and	Multiple	Nuclear	Receptors	
We performed co-immunoprecipitation experiments to examine whether DC-
SCRIPT interacts with the steroid nuclear receptors ERα and PR-B or with the 
RXR heterodimers RARα and PPARγ. For this experiment, whole-cell lysates were 
prepared from HEK293 cells that had been co-transfected with expression vectors 
encoding YFP-tagged DC-SCRIPT or YFP (control) and HA-tagged nuclear receptors 
ERα, PR-B, RARα, or PPARγ. YFP-DC-SCRIPT was immunoprecipitated with anti-
GFP antibody–coupled beads, and the immunoprecipitated fraction was subjected 
to immunoblotting with an anti-GFP antibody. Equal expression of the HA-tagged 
nuclear receptors was demonstrated by immunoblotting of total lysates of the 
transfected cells with an anti-HA antibody (figure 1, top panels). YFP-DC-SCRIPT and 
the control protein YFP were both effectively immunoprecipitated by the anti-GFP 
antibody–coupled beads (figure 1). 
Figure 1. Association of DC-SCRIPT with multiple nuclear receptors in transfected Hek293 cells.	Lysates	
from	Hek293	cells	that	were	co-transfected	with	YFP-DC-SCRIPT	or	YFP	and	with	the	indicated	HA-tagged	
nuclear	 receptors,	 were	 immunoprecipitated	 (IP)	 with	 mouse	 monoclonal	 anti-GFP	 antibody–coupled	
beads	(the	antibody	recognizes	YFP-tagged	proteins).	The	immunoprecipitated	proteins	were	subjected	to	
immunoblotting	(WB)	with	the	anti-GFP	antibody	to	detect	YFP-tagged	proteins	or	with	a	rat	monoclonal	
anti-HA	 antibody	 to	 detect	 the	 co-immunoprecipitated	 HA-tagged	 nuclear	 receptors	 (NR-HA).	 Data	
shown	are	from	one	of	at	 least	three	experiments	that	produced	similar	results.	YFP-DC-SCRIPT	protein	
degradation	products	are	indicated	with	an	asterisk.
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In addition to the intact YFP-DC-SCRIPT protein, some additional protein bands were 
also observed that correspond to YFP-DC-SCRIPT breakdown products (figure 1 and 
data not shown). Interestingly, in cells transfected with YFP-DC-SCRIPT, the HA-
tagged nuclear receptor ERα was efficiently co-immunoprecipitated by the anti-GFP 
antibody–coupled beads (Figure 1, lane 2). HA-tagged PR-B (lane 4), RARα (lane 6), 
and PPARγ (lane 8) were also specifically co-immunoprecipitated with YFP-DC-SCRIPT, 
but not with the control protein YFP. We repeated these co-immunoprecipitation 
experiments using the same stringent lysis conditions in the presence or absence 
of the ligand and observed no substantial effect on the efficiency of the co-
immunoprecipitation experiments (data not shown). Additional yeast two-hybrid 
experiments showed no direct interaction between DC-SCRIPT and RAR, RXR, or ER 
(supplementary figure S1). These co-immunoprecipitation data combined with the 
yeast-two-hybrid results demonstrate that DC-SCRIPT is present in a protein complex 
with either of these nuclear receptors, and imply that these interactions are indirect 
and ligand independent.
Supplementary figure S1. DC-SCRIPT interactions in yeast two-hybrid assays.	Yeast	 two-hybrid	assays	
were	performed	using	bait	(-	=	the	negative	control	empty	plasmid	,	P	=	proline-rich	region	of	DC-SCRIPT,	
or	ZnAc	=	the	zinc	acidic	region	of	DC-SCRIPT)	and	prey	(RAR,	RXR,	ER,	or	CtBP1	[positive	control	for	binding	
to	DC-SCRIPT]	plasmids	in	the	absence	(white	bars)	and	presence	(black	bars)	of	ligand	(10	µM	all-trans-
retinoic	acid	for	RAR	and	RXR	prey	and	10	nM	β-estradiol	for	ER	prey).	The	physical	interaction	between	
the	 bait	 and	 prey	 proteins	 activates	 transcription	 of	 a	 reporter	 gene	 that	 encodes	 β-galactosidase. 
β-Galactosidase	activity	was	used	as	an	indicator	of	protein–protein	interactions.	β-Galactosidase	activity	
from	 the	 yeast	 clones	 containing	 bait	 and	 prey	was	 assayed	with	 the	 use	 of	 a	 Yeast	 β-Galactosidase	
Assay	Kit	 (Pierce)	and	measured	using	the	 following	equation:	 (1000	×	A420)/(t	×	V	×	OD660),	where	A420 
=	absorbance	value	at	420	nm, t	=	time	(in	minutes)	of	incubation,	V	=	volume	of	cells	(mL),	and	OD660	=	
optical	density	at	660	nm. We	analyzed	10	colonies	per	each	bait–prey	combination	per	experiment	for	
their	β-galactosidase	activity,	and	the	data	are	expressed	as	the	mean	values	of	three	experiments;	error	
bars	correspond	to	95%	confidence	intervals.
Effect	of	DC-SCRIPT	on	ER-	and	PR-B–Mediated	Transcription
Next, we used luciferase reporter assays to assess the effect of DC-SCRIPT on the 
transcriptional activity of the steroid-induced nuclear receptors ER and PR. Hep3B 
Chapter 5
96
cells were transfected with a reporter construct containing response elements for 
ER (ERE3-TATA-luc)29 and stimulated with the ER ligand estradiol. In the absence 
of exogenous ER very little luciferase was produced by transfected cells that were 
exposed to estradiol (figure 2A, left). By contrast, Hep3B cells that were co-transfected 
with a mammalian expression vector encoding ER displayed luciferase activity in an 
estradiol-dependent manner (figure 2A, right). Introduction of increasing amounts of 
an expression vector encoding DC-SCRIPT into cells expressing exogenous ER revealed 
a dose-dependent repression of estradiol-dependent ER-mediated luciferase 
activity (figure 2A, right). These data are in agreement with previous findings that 
demonstrated that DC-SCRIPT can repress expression levels of endogenous targets of 
ER (ie, cathepsin D and pS2).22 Similarly, DC-SCRIPT strongly repressed the hormone-
induced (ie, progesterone and R5020) transcription mediated by PR-B on the MMTV 
promoter in a dose dependent manner (figure 2B). These data indicate that DC-
SCRIPT specifically represses transcription mediated by the steroid receptors ER and 
PR-B in a dose- and hormone ligand–dependent manner.
Figure 2. Effect of DC-SCRIPT on estrogen receptor (ER)– and progesterone receptor (PR)-B–mediated 
transcription.	 A)	 ER-mediated	 transcription.	 Hep3b	 cells	 were	 transfected	 with	 the	 firefly	 luciferase	
reporter	plasmid	ERE3-TATA-luc	in	the	absence	(−)	or	presence	(+)	of	a	cotransfected	ER	expression	plasmid	
and	increasing	amounts	of	DC-SCRIPT	expression	plasmid.	The	cells	were	treated	for	24	hours	with	vehicle	
(white	bars)	or	10	nM	β-estradiol	(black	bars),	and	luciferase	activity	was	measured	with	a	luminometer.	
B)	PR-B–mediated	transcription.	Hep3b	cells	were	transfected	with	the	firefly	luciferase	reporter	plasmid	
MMTV-luc,	co-transfected	expression	vector	encoding	for	PR-B	as	indicated,	and	increasing	amounts	of	co-
transfected	DC-SCRIPT	expression	vector.	The	cells	were	treated	for	24	hours	with	vehicle	(white	bars),	100	
nM	progesterone	(grey	bars),	or	with	10	nM	R5020	(black	bars),	and	luciferase	activity	was	measured	with	
a	luminometer.	All	data	were	corrected	for	transfection	efficiency	by	dividing	the	firefly	luciferase	values	by	
the	value	of	a	co-transfected	Renilla	luciferase	reporter	construct.	Luciferase	data	are	expressed	relative	to	
luciferase	production	in	cells	transfected	with	the	nuclear	receptor,	stimulated	with	the	appropriate	ligand,	
and	in	the	absence	of	co-transfected	DC-SCRIPT.	Data	are	expressed	as	the	mean	values	of	at	least	four	
independent	experiments;	error	bars	correspond	to	95%	confidence	intervals.
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Effect	of	DC-SCRIPT	on	RARα/RXRα-	and	PPARγ/RXRα-Mediated	Transcription
To examine the effect of DC-SCRIPT on transcription mediated by two members of 
the RXR subclass of nuclear receptors, the RXR heterodimers with RARα and PPARγ, 
we performed additional luciferase reporter assays in Hep3B cells. Hep3B cells 
transfected with the luciferase reporter construct ptk-RARE3-luc,23 which contains 
three response elements for the heterodimer RARα/RXRα, exhibited luciferase 
activity after stimulation with the RARα/RXRα ligand AtRA (figure 3A). Strikingly, 
co-expression of increasing amounts of DC-SCRIPT resulted in a dose-dependent 
increase in luciferase activity upon addition of AtRA (figure 3A), which is in contrast 
to the repressive effect of DC-SCRIPT on the transcriptional activity of the steroid 
receptors. To unequivocally demonstrate that the observed increase in luciferase 
activity was mediated by RARα/RXRα, we repeated the experiment in insect SL2 
cells, which do not express RARα or RXRα38 (figure 3B). DC-SCRIPT activated AtRA-
dependent transcription in a dose-dependent fashion in SL2 cells only when RAR/
RXR was co-expressed. In addition, removal of the RARα/RXRα response elements 
in the reporter construct completely abolished luciferase production in both Hep3b 
and SL2 cells (data not shown). We further demonstrated that DC-SCRIPT enhanced 
the transcriptional activity of PPARγ/RXRα in Hep3B cells. Hep3B cells transfected 
with a reporter construct containing the response elements for PPARγ/RXRα (PPRE-
luc27) failed to display luciferase activity when exposed to the PPARγ ligands GW1929 
and troglitazone. However, co-expression of PPARγ/RXRα in these cells resulted in 
ligand-dependent induction of luciferase activity that was enhanced by DC-SCRIPT 
in a dose-dependent manner (figure 3C). These data indicate that in contrast to the 
repressive effect of DC-SCRIPT on the transcriptional activity of the steroid receptors 
ERand PR-B, DC-SCRIPT enhances transcription mediated by the RXR heterodimers 
RARα and PPARγ.
Chapter 5
98
Figure 3. Effect of DC-SCRIPT on RARα/RXRα- 
and PPARγ/RXRα-mediated transcription. 
A)	RARα/RXRα-mediated	transcription	in	Hep3b	
cells.	 Hep3b	 cells	 were	 transfected	 with	 the	
firefly	 luciferase	 reporter	 ptk-RARE3-luc	 and	
increasing	 amounts	 of	 a	 co-transfected	 DC-
SCRIPT	expression	vector.	The	cells	were	treated	
for	16	hours	with	vehicle	(white	bars)	or	1	µM	all-
trans-retinoic	acid	(AtRA)	(black	bars).	Luciferase	
activity	was	measured	with	a	luminometer	and	is	
expressed	relative	to	luciferase	production	upon	
stimulation	with	AtRA	and	in	the	absence	of	DC-
SCRIPT.	 B)	 RARα/RXRα-mediated	 transcription	
in	SL2	cells.	SL2	cells	were	transfected	with	the	
reporter	 firefly	 reporter	 ptk-RARE3-luc,	 the	 co-
transfected	expression	plasmids	RARα	and	RXRα	
as	 indicated	 and	 increasing	 amounts	 of	 the	
expression	vector	 for	DC-SCRIPT.	The	cells	were	
treated	for	16	hours	with	vehicle	(white	bars)	or	
1	µM	AtRA	(black	bars).	Luciferase	activity	was	
measured	with	a	 luminometer.	C)	PPARγ/RXRα-
mediated	 transcription	 in	 Hep3b	 cells.	 Hep3b	
cells	were	transfected	with	the	firefly	luciferase	
reporter	 PPRE2-luc,	 the	 PPARγ	 expression	
plasmid	 as	 indicated,	 and	 increasing	 amounts	
of	 the	 expression	 plasmid	 for	 DC-SCRIPT.	 Cell	
were	 treated	 for	 24	 hours	 with	 vehicle	 (white	
bars),	 the	 PPARγ	 ligand	 1	 µM	 GW1929	 (grey	
bars),	 or	 the	 PPARγ	 ligand	 10µM	 troglitazone	
(black	bars)	Luciferase	data	(B–C)	are	expressed	
relative	to	luciferase	production	in	the	presence	
of	 cotransfected	 nuclear	 receptor,	 upon	
stimulation	with	the	ligand,	and	in	the	absence	
of	 cotransfected	 DC-SCRIPT.	 All	 data	 (A–C)	 are	
corrected	 for	 transfection	efficiency	by	dividing	
the	 firefly-	 luciferase	 values	 by	 the	 value	 of	 a	
co-transfected	Renilla	luciferase	reporter	construct.	The	data	are	expressed	as	the	mean	of	at	least	four	
independent	experiments;	error	bars	correspond	to	95%	confidence	intervals.
Effect	of	DC-SCRIPT	on	nuclear	receptor–induced	transcription	 in	breast	carcinoma	
MCF7	cells	
Our finding that DC-SCRIPT can repress transcription mediated by the steroid 
receptors ER and PR-B, whereas on the other hand it can enhance the transcriptional 
activity of the RXR heterodimers RARα and PPARγ, implies that DC-SCRIPT may 
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be a key regulator that balances the cell’s response to multiple nuclear receptor 
ligands such as vitamins, fatty acids, and hormones. To corroborate these findings, 
we examined the effect of DC-SCRIPT on nuclear receptor–induced transcription 
in human breast carcinoma MCF-7 cells which endogenously express both PR and 
RARα. Therefore, MCF-7 cells were cotransfected with MMTV-Rluc, a progesterone-
inducible reporter construct that drives the expression of Renilla luciferase, and ptk-
RARE3-luc, an AtRA-inducible reporter construct that drives the expression of firefly 
luciferase. Control experiments showed that both types of luciferase are induced in 
cells that are exposed to either the corresponding specific nuclear receptor ligand 
(PR ligand: R5020 and RARα/RXRα ligand: AtRA) or both nuclear receptor ligands 
compared with MCF-7 cells treated with vehicle (figure 4A and B). In addition, the 
effect of DC-SCRIPT on the activity of these endogenously expressed nuclear receptors 
was in agreement with our findings in transfected Hep3b cells (figure 2B and figure 
3A). Interestingly, co-expression of DC-SCRIPT together with both the AtRA-inducible 
reporter and the progesterone-inducible reporter enhanced RARα/RXRα-mediated 
transcription (white bars) and concurrently repressed the activity of PR (black bars) 
(figure 4C). We further found that DC-SCRIPT overexpression inhibited MCF-7 cell 
growth, as did treatment of MCF-7 cells with the known ER antagonist tamoxifen 
(supplementary figure S2). These data demonstrate that the presence of DC-SCRIPT 
can simultaneously modulate the activity of endogenously expressed PR and RARα/
RXRα in MCF-7 cells and affects MCF-7 cell growth.
Supplementary figure S2. Effect of DC-SCRIPT on 
the growth of MCF-7 cells.	Human	breast	cancer	
MCF-7	cells	were	transfected	with	pEYFP	(control,	
white	bars)	or	pEYFP-DCSCRIPT	 (black	bars)	and	
incubated	for	16	hours.	The	cells	were	incubated	
in	the	presence	or	absence	of	1	µM	tamoxifen	for	
96	hours,	harvested	and counted using	a	Bürker	
cell	 counting	 chamber	 (Optik	 Labor,	 Germany)	
and	 analyzed	 for	 YFP	 expression	 by	 means	 of	
fluorescence-activated	 cell	 sorting	 on	 a	 FACS-
Calibur	 (BD	 bioscience)	 and	 analyzed	 using	
WinMDI	 2.8	 software	 by	 J.	 Trotter	 (The	 Scripps	
institute).	Thereafter,	the	number	of	transfected	cells	was	calculated.	Number	of	cells	plotted	in	the	graph	
is	relative	to	the	number	of	cells	at	the	start	of	incubation	in	the	presence	or	absence	of	tamoxifen.	Data	
are	 expressed	 as	 the	 mean	 values	 of	 three	 independent	 experiments;	 error	 bars	 correspond	 to	 95%	
confidence	intervals.
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Figure 4. Effect of DC-SCRIPT on nuclear 
receptor–induced transcription in breast 
carcinoma MCF7 cells. 
A)	 RARα/RXRα-mediated	 transcription.	 MCF7	
cells	 were	 transfected	with	 the	 AtRA	 sensitive	
reporter	 ptk-RARE3-luc	 (firefly	 luciferase)	 and	
in	 the	 presence	 or	 absence	 of	 an	 expression	
plasmid	of	DC-SCRIPT.	Cells	were	treated	for	24	
hours	with	vehicle	(white	bars),	with	1	µM	AtRA	
(grey	 bars),	 or	 1	 µM	 AtRA	 and	 10	 nM	 R5020	
simultaneously	 (black	 bars).	 B)	 PR-B	mediated	
transcription.	MCF7	cells	were	transfected	with	
the	 progesterone-sensitive	 Renilla	 luciferase	
reporter	 plasmid	 MMTV-RLuc	 and	 with	 a	 DC-
SCRIPT	 expression	 plasmid	 as	 indicated.	 Cells	
were	 treated	 for	 24	 hours	with	 vehicle	 (white	
bars),	with	the	PR-B	ligand	10	nM	R5020	(grey	
bars),	 or	 with	 1	 µM	 AtRA	 and	 10	 nM	 R5020	
simultaneously	(black	bars).	The	luciferase	data	
in	A	and	B	are	expressed	 relative	 to	 luciferase	
activity	 in	 the	absence	of	DC-SCRIPT	and	upon	
stimulation	 with	 AtRA	 and	 R5020.	 C)	 RARα/
RXRα-	and	PR-B-mediated	 transcription.	MCF7	
cells	were	co-transfected	with	the	AtRA	sensitive	
ptk-RARE3-luc	 (firefly	 luciferase	 reporter)	 and	
with	 the	 progesterone-sensitive	 MMTV-RLuc	
(renilla	luciferase	reporter)	and	with	increasing	
amounts	 of	 DC-SCRIPT	 and	 stimulated	
simultaneously	 for	 24	 hours	 with	 10nM	
R5020	 and	 1	 µM	 AtRA.	 White	 bars	 indicate	
AtRA-mediated	 luciferase	 production	 (firefly	
luciferase)	 and	 black	 bars	 R5020-mediated	
luciferase	 production	 (Renilla	 luciferase).	
Luciferase	 activity	 is	 expressed	 relative	 to	
luciferase	 production	 upon	 stimulation	 with	
AtRA	 and	 R5020	 and	 in	 the	 absence	 of	 DC-
SCRIPT.	 All	 luciferase	 data	 are	 expressed	
as	 the	 mean	 of	 at	 least	 three	 independent	
experiments;	 error	 bars	 correspond	 to	 95%	
confidence	intervals
DC-SCRIPT	Expression	in	Breast	Epithelial	Cells
Among immune cells, DC-SCRIPT expression appears to be restricted to the dendritic 
cell lineage.19 Less is known about DC-SCRIPT expression in non-immune cells. 
Because DC-SCRIPT regulates transcription mediated by multiple nuclear receptors 
that play an important role in breast cancer and affects growth of the breast 
carcinoma MCF-7 cells, we examined DC-SCRIPT mRNA levels in normal breast tissue 
and corresponding breast tumor tissue from nine patients. 
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Figure 5. DC-SCRIPT expression in breast epithelial cells.	A)	DC-SCRIPT	mRNA	expression	in	paired	tissue	
samples.	DC-SCRIPT	mRNA	levels	 in	healthy	tissues	(black	bars)	and	corresponding	breast	tumor	(white	
bars)	 tissue	 (n	 =	 9	 patients)	 relative	 to	 PBGD	mRNA	 as	 determined	 by	 quantitative	 RT-PCR.	 B)	mRNA	
expression	 in	CD326-positive	and	CD326-negative	breast	 cells.	 Expression	of	CD326,	CD45,	CD11c,	and	
DC-SCRIPT	 mRNA	 in	 CD326-positive	 (white	 bars)	 and	 CD326-negative	 (black	 bars)	 cells	 purified	 from	
breast	tissue	relative	to	PBGD	mRNA	as	determined	by	quantitative	real-time	RT-PCR.	Data	from	one	of	the	
two	DC-SCRIPT–positive	patients	out	of	six	are	shown.	Data	are	expressed	as	the	mean	of	at	least	three	
independent	quantitative	PCR	assays;	error	bars	correspond	to	95%	confidence	intervals	C,D)	DC-SCRIPT	
and	CD326	protein	 expression	 in	 breast	 tumor	 sections.	 Epcam	was	 stained	with	 an	 anti-CD326	 (red),	
DC-SCRIPT	with	anti-DC-SCRIPT	(red)	or	matched	isotypes	(red)	as	control	staining	on	frozen	breast	tumor	
sections	 as	 detected	 by	 immunohistochemistry	 staining.	 Nuclei	 are	 counter-stained	 with	 hematoxylin	
(blue).	Magnification	is	indicated	by	size	bars	(C)	0.1	μm	and	D)	1	μm)	in	lower	left	corner.	Representative	
sections	are	shown.
DC-SCRIPT mRNA expression was readily detected in normal breast tissue by 
quantitative PCR. Statistically significantly lower DC-SCRIPT mRNA levels were 
present in the corresponding breast tumor samples (P	= .010 [paired t test]; figure 
5A) DC-SCRIPT mRNA was essentially undetectable in more than 50 different cell 
lines analyzed, including a panel of 16 breast tumor cell lines (data not shown). 
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To identify which cells in the breast tissue samples expressed DC-SCRIPT mRNA, total 
cells isolated from fresh normal breast tissue biopsy samples were separated into 
an epithelial cell–positive and an epithelial cell–depleted fraction by magnetic bead 
sorting using the epithelial cell marker EpCaM (CD326). Quantitative PCR analysis of 
these samples showed that, as expected, DC-SCRIPT mRNA was present in the CD326-
depleted leukocyte-containing fraction, as were the mRNAs encoding the dendritic 
cell–specific marker CD11c and the leukocyte marker CD45 (figure 5B). Importantly, 
DC-SCRIPT mRNA was also detected in the CD326-positive epithelial cell fraction. 
The absence of CD11c mRNA in the CD326-positive fraction indicates that epithelial 
cells and not contaminating dendritic cells were the cells that expressed DC-SCRIPT 
mRNA. Immunohistochemistry on frozen breast tumor sections confirmed that 
morphologically normal and malignant CD326-positive ductal epithelial cells express 
DC-SCRIPT protein (figure 5C and D). In concordance with the PCR data (figure 5A), a 
wide range of DC-SCRIPT protein expression levels was observed in the breast tumor 
biopsy samples (data not shown).
Prognostic	Significance	of	DC-SCRIPT	mRNA	Expression	in	Breast	Cancer	
Next, we explored the prognostic value of DC-SCRIPT mRNA expression in three 
cohorts of breast cancer patients. Characteristics of these patient cohorts and tumor 
tissues used in this study are described in table 1. Most patients (70%–80%) in the 
untreated patient (ie, the discovery and validation) cohorts were postmenopausal at 
the time of primary surgery, whereas all patients that were treated with tamoxifen 
were postmenopausal (P < .001). The discovery group consisted only of pT1 or pT2 
tumors without axillary nodal involvement, whereas both the validation and the 
tamoxifen cohorts consisted of larger tumors (8%–16% were pT3; P < .001) and 
included patients with positive lymph nodes (validation vs tamoxifen: 17% vs 74%, P	<	
.001). The discovery group mostly (72%) underwent breast-conserving lumpectomy, 
whereas most patients in both the non-treated and tamoxifen-treated cohorts 
underwent modified radical mastectomy (69%–70%, P < .001). Patients treated with 
endocrine therapy received tamoxifen 40 mg twice daily for at least 2 years. The 
three study groups did not differ in the relative size of their subgroups as defined by 
DC-SCRIPT expression (chi-square P = .543) (table 1).
 First, we measured the DC-SCRIPT mRNA levels in primary breast tumors from a 
cohort of patients who had not received systemic adjuvant treatment (the discovery 
group; n= 47). 
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Table 1. Patient and tumor characteristics by study group*
Characteristic
Discovery
N (%)
Validation
N (%)
Tamoxifen-treated
N (%) P†
Menopausal status
 Premenopausal 9 (19) 26 (27) 0 (0) <.001
 Postmenopausal 38 (81) 71 (73) 68 (100)
Tumor type 
 Ductal 42 (89) 61 (63) 34 (50) <.001
 Lobular 5 (11) 10 (10) 6 (9)
 Other/unknown 0 (0) 26 (27) 28 (41)
Tumor grade‡
 1 7 (15) 3 (3) 5 (7) .026
 2 15 (32) 27 (28) 20 (29)
 3 19 (40) 33 (34) 29 (43)
    Unknown/missing 6 (13) 34 (35) 14 (21)
Tumor stage§ (size in mm)
 pT1 (<20) 31 (66) 33 (34) 17 (25) <.001
 pT2 (20–50) 16 (34) 55 (57) 39 (58)
 pT3 (>50) 0 (0) 8 (8) 11 (16)
    Unknown/missing 0 (0) 1 (1) 1 (1)
No. of positive lymph nodes
 0 47 (100) 74 (76) 5 (7) <.001
 1–3 0 (0) 7 (7) 38 (56)
 >4 0 (0) 10 (10) 12 (18)
    Unknown/missing 0 (0) 6 (6) 13 (19)
ER and PR status
 ER and PR negative 10 (21) 32 (33) 21 (31) .342
 ER and/or PR positive 37 (79) 65 (68) 47 (69)
Type of surgery
 Lumpectomy 34 (72) 29 (30) 21 (31) <.001
 Mastectomy 13 (28) 68 (70) 47 (69)
Radiotherapy
 No 14 (30) 35 (36) 7 (10) .001
 Yes 33 (70) 62 (64) 61 (90)
Systemic adjuvant therapy
 No 47 (100) 97 (100) 0 (0) <.001
 Yes 0 (0) 0 (0) 68 (100)
DC-SCRIPT mRNA level║
 Low 16 (34) 33 (34) 18 (26) .543
 High 31 (66) 64 (66) 50 (74)
*ER = estrogen receptor; PR = progesterone receptor.
† Chi-square test (two-sided).
‡ Bloom–Richardson grade.39
§ American Joint Committee on Cancer staging.35
║DC-SCRIPT/PBGD ratio higher or lower than 0.15, the optimal prognostic cutpoint in the discovery group.
Chapter 5
104
Figure 6. DC-SCRIPT expression as a prognostic marker in ER- and PR-positive breast cancer.	A)	Kaplan–
Meier	analysis	of	disease-free	 interval	according	to	DC-SCRIPT	mRNA	expression	 in	tumors	from	breast	
cancer	patients	who	did	not	have	axillary	lymph	node	metastases	and	did	not	receive	systemic	adjuvant	
therapy	(discovery	group;	n	=	47).	B)	Kaplan–Meier	analysis	of	disease-free	interval	according	to	DC-SCRIPT	
mRNA	 expression	 in	 tumors	 from	 an	 independent	 validation	 group	 that	 included	 patients	 with	 larger	
tumors	than	those	in	the	discovery	group	and	with	axillary	lymph	node	metastases	(n	=	97).	C)	Kaplan–
Meier	analysis	of	disease-free	interval	according	to	DC-SCRIPT	mRNA	expression	in	tumors	from	patients	
in	the	validation	group	with	ER-	and	PR-positive	tumors	(n	=	65).	D)	Kaplan–Meier	analysis	of	disease-free	
interval	according	to	DC-SCRIPT	mRNA	expression	 in	tumors	from	patients	 in	the	validation	group	with	
DC-SCRIPT:	NR	modulation	and	breast	cancer
105
ER-	and	PR-negative	tumors	(n	=	32).	E)	Kaplan–Meier	analysis	of	disease-free	interval	according	to	DC-
SCRIPT	mRNA	expression	 in	 tumors	 from	patients	 treated	with	 tamoxifen	 (n	=	68).	 (A–E)	Patients	with	
high	DC-SCRIPT	expression	were	compared	with	patients	with	lower	DC-SCRIPT	expression.	High	DC-SCRIPT	
expression	(dotted	line)	indicates	expression	above	the	optimal	cutoff	of	DC-SCRIPT/PBGD	transcript	ratio	
of	0.15;	low	DC-SCRIPT	expression	(solid	line)	indicates	expression	below	DC-SCRIPT/PBGD	transcript	ratio	
of	0.15.	F)	Kaplan–Meier	analysis	of	disease-free	 interval	according	 to	 tumor	ER	and	PR	status	among	
patients	treated	with	tamoxifen	(n	=	68).	Dotted	line	corresponds	to	patients	with	ER-	and/or	PR-positive	
tumors;	solid	line	corresponds	to	patients	with	ER-	and	PR-negative	tumors.	All	P	values	are	two-sided	(Cox	
proportional	hazards	tests).	Tick	marks	indicate	censored	events,	and	vertical	lines	indicate	95%	confidence	
intervals.	Numbers	below	graphs	are	the	number	of	patients	at	risk	at	that	time	point.
The DC-SCRIPT mRNA level in this patient group was not associated with any of the 
clinicopathological parameters [ie, menopausal status, tumor type, grade,39 tumor 
size, lymph node status, hormone receptor status, or type of surgery or therapy or 
with the percentage of tumor cells in the biopsy sample (data not shown). We then 
analyzed the prognostic value of DC-SCRIPT mRNA level in the discovery group after 
dichotomization of the patients according to an optimal DC-SCRIPT to PBGD transcript 
ratio cutoff of 0.15, which resulted in 16 (34%) patients with low levels of DC-SCRIPT 
mRNA and 31 (66%) patients with high levels of DC-SCRIPT mRNA in their primary 
tumors. In a Kaplan–Meier survival analysis, these two groups of patients differed 
statistically significantly with respect to disease-free interval: those with a high DC-
SCRIPT mRNA level had a statistically significantly longer disease-free interval than 
those with a low DC-SCRIPT mRNA level (hazard ratio [HR] of recurrence = 0.23, 95% 
confidence interval [CI] = 0.06 to 0.93, P = .039) (figure 6A).
 To validate this finding, we analyzed DC-SCRIPT expression in an independent 
Cohort of patients who also had not received adjuvant systemic treatment (the 
validation group; n = 97). Overall, the validation group included more patients with 
advanced disease than the discovery group (eg, pT3 tumors: 8% vs 0%; axillary nodal 
involvement: 17% vs 0%) (table 1). Nevertheless, when we applied the same cutoff, 
the 64 patients (66%) with a high tumor DC-SCRIPT mRNA level had statistically 
significantly better prognosis than the 33 patients (34%) with low tumor DC-SCRIPT 
mRNA level (HR of recurrence = 0.50, 95% CI = 0.26 to 0.95, P	= .034) (figure 6B). 
 Because DC-SCRIPT represses the activity of both ER and PR, we explored the 
prognostic value of DC-SCRIPT in relation to the ER and PR status of the primary 
tumor. We found that the tumor DC-SCRIPT mRNA level had statistically significant 
prognostic value for patients in the discovery and validation groups with ER- and/
or PR-positive tumors but not for those with ER- and PR-negative tumors (discovery 
group, patients with ER- and/or PR-positive tumors: HR of recurrence = 0.16, 95% CI 
= 0.03 to 0.89, P = .030; discovery group, patients with ER- and PR-negative tumors: 
HR of recurrence = 0.73, 95% CI = 0.07 to 8.07, P = .797; validation group, patients 
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with ER- and/or PR-positive tumors: HR of recurrence = 0.42, 95% CI = 0.19 to 0.91, P	
= .028 [figure 6C]; validation group, patients with ER- and PR-negative tumors: HR of 
recurrence = 0.68, 95% CI = 0.21 to 2.22, P = .519 [figure 6D]). 
Supplementary Figure S3. 
DC-SCRIPT expression as a 
prognostic marker in 
breast cancer. 
Kaplan–Meier	 estimates	
of	 disease-free	 interval	
according	to	quartiles	of	DC-
SCRIPT	mRNA	expression	in	
tumors	from	patients	in	the	
combined	 validation	 and	
tamoxifen-treated	 groups	
(n	=	165).	Q1	 is	 the	 lowest	
quartile	 of	 DC-SCRIPT	
mRNA	expression,	and	Q4	is	
the	highest	quartile.
We next assessed the prognostic value of DC-SCRIPT expression and tumor ER and 
PR status in a third cohort of patients who received anti-estrogen therapy with 
tamoxifen (n = 68). Strikingly, when we applied the same cutoff that was established 
in the discovery group, DC-SCRIPT expression had approximately the same prognostic 
value in the tamoxifen-treated cohort as was found in the validation group (HR of 
recurrence = 0.46, 95% CI = 0.22 to 0.97, P = .040) (figure 6E). As expected, tumor ER 
and PR status predicted the response to endocrine therapy in this group of patients 
(P = .011, figure 6F).
 We next performed univariate and multivariable Cox regression analyses in the 
combined validation and tamoxifen cohorts (n = 165) to assess the independence of 
the prognostic value of DC-SCRIPT mRNA expression after correction for standard 
clinicopathological parameters (table 2). In the univariate analysis, tumor grade (P = 
.022), tumor size (P = .020), lymph node status (P < .001), the type of surgery (P =.018), 
and DC-SCRIPT mRNA level (P = .004) were statistically significantly associated with 
prognosis but tumor ER and PR status was not. In this combined cohort, DC-SCRIPT 
mRNA level was statistically significantly associated with prognosis when entered as 
a continuous variable in a Cox regression analysis independent of cutpoint (P = .013; 
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data not shown) and after dividing the patients into quartiles of DC-SCRIPT mRNA 
level (P = .001, log-rank test for trend; supplementary figure S3, available online). 
The multivariable analysis (table 2) revealed that DC-SCRIPT is an independent factor 
contributing to prognosis after correction for tumor size, lymph node status, systemic 
adjuvant treatment (n = 145; HR of recurrence = 0.50, 95% CI = 0.29 to 0.85, P	= .010). 
 The interaction between DC-SCRIPT mRNA level and tamoxifen treatment was 
not statistically significant (P = .470), whereas the interaction between DC-SCRIPT 
mRNA level and tumor ER and PR status was (P = .017) (table 2). These data indicate 
that the prognostic value of DC-SCRIPT mRNA level is independent of whether or 
not the patient received tamoxifen, but does depend on whether or not the tumor 
expresses ER and PR. 
Table 2. Univariate and multivariable Cox proportional hazards modeling of factors associated with 
disease-free survival in the combined validation and tamoxifen-treated patient groups (n=165)*
Factor and comparison
Univariate analysis Multivariable analysis
HR of recurrence
(95% CI)
P†
HR of recurrence
(95% CI)
P†
Postmenopausal vs premenopausal 0.69 (0.38 to 1.26) .224 0.58 (0.27 to 1.24) .157
Tumor type
 Lobular vs ductal 1.94 (0.96 to 3.92) .216 1.18 (0.45 to 3.10) .771
 Other or unknown vs ductal 1.03 (0.61 to 1.75) 1.25 (0.67 to 2.32)
Tumor grade ‡
 2 vs 1 0.94 (0.21 to 4.19) .022 0.86 (0.18 to 4.03) .337
 3 vs 1 2.29 (0.55 to 9.57) 1.67 (0.38 to 7.33)
Tumor stage §
 pT2 vs pT1 1.73 (0.96 to 3.13) .020 1.74 (0.91 to 3.32) .133
 pT3 vs pT1 2.97 (1.39 to 6.37) 2.19 (0.96 to 5.02)
No. of positive lymph nodes
 1–3 vs 0 1.63 (0.89 to 2.97) <.001 4.13 (1.86 to 9.16) <.001
 >4 vs 0 4.68 (2.48 to 8.84) 11.6 (5.17 to 26.2)
ER- and/or PR-positive vs ER- and PR- negative 0.81 (0.49 to 1.33) .411 0.95 (0.52 to 1.75) .879
Mastectomy vs lumpectomy 1.93 (1.09 to 3.43) .018 0.71 (0.29 to 1.70) .439
Radiotherapy (yes vs no) 1.23 (0.69 to 2.17) .480 0.59 (0.29 to 1.21) .149
Systemic adjuvant therapy (yes vs no) 1.14 (0.71 to 1.84) .593 0.33 (0.16 to 0.67) .002
DC-SCRIPT mRNA level (high vs low)║ 0.49 (0.30 to 0.80) .004 0.50 (0.29 to 0.85) .010
DC-SCRIPT interaction
 With systemic adjuvant therapy 0.83 (0.49 to 1.39) .470 NA
 With ER and PR status 0.56 (0.34 to 0.91) .017 NA
* HR = Hazard ratio; ER = estrogen receptor; PR = progesterone receptor; NA = not applicable.
† Cox proportional hazards
‡ Bloom–Richardson Grade39.
§ American Joint Committee on Cancer staging35
║ DC-SCRIPT/PBGD ratio higher or lower than 0.15, the optimal prognostic cutpoint in the discovery group.
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DISCUSSION
Here we have identified DC-SCRIPT as a regulator of the activity of several subclasses 
of nuclear receptors and as a prognostic marker for ER- and/or PR-positive breast 
cancer. We have shown that expression of DC-SCRIPT in Hep3B cells and MCF-7 cells 
represses the hormone-induced activity of ER and PR while it concurrently enhances 
RARα/RXRα-and PPARγ/RXR-mediated transcription. In addition, we showed that 
ductal epithelial cells express DC-SCRIPT mRNA, that breast tumors express lower 
levels of DC-SCRIPT than normal breast tissue from the same patient, and that breast 
tumor cell lines do not express DC-SCRIPT mRNA. Moreover, quantification of DC-
SCRIPT mRNA expression in three cohorts of breast cancer patients revealed that 
DC-SCRIPT mRNA expression is an independent prognostic factor for breast cancer 
patients with ER- and/or PR-positive tumors.
 To our knowledge, we have provided the first evidence for the presence of 
DC-SCRIPT in multiple nuclear receptor protein complexes based on data from co-
immunoprecipitation experiments. Results of yeast two-hybrid experiments imply 
that DC-SCRIPT, unlike its direct binding to CtBP1,19 does not bind directly to nuclear 
receptors. This finding suggests that the interaction between DC-SCRIPT and nuclear 
receptors is likely to be mediated by other nuclear receptor co-regulators that are 
present in these large multi-protein complexes.14 Because DC-SCRIPT was previously 
shown to interact with multiple proteins known to be present in these protein 
complexes,19,22 it will be interesting to investigate the molecular mechanism by 
which DC-SCRIPT differentially modulates the activity of multiple classes of nuclear 
receptors.
 Because malfunction of nuclear receptors and their co-regulators has been 
associated with breast cancer,2-4 we evaluated the expression of DC-SCRIPT in breast 
tissue. We found that DC-SCRIPT is expressed by normal breast tissue whereas 
less DC-SCRIPT mRNA could be detected in the corresponding breast tumor tissue. 
Combined with our finding that DC-SCRIPT inhibits cell growth of the breast carcinoma 
cell line MCF-7, these data suggest that DC-SCRIPT may act as a tumor suppressor in 
breast cancer development. Such a function for DC-SCRIPT is also consistent with 
our finding that DC-SCRIPT overexpression in Hep3B and MCF-7 cells inhibits the 
activity of ER and PR, which were previously shown6 to exhibit proliferative and anti-
apoptotic activities in breast cancer cells. In contrast, RARα/RXRα and PPARγ/RXR, 
the transcriptional activities of which are enhanced by DC-SCRIPT, are reported to 
have anti-proliferative and pro-apoptotic effects in breast cancer cells.40-42 Moreover, 
a recent report showed that expression of RARα/RXRα target genes identified in 
MCF-7 cells predicted a positive clinical outcome in breast cancer patients.43 Our 
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findings in MCF-7 cells indicate that DC-SCRIPT affects the balance in the activities 
of endogenous PR and RARα/RXRα in favor of RARα/RXRα activity when the breast 
cancer cells are simultaneously stimulated with the respective ligands. To directly 
demonstrate a tumor suppressor function for DC-SCRIPT and to assess the impact 
of DC-SCRIPT expression on transcription at a genome-wide level is very difficult 
because prolonged overexpression of DC-SCRIPT in all of the cell lines tested thus 
far resulted in growth inhibition and death of the DC-SCRIPT-expressing cells (data 
not shown). Moreover, none of the cell lines analyzed endogenously expressed DC-
SCRIPT, which prevented us from performing the obvious knock-down experiments 
of endogenous DC-SCRIPT to further investigate its anti-proliferative effect. It will 
therefore be important to define the conditions and factors that regulate DC-SCRIPT 
expression, from both a physiological and a therapeutic perspective. 
 To our knowledge, this is the first time that DC-SCRIPT mRNA expression has been 
identified as a prognostic marker in breast cancer. Over the years, molecular profiling 
has yielded genetic signatures for many solid tumors44-49 including breast cancer,50 
however DC-SCRIPT was not present in these signatures. The absence of DC-SCRIPT 
from these signatures can be explained by the fact that on older microarrays used to 
determine breast cancer signatures, the DC-SCRIPT gene was not yet present and the 
relatively low DC-SCRIPT mRNA expression may have prevented its detection in more 
recent studies. Our discovery of DC-SCRIPT as an independent prognostic marker for 
breast cancer patients with ER- and/or PR-positive tumors was possible because we 
used a unique cohort of patients who were treated with systemic adjuvant therapy 
and followed up for 10 years.34,36 Prognostic significance can only be ascertained in 
such patient groups,51,52 which are becoming increasingly scarce because currently 
even patients with negative axillary lymph nodes almost all receive systemic adjuvant 
therapy. Our finding that DC-SCRIPT has prognostic value independent of a specific 
treatment suggests that DC-SCRIPT may contribute to tumor growth characteristics 
and is consistent with the proposed tumor suppressor function of DC-SCRIPT. The 
potential clinical significance of DC-SCRIPT extends beyond untreated patients 
given that we showed that high DC-SCRIPT expression, like ER and PR status, is also 
prognostic in tamoxifen-treated patients. In line with this finding is our demonstration 
that DC-SCRIPT inhibited the growth MCF-7 cells treated without tamoxifen or with 
tamoxifen to block ER function. These data imply that DC-SCRIPT expression may be 
used to select ER- and/or PR-positive patients who might be candidates for more 
aggressive adjuvant therapy. 
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This study has several limitations. First, we have not found independent validation 
of DC-SCRIPT mRNA expression as a prognostic marker in breast cancer in publicly 
available databases; the absence of the DC-SCRIPT gene on older microarrays and 
the relatively low abundance of DC-SCRIPT mRNA may have prevented its detection. 
Second, our clinical conclusions are therefore based on nonrandomized retrospective 
analyses. To attain a higher level of evidence, independent multicenter and/or 
randomized prospective studies of DC-SCRIPT expression analyses are necessary. 
 It will be extremely interesting to assess in future validating studies whether the 
RARα and/or PPARγ status of the tumors is of relevance regarding the prognostic value 
of DC-SCRIPT. The presence of RARα/RXRα target genes in the genetic signature of 
breast tumor samples predicts a positive clinical outcome in breast cancer patients.43 
Stimulation of the nuclear receptors RAR/RXR and PPARγ/RXR has been explored 
as a novel therapy for breast cancer.53,54 So far these therapies have shown only 
limited success due to retinoic acid resistance.18,55 Intriguingly, our data demonstrate 
that DC-SCRIPT is able to simultaneously enhance the activities of RARα/RXRα 
and PPARγ/RXRα and repress the activities of ERα and PR-B. On the basis of these 
findings we hypothesize that the anti-proliferative effect of DC-SCRIPT in breast 
cancer cells is mediated by modulating the activity of multiple nuclear receptors. It 
will be interesting therefore to also examine DC-SCRIPT expression levels in clinical 
trials that have explored the effect of stimulation of the RAR/RXR and PPARγ/RXR on 
the clinical outcome in breast cancer patients. 
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ABSTRACT
Nuclear Receptors (NR) are intracellular receptors that execute a transcriptional 
program upon binding to hormones, vitamins and metabolic products. They are key 
regulators of distinct physiological processes, including growth and differentiation, 
metabolism, and immunity. The impact of NR activation on a given cell can differ 
from proliferation induction to programmed cell death. NR malfunction is associated 
with different diseases, such as diabetes, chronic inflammatory diseases and cancer. 
Much progress has been made towards understanding the transcriptional regulation 
by individual NR at the molecular level. However, essentially every cell expresses 
multiple NR and will encounter complex mixtures of NR ligands during its life cycle. 
In this review, we will focus on novel insights in balancing NR activity via NR crosstalk 
and DC-SCRIPT/ZNF366, a bi-functional NR coregulator. The impact on breast cancer 
development and prognosis will be discussed.
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INTRODUCTION
In a physiological context cells are not alone, they communicate with surrounding 
cells and interact with the extracellular matrix (ECM). Within their local environment 
they experience complex mixtures of compounds and substrates, including growth 
factors, hormones, vitamins, organic constituents and their metabolic products. 
These cellular cues and the nature of the ECM offer a highly dynamic setting for cells. 
To maintain a healthy phenotype and avert malignant cell growth, cells require strict 
regulation of cell growth, -division and -death, processes in which nuclear receptors 
(NR) play an important role. In fact, dysfunction of NR can lead to uncontrolled 
proliferation and cell survival, allowing for cancer development.
 The NR family of ligand-inducible transcription factors recognize a diversity of 
ligands, including hormones (e.g. estrogens, corticosteroids and androgens), vitamins 
(e.g. vitamin A and D) and metabolic products (e.g. fatty acids, eicosanoid derivatives 
and oxidized lipids).1 In men 48 family members have been described that all share 
common functional domains: they contain an amino-terminal transactivation domain, 
a DNA binding domain (DBD) and a carboxy-terminal ligand-binding domain.2-4 Based 
on their mode of action NR are divided into two main subclasses. Type I NR comprise 
the steroid receptors, including the Estrogen Receptor (ER), Progesterone Receptor 
(PR), Androgen Receptor (AR) and Glucocorticoid Receptor (GR). Steroid receptors are 
classically sequestered in the cytoplasm of cells by binding to heat shock proteins. 
Upon ligand binding, they homodimerize and translocate to the nucleus where they 
bind to specific DNA sequences. Binding to these DNA response elements will lead to 
recruitment of coactivator complexes ultimately resulting in transcriptional activation 
of the target gene. Type II NR consists of the Retinoid X Receptor (RXR) heterodimers. 
Well-known members of this class are the Retinoic Acid Receptor (RAR), peroxisome 
proliferator-activated receptors (PPAR) and the Vitamin D Receptor (VDR). In contrast 
to type I NR, type II receptors generally reside in the nucleus in the absence of ligand. 
They bind to their response elements and are often complexed with corepressor 
proteins. Upon ligand binding, conformational changes occur, corepressor proteins are 
released, coactivators are recruited and transcription is initiated. (For reviews, see 2-6)
 Pathways affected by both type I and type II NR signalling in cells include those 
involved in apoptosis, cell cycle regulation and growth factor signalling. This has 
been particularly well-studied in the development and progression of breast 
cancer,7 where the type I NR ER and the type II NR RAR exert opposing effects on 
these pathways. Typically, estrogens are referred to as pro-tumourigenic, displaying 
proliferative and anti-apoptotic effects via ER activation, whereas RAR stimulation 
by retinoids is considered anti-tumourigenic, repressing cell growth while inducing 
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differentiation and/or apoptosis. These observations indicate that balancing the 
activity of NR is of major importance in keeping a healthy cell phenotype. The effects 
of a particular NR ligand on a cell will thus not only depend on its own concentration, 
the expression levels of its receptor and its coregulators, but also on the presence or 
absence of other ligands, other NR and their coregulators. Indeed, NR coregulators, 
like the coactivators SRC-1 (steroid receptor coactivator 1) and AIB1 (amplified in 
breast cancer-1 also known as SRC3) and NR corepressors (NcoRs) play a key role in 
regulating the cell’s response to NR ligands and have been associated with breast 
cancer.7,8 They play a central role in NR crosstalk, customizing the effect of NR to each 
target in relation to the local environment. 
 A protein termed dendritic cell-specific transcript (DC-SCRIPT or ZNF366) was first 
described in 2006 and recently shown to act as a coregulator of multiple NR.9 DC-
SCRIPT is a highly conserved protein10,11 originally identified in a unique immune cell 
subset, the antigen presenting dendritic cells (DC).12 The DC-SCRIPT protein consists 
of an N-terminal proline-rich region, 11 Cys2His2-type zinc fingers and a C-terminal 
acidic region. Beyond its zinc fingers, it shares no homology with proteins alike and 
has a restricted expression pattern, including epithelial cells. Remarkably, DC-SCRIPT 
could regulate the activity of several subclasses of NR. DC-SCRIPT overexpression 
inhibited the activity of ER and PR, known for their proliferative and anti-apoptotic 
activities in breast cancer cells. In contrast, the transcriptional activities of RAR/RXR 
and PPAR/RXR, mostly known for their anti-proliferative and pro-apoptotic effects in 
breast cancer cells, were enhanced by DC-SCRIPT. In this review, we will focus on NR 
crosstalk and DC-SCRIPT. The importance of balancing NR activity in breast cancer 
development and prognosis will be discussed.
NUCLEAR RECEPTOR COREGULATORS
Balancing NR activity is of major importance in keeping a healthy cell phenotype. 
It is becoming more and more apparent that the composition of NR coregulator 
complexes is crucial for maintaining this balance, as these complexes are essential 
for appropriate NR responses to ligands and other extra- and intracellular signals. 
Coregulator complexes are involved in multiple transcriptional processes such as 
catalyzing the process of chromatin condensation and facilitating the communication 
with the general transcription apparatus at target gene promoters.13 Coregulators are 
classically divided into coactivators known to enhance NR-mediated transcription and 
corepressors that dampen the agonistic effect of NR ligands. Coactivator proteins can 
be present in three different multiprotein complexes, i) in the SWI/SNF complex that 
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is associated with ATP-dependent alteration in chromatin structure, ii) in the p160/
CBP complex which is mostly related to histone acetylation and iii) in the mediator 
complex which is involved in the activation of RNA polymerase II and the initiation 
of transcription. Conversely, corepressors can inhibit NR-mediated transcription 
by interfering with the access of coactivators or by associating with HDAC (histone 
deacetylase) complexes that repress transcription by catalyzing the condensation of 
chromatin. Initially it was thought that corepressors and coactivators reside in distinct 
protein complexes. However, current studies imply that these molecules can exist 
in the same large complexes suggesting that transcription repression and activation 
are more closely integrated than initially suggested.14,15 Depending upon cell and 
signalling context, coactivators and corepressors can on occasion switch roles.16-19 
Evidence indicates that the operational definition between repressors and activators 
can be modified by gene, cell, and signalling context for any one coregulator. 
Posttranslational modification is an important mode of regulation. Phosphorylation, 
acetylation, ubiquitination, methylation and/or sumoylation of NR but also of their 
coregulators have been reported to regulate the assembly, dissociation and the 
content of the regulatory protein complexes. These modifications allow for the 
dynamic modulation and integration of extracellular signalling pathways that will 
ultimately enhance or decrease the transcriptional efficacy of NR-cofactor containing 
complexes.13,20 The complex network of coactivators and corepressors thus provides 
a balanced and sensitive control mechanism to regulate NR target gene expression.
 A major boost in understanding NR function has been obtained by the introduction 
of genome wide ChIP (Chromatin ImmunoPrecipitation) technology. This technique 
enables the identification of specific transcription factors and the kinetics of cofactor 
recruitment to a specific locus. The order of recruitment, information on the local 
chromatin structure and the epigenetic state can also be determined. Especially 
the ERα-mediated transcriptional regulation has been elucidated by the use of 
multiple ChIP profiling studies. Excellent reviews detailing the recent advances in 
the identification of the ERα-binding sites, their target gene network and clinical 
applications can be found elsewhere.21,22 A perfect example for the identification of 
new factors involved in ER transcriptional regulation using these new techniques is 
the FoxA1 protein. FoxA1 is involved in ERα mediated transcriptional regulation by 
acting as a pioneer factor. Through its chromatin-remodelling activity, FoxA1 allows 
for the opening of genomic regions in the absence of hormone.23-26 FoxA1 binds 
DNA adjacent to response elements for ER, thereby facilitating the local recruitment 
of ER.27 FOXA1/ER binding sites are often located in distal enhancers far from the 
transcription start site of target genes. Gene transcription thus requires chromatin 
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looping to allow physical contact between the protein complexes binding to the 
enhancer and the proximal promoter.27,28 Recently, FoxA1 binding was suggested to 
be required but not sufficient to trigger functional activity of a given (cis)-regulatory 
region.29 The cellular and physiological context co-determines whether FoxA1-bound 
enhancers are active or inactive.29 The number of ER binding sites in MCF-7 cells 
identified by ChIP that do contain a FOXA1 motif has variably been estimated from 
less than 10% to approximately halve of the ER binding sites.23-26,28,30,31 The important 
role of FoxA1 in NR regulation is further emphasized by the finding that also AR 
activity is regulated by this pioneer factor.32,33 
FUNCTIONAL IMPACT OF NUCLEAR RECEPTOR ACTIVATION
NR activation induces a plethora of different proteins that take part in distinct 
biological pathways. Dysfunction of NR and/or their coregulators may affect one or 
more of these pathways and can lead to uncontrolled proliferation and cell survival, 
allowing for cancer development. Dominant pathways affected by NR in oncogenic 
cells include the apoptosis pathway, cell cycle regulation and growth factor 
signalling. These pathways have been particularly well studied in the development 
and progression of breast cancer, where the type I NR ER and the type II NR RAR exert 
opposing effects.
 Estrogens proliferative effects are held to be responsible for its role as a causative 
agent in breast cancer.34 In the breast cancer cell line MCF-7, ERα induces the G
1
- to 
S-phase transition, accelerating cell proliferation.35 This is driven by the increased 
activity of the ERα responsive cell cycle-related genes c-myc, cyclin D1 (CCND1), 
cyclin E1 (CCNE1) and E2 (CCNE2).25,34,36 siRNA mediated knock-down of either 
CCND1, CCNE1 or CCNE2 abrogates estrogen induced proliferation in breast cancer 
cells.34 Repressive cell cycle-regulators such as cyclin G2 (CCNG2) are also affected 
by ERα activation. Binding of ERα to the CCNG2 promoter initiates corepressor 
recruitment, negatively regulating expression of CCNG2.37 A potent feed forward 
loop has been reported for the autocrine protein trefoil factor-1 (TFF1), a direct 
ERα target. TFFs are overexpressed in several solid tumours including breast. They 
function in wound healing, where they promote migration and prevent apoptosis.38 
Forced TFF1 expression in MCF-7 and T47D breast cancer cells was associated with 
up-regulation of c-myc, CCND1 and CCNE1, and resulted in increased proliferation 
and survival, as well as enhanced migration and metastatic properties. Enhanced 
expression of several cyclins and c-myc also occurs through the Insulin-Like Growth 
Factor-1 (IGF-1) receptor system36 known to stimulate breast cancer mitosis, anti-
apoptosis and metastasis. ERα is critical in the activation of this pathway, inducing 
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expression of several IGF-1 family members.39,40 Re-expression of ERα in ER-negative 
MCF-7 breast cancer cell sub-lines also reactivated the IGF-1 pathway, which could 
be reversed with ERα antagonists.41 IGF-1R/ERα crosstalk is also bi-directional, as 
IGF-1 induces transcriptional activity of ERα and increases expression of estrogen-
inducible genes. In human breast cancer cells ERα activity could be blocked with 
IGF-binding protein-1.42 In addition, stimulating MCF-7 cells with estrogens rapidly 
induces IGF-IR, EGFR and MAPK activation through non-genomic ER signalling. EGF-R 
was was demonstrated to act in a linear sequence downstream of the IGF-R pathway. 
Blocking this pathway diminished estrogen induced mitogenic and anti-apoptotic 
effects.43 Furthermore, estrogens are potent apoptosis inhibitors, in contrast to anti-
estrogens that have a profound pro-apoptotic effect. ERα enhances the expression 
of several anti-apoptotic genes, including Bcl-2 and BclxL.
44 Moreover, the before-
mentioned increased TFF1 expression also downregulates the pro-apoptotic genes 
BBC3 (PUMA) and MDM2.45 
 While ERα skews cancer cells towards highly proliferative and apoptosis resistant 
tumour cells, RAR is typically referred to as tumour suppressive. Remarkably, ER 
and RAR counteract each other in cell cycle control and apoptosis pathways. In 
vitro studies have demonstrated that RAR ligands effectively repress proliferation 
in normal epithelial cells and ER positive breast cancer cells through G1 cell cycle 
arrest, associated with reduced cyclin D1 and -D3 expression.46 Additionally, retinoic 
acid (RA) triggers cell cycle arrest through immediate early RAR targets including the 
cell cycle regulator Btg-2. Induction of Btg-2 by RA was accompanied by a marked 
decrease in cyclin D1 expression, hampering G
1
- to S-phase transition.47 Apart from 
cell cycle regulation, RAR also counteracts ER function in the apoptotic pathway. 
The anti-apoptotic protein Bcl-2 was clearly downregulated in RA induced apoptotic 
cells, as was survivin, another suppressor of apoptosis.48,49 In addition, RA-induced 
apoptosis in MCF-7 cells was associated with an increased expression of several 
pro-apoptotic genes including caspase 7 and 9. Opposite to caspase 7, caspase 9 
harbors a retinoic acid response element (RARE) and transcription is depended on 
RAR activation.50
 It is clear from these functional studies that ER and RAR use similar pathways 
and even genes to exert opposite effects. In many studies breast cancer cells are 
usually treated with single ligands. Since physiologically cells are constantly triggered 
by multiple NR ligands, crosstalk between NR is inevitable. We need to learn much 
more about the physiological settings in which multiple NR ligands are around to 
determine the effect of their copresence on cell growth, -division and –death and the 
consequences for epithelial cell behaviour and breast cancer aetiology. 
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CROSSTALK OF ER & RAR AT THE NUCLEAR RECEPTOR LEVEL
Crosstalk of NR has been suggested for years and may involve different steps in the 
pathway.3 NR can share or compete for ligands, DNA response elements, or binding 
partners. They can also regulate the expression of other NR or behave as coregulators. 
Moreover, target gene products of a certain NR may affect the functionality or 
biosynthesis of other NR ligands. The consequences of crosstalk is that the expression 
of given set of target genes expected to be regulated by a given signalling pathway, 
is in fact dependent on the functioning of other signalling pathways.51 Crosstalk 
between different pathways will ultimately lead to an appropriate response of cells 
in a certain condition. 
 In breast cancer research the crosstalk between RAR and ER has recently 
regained increasing attention. It is known for long that estrogens can induce RAR 
expression,52,53 whereas RA induced RAR stimulation in breast cancer cells correlates 
with the decreased ERα expression.54 In addition it has been shown that ER repressed 
the transcriptional activity of RAR/RXR mediated transcription and this could be 
overcome by the addition of RA.55 Recently, three relevant research papers were 
published that provide novel insight in the mechanism of crosstalk between ER and 
RAR in breast cancer cells.9,56,57
 Hua and colleagues56 analyzed the genomic actions of RA signalling through RAR in 
MCF-7 breast cancer cells. By genome-wide mapping of RAR binding sites the authors 
found that RA signalling regulates the expression of many genes that are implicated 
in breast carcinogenesis. They also found extensive colocalization of RAR with ER DNA 
binding sites in the vicinity of genes that are antagonistically regulated by estrogen 
and RA. The majority of RAR binding sites were found in intronic or promoter-distal 
intergenic regions. As many ER and RAR binding sites appeared as neighbouring 
or even (partially) overlapping elements, the authors propose NR competition for 
the same closely spaced binding element as one mechanism for the antagonistic 
regulation of these genes upon RA treatment. Moreover, they demonstrated that 
FoxA1 and GATA3 binding coincided with RAR and ER binding, indicating that these 
transcription factors may also play an important role by coregulating ER and RAR on 
shared ER/RAR-binding elements. Hua et al.,56 postulate that ER and RAR are the “Yin 
and Yang” for the genetic regulation of proliferation and survival that are promoted by 
ER and inhibited by RARs. The ER/RAR antagonism appears to regulate itself through 
cross regulatory loops between ER, RARs and their cofactors. This balanced control 
of gene expression regulates fundamental cellular processes that when dysregulated 
can lead to cancer.56
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Ross-Innes and colleagues57 also mapped the RAR-binding events in MCF-7 and did 
this in the presence of the ER-ligand estrogen instead of RA. Moreover, these authors 
were the first to succeed in mapping the endogenous RAR-binding events. Their data 
demonstrated that RAR and ER can be part of the same transcriptional complex. 
Using Re-ChIp and co-immunoprecipitation experiments they show that RAR/ER co-
occupancy does occur in a cooperative manner in the presence of estrogen. Analysis 
of the genomic location of the RAR binding events revealed that most binding events 
of RAR occurred in intergenic regions. However, RAR could also bind to ER-binding 
regions and depended in half of these sites on the presence of ER. In contrast, ER 
binding to chromatin was independent of the presence of RAR; RAR rather functioned 
as a scaffold in the ER complex for maintaining cofactor interactions. Upon addition 
of RA, the estrogen-ER-dependent role for RAR could be inhibited and could have 
antagonistic effects on ER transcriptional activity similar to as what has been 
described by Hua et al..56 ChIP analysis of hormone-depleted MCF-7 cells revealed 
that in estrogen treated cells the co-presence of RA did not perturb binding of either 
receptor. The co-presence of RA rather diminished the amount of the cofactors p300 
and TRAP220 that are essential for effective transcription at ER/RAR regulated genes. 
The authors postulate two independent functions for RAR. In response to natural 
ligands such as RA it exerts its classical role as heterodimeric partner of RXR while 
during estrogen treatment it can function as an ER-associated protein required for 
maintaining cofactor interactions. Therefore, any shift between the classic and novel 
pathways may influence ER function in breast cancer cells. RA promotes the classic 
role of RAR at the cost of Estrogen-ER function.57
 The recent identification of a novel NR modulator, termed DC-SCRIPT, suggest 
that ER/RAR crosstalk might not only take place at the NR level, but also on the 
coregulator level. The 11 zinc fingers containing protein DC-SCRIPT also contains a 
functional CtBP1 binding motif10 and a putative LxxLL NR interaction motif. It has been 
shown that DC-SCRIPT can interact with multiple transcription regulatory proteins 
such as CtBP1, RIP140 and HDAC1, 3 and 6, suggesting that DC-SCRIPT is present in 
very large multiprotein complexes known to be involved in NR regulation.9,58-60 DC-
SCRIPT was shown to interact with multiple NR, including ER and RAR. DC-SCRIPT was 
able to repress transcription mediated by ER and surprisingly enhanced transcription 
mediated by RAR. Interestingly, exogenous DC-SCRIPT in MCF-7 was shown to 
opposingly regulate transcription mediated by multiple NR at the same time. In 
the presence of multiple NR ligands, DC-SCRIPT was able, in a single cell, to repress 
transcription mediated by the type I NR PR and activate transcription mediated by 
the type II receptor RAR. To our knowledge, there are currently no coregulators 
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known that have such a distinct effect on type I and type II mediated transcription. So 
far, studies investigating crosstalk between ER and RAR have mostly been performed 
in MCF-7. As this cell line and all other cell lines tested so far are essentially negative 
for DC-SCRIPT, in contrast to breast epithelial cells, the effect of DC-SCRIPT on the 
estrogen and RA signalling pathways in breast cancer cells remains to be investigated. 
This may shed novel insight into the crosstalk between ER and RAR.
 Collectively, these novel data are indicative for the high level of complexity in 
transcriptional crosstalk between ERα, RAR and DC-SCRIPT (see figure 1). Upon 
estrogen or RA stimulation, the corresponding NR can exert their classical role or 
behave as a coregulator or cofactor of the other. Depending on cellular context, 
expression levels of DC-SCRIPT, different NR and their coregulators and the presence 
or absence of (multiple) ligands, cells are skewed to a certain genetic program. 
Extensive crosstalk between NR is essential to enable cells to fine-tune their response 
and promptly adapt to different environmental situations.
Figure 1. Transcriptional crosstalk between DC-SCRIPT, RAR and ER
Hypothesized	model	of	the	 induction	of	an	estrogen	and	retinoid	responsive	gene.	RAR	and	ER	binding	
sites	have	been	shown	to	be	in	close	proximity.	RAR	can	function	as	a	scaffold	for	ER	binding	or	can	act	in	
its	more	classical	role	as	heterodimeric	partner	of	RXR.	FOXA1	acts	as	a	pioneering	factor	for	ER	binding.	
Both	coactivators	and	corepressors	regulate	RAR	and	ER	function.	DC-SCRIPT	can	exert	a	dual	role	in	this	
regulation.	It	represses	ER	function,	and	stimulates	RAR	function.	The	available	ligands	present	will	induce	
the	crosstalk	between	DC-SCRIPT,	NR,	its	regulators/cofactors	and	will	ultimately	lead	to	an	appropriate	
cell	response.
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NUCLEAR RECEPTORS, COREGULATORS AND BREAST CANCER
The incidence of breast cancer is known to be affected by the hormonal milieu breast 
cells experience over time. Important hormone-related risk factors for breast cancer 
include early menarche, nulliparity or late age at first birth and late menopause.61 
The type I hormone-inducible NR play an important role in the tumourigenesis of 
breast cancer. Breast tumour tissue expressing the type I NR, ER and/or PR, exhibit a 
well-differentiated phenotype indicating a good prognosis for the patient. Large scale 
expression profiling studies to classify tumours62-64 confirmed that ER/PR positive 
tumours are distinct from other breast tumour types on the basis of their gene 
expression pattern.63,65-67 Within the ER/PR positive tumours, two distinct types could 
be distinguished showing a different prognosis; the histologically low-grade luminal 
A subtype and the more often high-grade luminal B subtype.63,65,68 These data show 
the importance of ER/PR status for prognosticating of breast tumours. In addition, 
ER/PR status is predictive for tamoxifen sensitivity, a highly effective anti-estrogen 
treatment for breast cancer patients.69,70 These findings emphasize the importance 
of molecular signatures but also indicate that additional markers are needed to 
enhance the understanding of breast cancer etiology and improve prognosis and 
treatment selection. 
 Besides the type I NR, also type II NR have clinical implications in breast cancer. 
Both low vitamin D ingestion and low circulating 25-hydroxyvitamin D3 levels are 
associated with increased breast cancer risk, indicating a protective role of the type 
II NR VDR in breast cancer tumourigenesis.71 RARα mRNA expression has recently 
shown to be associated with a good prognosis in endocrine treated breast cancer 
patients.57 Moreover, Hua et al.56 were able to define a RA-induced gene expression 
profile associated with a favourable prognosis. Furthermore, increased expression 
of another type II NR, PPARγ, in the primary tumour also correlated with improved 
survival.72 Collectively, these data imply that through their anti-proliferative and 
pro-apoptotic effects the type II NR and their target genes are correlated with a 
positive clinical outcome. Currently, no adjuvant treatments directed at type II NR are 
routinely available for breast cancer. Stimulation of the NR RAR/RXR and PPAR/RXR 
has been explored73,74 and synthetic RAR ligands have been shown to reduce second 
breast cancers.75 However, so far efficacy has been limited because of retinoic acid 
resistance acquired during cancer development.76,77 Therefore, the effect of RA in 
oncology has so far been limited. The only successful application of RA treatment is 
in APL (acute promyelocytic leukemia) patients78 where it drives cell differentiation. 
Whether RA has a similar effect in breast cancer cells is not known. 
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Consistent with the finding that both type I and type II NR function are dependent 
on coregulators, several groups have reported that NR co-regulator function is highly 
relevant for prognosis and endocrine therapy sensitivity in breast cancer as well.7,79 A 
well-studied example with relevance to breast cancer is the ER coactivator Amplified 
in Breast Cancer-1 (AIB1 or SRC380). Overexpression of AIB1 results in increased 
ER activity and is generally associated with a poor prognosis in breast cancer.81-83 
Some studies, however, do find a relation between AIB1 and a good prognosis.84,85 
As AIB1, like other coactivators, is positively correlated with ER status86 it might be 
indirectly associated with a good prognosis through association with the ER-positive 
luminal subtype of breast cancer. Possibly, within this ER-positive luminal subtype, ER 
coactivators might be associated with a relatively poor prognosis.87 The ambivalent 
prognostic value of AIB1 in breast cancer might thus be explained by the fact that 
these ER/PR positive patients are most often treated with adjuvant tamoxifen and 
that AIB1 is associated with tamoxifen resistance.82,85 Furthermore, coexpression of 
growth factor receptors82,85 or the subcellular localization of AIB184 has been suggested 
to affect its prognostic value in breast cancer. Other cofactors that play a critical role 
in hormonal signalling, including the coactivators FOXA1 and GATA3, appear to be 
markers of luminal A breast cancers. Expression of these factors has shown to be 
related to good prognosis and to endocrine therapy sensitivity.88 Another coactivator 
whose function in determining breast cancer prognosis is unclear, is steroid receptor 
coactivator 1 (SRC1 or NCOA1). SRC1 was originally described as denoting a good 
response to tamoxifen treatment,89 then found to be associated with poor survival 
and poor response to tamoxifen.87,90,91 More recently it has been found again to be 
associated with a good prognosis.86 For SRC1, the coexpression of other transcription 
factors such as Ets-1 and Ets-2 might be important in determining its effect on 
prognosis.87,91 Corepressors like NR corepressor 1 (NCOR1) and -2 (NCOR2 or SMRT) 
were also found to be associated with a good response to tamoxifen,87,91,92 although 
these studies did not include a non-treated cohort to distinguish a prognostic from 
predictive biomarker. Conversely, NCOR2 has also been shown to be associated with 
poor survival in a large breast cancer cohort.86
 Approximately 300 coregulators have now been identified, of which at least 165 
have so far been directly associated with human diseases.33,93,94 It will be important to 
further delineate the positive or negative effects on the transcription factor pathways 
involved. Of note, many coregulators are able to bind to, and regulate, both type I 
and type II NR.15 Remarkably, most -if not all- coregulators have either a stimulatory 
or inhibitory effect on both type I and type II NR, with the notable exception of the 
newly discovered NR coregulator DC-SCRIPT.9 DC-SCRIPT acts as a unique coregulator 
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of multiple NR having opposite effects on type I vs type II NR. Recently, Ansems and 
colleagues9 evaluated DC-SCRIPT expression in breast tissue and showed that DC-
SCRIPT is expressed in breast ductal epithelial cells. In addition it was demonstrated 
that breast tumours expressed lower levels of DC-SCRIPT than normal breast tissue 
from the same patient. Moreover, quantification of DC-SCRIPT mRNA expression in 
three cohorts of breast cancer patients revealed that DC-SCRIPT mRNA expression is 
an independent prognostic factor for good survival for breast cancer patients with 
ER- and/or PR-positive tumours.9 The prognostic significance was maintained in 
a cohort of tamoxifen treated patients. Together with our finding that DC-SCRIPT 
inhibits cell growth of breast carcinoma cells our data suggests that DC-SCRIPT can 
act as a tumour suppressor in breast cancer development (see figure 2). This makes 
DC-SCRIPT an attractive target for NR coregulator specific therapy for either breast 
cancer prevention or adjuvant therapy.
Figure 2. Balance of Nuclear Receptor function by DC-SCRIPT expression
Hypothesized	model	of	DC-SCRIPT	function	in	ER+	breast	epithelial	cells.	DC-SCRIPT	represses	the	activity	
of	 the	 pro-tumourigenic	 type	 I	NR	 ERα	 and	 PR	 and	 conversely	 enhances	 the	 anti-tumourigenic	 type	 II	
NR	PPARγ	and	RARα,	thereby	actively	regulating	the	NR	balance.	During	malignant	transformation	and	
tumour	progression,	 higher	DC-SCRIPT	expression	 leads	 to	a	more	balanced	NR	 function	 resulting	 in	a	
better	prognosis,	whereas	low	expression	of	DC-SCRIPT	results	 in	an	imbalance	in	NR	function	and	to	a	
bad	prognosis.
FUTURE PERSPECTIVES
Molecular and functional studies on individual NR are at the forefront of life science 
research. They have led to novel insights into genome-wide transcription factor 
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binding patterns and gene regulation. An emerging challenge is to unravel how NR 
family members act in concert to regulate complex cellular processes in tissues 
where multiple NR ligands are present. The examples presented in this review, the 
crosstalk between ER and RAR and the action of the recently identified bi-functional 
transcription modulator DC-SCRIPT, only provide initial insights in these processes. 
It will be interesting to further unravel both the genomic as well as non-genomic 
effects of NR on cellular behaviour and how they relate to malignant transformation. 
Regarding its function as a type I and type II NR coregulator and its prognostic 
relevance in breast cancer, it will be rewarding to investigate the impact of DC-
SCRIPT and ER/RAR crosstalk in other hormone sensitive tumours like prostate and 
endometrium cancer. An important question that remains to be answered is how DC-
SCRIPT genotype and expression levels will affect the cell’s response to hormones, 
vitamins and metabolites and whether DC-SCRIPT malfunction is sufficient to act as 
a priming event in malignant transformation. 
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TRANSCRIPTION REGULATION
Regulation of gene expression by transcription factors (TFs) is essential for proper 
cell differentiation, proliferation and function. Aberrations in this process through 
misregulation or dysfunction of TFs cause a wide variety of human diseases, 
including developmental disorders and cancer.1 Activation of gene transcription 
occurs via Histone Acetylation by Histone Acetyl Transferases (HATs), inducing 
chromatin opening and recruitment of the transcription initiation complex for RNA 
polymerization. In contrast, gene repression involves the recruitment of Histone 
DeACetylases (HDAC), that cause chromatin condensation and thereby prevent 
binding of RNA polymerases. Classically, TFs are thought to function as individuals, 
regulating a particular subset of genes via factor specific mechanisms. Recent insights 
from genome-wide profiling studies, however, suggest a more complex reality in 
transcription regulation. Instead of targeting specific gene subsets, TFs were found 
to bind thousands of places throughout the genome, often located outside proximal 
promoter regions and lacking factor specific consensus motifs. These sites regulate 
transcription of distal genes via cooperative binding of TFs. This implies that each TF 
can exert multiple roles depending on the binding site and the recruitment of other 
factors. Moreover, not only do these factors bind directly to the DNA motifs, they 
can also engage in protein-protein interactions, hence functioning as transcriptional 
co-regulators.2 
 In this thesis we investigated the transcriptional co-regulatory properties of DC-
SCRIPT (DC-Specific transCRIPT) in both dendritic cell (DC) and tumor cell biology, 
and found both repressive and activating roles. In this chapter we further discuss our 
findings, and provide insight into the potential implications.  
DC-SCRIPT AS TRANSCRIPTION (CO-)REGULATOR
Previous studies have identified DC-SCRIPT as a putative transcription factor that 
is specifically expressed by DCs within the immune system. Its 11 zinc-fingers 
were suggested to function in DNA binding, allowing transcriptional regulation of 
specific genes.3,4 Albeit no direct target genes for DC-SCRIPT have been identified 
to date, a regulatory role in gene expression was indeed observed. In chapter 3 we 
identified DC-SCRIPT to be an important factor in the control of IL-10 expression,5 
whereas chapter 4 (S. Hontelez et al., submitted) and chapter 56 show a role in NR 
co-regulation. 
 In general, transcription regulators can be either ubiquitously (>30 tissues), or 
specifically expressed (<3 tissues), suggesting very broad, or very specific functions.1 
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DC-SCRIPT apparently falls into the second category, as its expression was only 
detected in DCs and epithelial cells. This suggests that regulation of gene expression 
by DC-SCRIPT is particularly important in these cell subsets. Indeed, transformation 
of epithelial cells towards tumor cells is accompanied by loss, or severe reduction 
of DC-SCRIPT levels, and knock-down in DCs results in impaired DC maturation, 
illustrating the importance of DC-SCRIPT expression in these cells. DC-SCRIPT possibly 
exerts overlapping roles in both cell types, however, since DCs and epithelial cells 
have a very different biology and function, DC-SCRIPT likely controls the expression 
of multiple gene subsets that play different roles in these cells. It would therefore 
be interesting to further investigate how DC-SCRIPT functions in these different cell 
types. 
NR	co-regulator
Wide-spread control of gene expression is a known feature of the Nuclear Receptor 
superfamily of TFs. In contrast to DC-SCRIPT, many NRs are ubiquitously expressed 
and are involved in a plethora of cellular processes and functions. However, cell- 
and tissue specific functions have also been described, and are based on variable 
expression of NR isoforms, post-translation modifications and cell specific expression 
of NR co-regulators.7,8 Interestingly, DC-SCRIPT has previously been identified as a 
NR co-regulator in epithelial breast carcinoma cells.9 In chapter 5 of this thesis we 
further investigated the role of DC-SCRIPT as NR co-regulator,6 and we have extend 
its regulatory function to DC biology in chapter 4 (S. Hontelez et al., submitted).
 As NR co-regulator, DC-SCRIPT was found to function both as co-repressor and 
co-activator, depending on the NR. In general, DC-SCRIPT was shown to co-repress 
Type I NR transcriptional activity, whereas co-activation was primarily detected on 
Type II NR mediated transcription. Transcriptional assays demonstrated repression 
on Type I NR ERα, PR-B, GR and AR, and activation of Type II NR RARα/RXR, PPARγ 
and VDR function. Besides co-repression of the Type I NR ERα, PR-B, GR and AR, DC-
SCRIPT was also shown to stimulate GR mediated transcription, depending on the 
promoter (discussed in Promoter	specific	effects, page 138). Furthermore, activation 
of endogenous VDR target genes, and repression of endogenous AR and GR target 
genes were demonstrated, suggesting an physiologically relevant mechanism. 
Modulation of other NR target genes could, however, not be demonstrated, possibly 
due to differences in promoter and cell context.
 As NR co-regulator, DC-SCRIPT was found to interact with both Type I and Type II 
NRs. Co-Immunoprecipitation experiments from cell-lines demonstrated exogenous 
DC-SCRIPT to co-exist in protein complexes with exogenous Type I NRs ERα, PR-B, 
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AR or GR, or Type II NRs RARα/RXR, VDR and PPARγ. Endogenous interactions could 
only be examined in DCs, the only DC-SCRIPT positive cell that can be obtained in 
sufficient numbers. However, despite efficient immunoprecipitation of DC-SCRIPT 
from DCs, co-presence of NRs in the IP fractions could not be discerned. DCs express 
20 different NRs that all possibly contain DC-SCRIPT in their repressor or activator 
complexes. Since the IP of DC-SCRIPT only pulls-down a fraction of the expressed 
protein, enrichment of a specific NR via DC-SCRIPT IP may be very difficult. In addition, 
endogenous unbound DC-SCRIPT may possibly bind more efficiently to the beads, 
and is therefore more likely to be purified. In transient expression systems, on the 
other hand, both DC-SCRIPT and NRs are over-expressed, what may result in a higher 
occurrence and stability of complex formation. Experiments that aim the Co-IP of DC-
SCRIPT by IP of a NR face the same problem, as NRs are also engaged in many different 
protein complexes. Recently, Co-IP of endogenous NRs with exogenous DC-SCRIPT did 
show the interaction with AR in prostate carcinoma derived cell-lines.10 Furthermore, 
Co-IP findings are supported by functional data that demonstrate the effect of DC-
SCRIPT expression on NR target gene expression. Proper assessment of endogenous 
interactions between DC-SCRIPT and NRs requires a more sensitive approach, such 
as Mass spectrometry (MS). This also importantly allows for comparative analysis 
between DCs and hormone responsive carcinoma cell-lines.
 In exogenous settings, the co-presence of NRs in DC-SCRIPT protein complexes 
was not dependent on stimulation with the respective NR ligands. In addition, the 
LxxLL domain was found to be expendable, and the interactions were not detected in 
Yeast-2-Hybrid assays, suggesting indirect binding. In contrast, previously published 
Yeast-2-Hybrid data did show a direct interaction between DC-SCRIPT and ERα.9 This 
discrepancy could originate from the cDNA library and yeast strains used in both 
studies. In our Yeast-2-Hybrid assays we used a DC-derived cDNA library and the 
YGHI yeast strain.4 Lopez-Garcia et al. (2006) on the other hand, employed a human 
placental cDNA expression library in the PL1α yeast strain, containing an integrated 
estrogen-responsive URA3 gene. This possibly provides a platform for more efficient 
interactions between DC-SCRIPT and ERα, suggesting that direct binding is possible 
on some target gene promoters. However, binding of DC-SCRIPT to the promoter 
independent of ERα cannot be completely excluded in this system. 
 The co-presence of DC-SCRIPT in NR protein complexes likely depends on 
interaction with other proteins within this complex. Indeed, we previously revealed 
a direct interaction between DC-SCRIPT and CtBP1 (C-terminal Binding Protein 1) 
using Yeast-2-Hybrid assays.4 Furthermore, DC-SCRIPT was previously shown to 
bind Receptor Interacting Protein 140 (RIP140) and HDAC1, -3 and -6.9 Both CtBP1 
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and RIP140 function as transcriptional co-repressors and recruit HDACs to the 
promoter bound complex. Hence DC-SCRIPT is suggestively present in large co-
repressor complexes, preventing NR mediated transcription. This fits with the ligand 
independent nature of the described NR interactions, since co-repressor complexes 
are usually associated with NR in the absence of ligand, or in the presence of 
antagonists. Importantly though, transcriptional assays demonstrate co-repression 
of Type I NR in the presence of their ligands, suggesting an central role for DC-SCRIPT 
as NR co-repressor. We have, however, also demonstrated DC-SCRIPT to function 
as NR co-activator, enhancing Type II NR. NR co-activators generally recruit other 
co-activator proteins that allow for chromatin remodeling, histone acetylation and 
recruitment of the RNA polymerase II complex.7 Assessing the role of DC-SCRIPT in 
the recruitment of these protein complexes using Co-IP and/or Mass Spectrometry 
would increase our insight into the co-activator mechanisms employed by DC-SCRIPT. 
Promoter	specific	effects
It is well known that most TFs differently modulate target genes. Co-factors, however, 
have also been demonstrated to have divergent effects on gene transcription. NR 
co-activators have been shown to repress gene expression in some cases,11 whereas 
gene activation was shown by co-repressors.12 This suggests that co-regulator 
action is variable depending on the gene, cell, and signaling context.13 The DC-
SCRIPT interacting co-repressor CtBP1 has also been shown to exert more than one 
function.14 In this thesis, we have demonstrated multiple roles for DC-SCRIPT in 
transcription regulation, acting as co-repressor or as co-activator, depending on the 
NR. This variation in function also occurs in the regulation of a single NR, the GR. In 
addition to its function as GR co-repressor on the MMTV promoter, DC-SCRIPT was 
also observed to function as GR co-activator when the MMTV HRE sequences were 
isolated from their context and placed in a minimal promoter (figure 1, unpublished 
data).
Various mechanisms that have been described to modulate TF function, could 
also potentially affect the regulatory role of co-factors such as DC-SCRIPT. These 
include (i) differences in TF DNA binding sequence (ii) interaction with other TFs 
or regulatory proteins, (iii) post-translational modifications and (iv) multifunctional 
protein domains (e.g. zinc fingers). Many TFs have been shown to bind multiple 
transcription regulatory elements, however, the TF DNA binding sequences often 
differ between these sites. For the Type I NR Glucocorticoid Receptor (GR) it has been 
shown that single base pair differences in the Glucocorticoid Responsive Elements 
(GREs, the DNA binding sites for GR) already affect the regulatory activity of GR. 
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Binding to these different GREs causes variations in GR conformation and alters co-
factor recruitment. A similar effect might be true for co-factors such as DC-SCRIPT. The 
binding properties of DC-SCRIPT possibly differ between TFs, or between different 
conformations of the same TF, affecting the subsequent recruitment of other co-
factors. Interestingly, we indeed found that DC-SCRIPT exerts both roles on the same 
NR, the glucocorticoid receptor, depending on the promoter (figure 1).
Figure 1. DC-SCRIPT function on isolated HRE sequences from MMTV-luc
Schematic	view	of	the	(A)	luciferase	reporter	plasmid	MMTVwt	displaying	the	four	HRE	sequences,	(B)	and	
the	luciferase	reporter	plasmids	HRE1-4-luc	where	the	4x	consensus	GRE	sequence	from	GRE-luc	is	replaced	
by	4x	repeat	of	the	HRE1,	2,	3	or	4	sequence	from	MMTVwt.	(C-D)	Hep3B	cells	were	co-transfected	with	
the	firefly	luciferase	reporter	plasmids	(C)	MMTV-luc,	(D)	HRE1-luc,	HRE2-luc,	HRE3-luc	or	HRE4-luc,	the	
expression	plasmid	 for	GR	and	 increasing	amounts	of	 the	expression	plasmid	 for	DC-SCRIPT.	Cells	were	
stimulated	with	vehicle	(white	bars)	or	100	nM	Dexamethasone	(black	bars)	for	24	hrs.	Luciferase	activity	is	
displayed	relative	to	luciferase	production	upon	Dexamethasone	stimulation	in	the	presence	of	(C)	MMTV-
luc	or	(D)	HRE1-luc	and	in	the	absence	of	DC-SCRIPT.
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Besides the TF binding site, also the promoter context plays an important role. 
Multiple TFs can target a specific transcription regulatory site and catalyze or inhibit 
the recruitment of other factors. The function of each TF or co-factor might therefore 
differ between promoters, depending on the present TF community.2 DC-SCRIPT 
function on GR, however, was not affected by deletion of transcriptional regulatory 
elements in the MMTV promoter. This suggests that binding of other factors does 
not affect DC-SCRIPT function in these conditions. In contrast, isolation of the MMTV 
Hormone Responsive Elements (HREs) from their context, in experiments where the 
GRE consensus sequence in the minimal promoter was replaced with one of the 
MMTV HRE sequences (figure 1), did affect DC-SCRIPT function. In these settings, 
DC-SCRIPT was found to function as GR co-activator, enhancing GR mediated gene 
transcription. These data therefore suggest an important role for the promoter 
context. 
 Since these results were obtained from transcription assays, it is important to 
assess the physiological relevance by testing the effect of DC-SCRIPT on endogenous 
target genes. In human moDCs, the endogenous Glucocorticoid Inducible Leucine 
Zipper (GILZ) was shown to be downregulated by DC-SCRIPT. Identification of other 
GR targets affected by DC-SCRIPT proved to be difficult (data not shown). GR-ligand 
dependent upregulation could not be detected for eight out of 10 tested target 
genes that were previously identified in other cell-types to be GC responsive. This 
could possibly be explained with cell-type specific differences such as differential 
expression of the repressive GRα-D and GRβ isoforms. Increased expression upon GR 
activation was detected for FKBP5 and PTX3, however no effect of DC-SCRIPT silencing 
could be discerned, possibly due to the GRE sequence or context. Furthermore, also 
functional redundancy and incomplete silencing could play a role. Although DC-
SCRIPT protein levels are greatly reduced upon silencing, some expression could still 
be detected, which may be sufficient for the repression of certain GR target genes in 
moDCs.
 Another important mechanism that affects TF and co-factor function are post-
translational modifications (PTMs), which modulate DNA and protein binding 
properties, subcellular localization, stability and activity. Combinatorial usage of 
these rapid and reversible modifications provide immense regulatory possibilities 
that can be appropriately adjusted to the situation and cell context. These 
modifications include phosphorylation, glycosylation, SUMOylation, acetylation and 
ubiquitinylation.15 NRs are known to be modulated by PTMs,8,16 possibly affecting DC-
SCRIPT binding. In addition, DC-SCRIPT itself might also be regulated by PTMs, since 
putative phosphorylation-, SUMOylation and N -glycosylation sites have also been 
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detected in its amino acid sequence.4 Future identification and functional analysis 
of PTM sites in DC-SCRIPT requires Mass Spectrometry and loss-of-function studies 
through mutations of specific PTM sites.
 Intrinsic protein properties of DC-SCRIPT might also account for the diverse 
transcriptional regulation. An important domain in the amino acid sequence is the zinc 
finger region, containing 11 Cys2-His2-type zinc fingers. This type of zinc fingers is well 
known for its DNA-binding activity, suggesting DC-SCRIPT directly targets promoter/
enhancer DNA of specific genes. However, these zinc fingers are also implicated in 
protein-RNA and protein-protein interactions. Interestingly, alternate usage of zinc 
fingers allows a protein to engage in different interactions.17,18 Combinations of the 
11 zinc fingers present in DC-SCRIPT can therefore be attributed for binding different 
TFs, co-factors and DNA sequences. In addition, we found different domains of DC-
SCRIPT to be important in NR co-regulation. For instance, co-repression of ER requires 
the presence of the proline-, zinc- and acidic domain, however, for the repression of 
GR and AR dependent transcription, the proline region was found to be sufficient 
(unpublished data). Likewise, all three domains are required for co-activation of 
PPARγ mediated transcription, whereas only the acidic domain was necessary for 
stimulation of RARα/RXR transcriptional activity. This illustrates that the zinc fingers 
are not always necessary, and that DC-SCRIPT utilizes different domains depending 
on the situation. Expression studies involving ChIP-seq and RNA sequencing or exon 
expression profiling in cells expressing wt DC-SCRIPT or DC-SCRIPT deletion mutants 
is necessary to identify regulated genes and the involved domains.
DC-SCRIPT IN DENDRITIC CELLS
Dendritic cells play an essential role in our immune system. They induce and 
modulated immune responses against pathogens and tumors, while protecting 
the host from auto-immunity.19 The preferential expression of DC-SCRIPT in DCs 
within the immune system suggests a specialized role in these cells.4 In chapter 3 
we have, to our knowledge, for the first time characterized endogenous DC-SCRIPT 
protein expression in different DC subsets both in	vitro	and in	vivo.5 Furthermore, 
we demonstrated an important role for DC-SCRIPT in DC maturation. Silencing of 
DC-SCRIPT expression induced IL-10 secretion upon TLR4 and TLR7/8 stimulation, 
which subsequently impaired IL-12 production. In chapter 4 we further elucidated 
the function of DC-SCRIPT as NR co-regulator in DCs and demonstrated co-repression 
on the GR dependent expression of GILZ (S. Hontelez et al., submitted). Here, we 
further discuss the function and implications of DC-SCRIPT expression in human DCs.
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DC	differentiation
Transcription factors have been shown to play an important role in DC development. 
Some factors are involved in the differentiation of all DC-subsets, whereas other 
factors are uniquely found in the development of a specific subset. The TFs Ikaros, 
PU.1 and Gfi1 for example are found in all DC subsets, and loss-of-function causes 
the ablation of most DC populations in mice. On the other hand, factors like IRF2, -4 
and -8, Id2, Spi-B and RelB have specialized functions in the differentiation of either 
cDCs, pDCs or LCs.20 
 All DC subsets tested to date, including myeloid DCs (MDCs), plasmacytoid DCs 
(PDCs) and Langerhans cells (LCs) were found positive for DC-SCRIPT protein expression. 
In	vitro differentiation of DCs from monocytes requires stimulation with IL-4 and GM-
CSF.21 Remarkably, expression of DC-SCRIPT protein was detected within 4 hours upon 
differentiation from monocytes towards DCs, and was found to be largely dependent 
on IL-4 stimulation. Protein expression levels further increased during development, 
with maximum levels detected in fully differentiated immature and mature DCs. 
Interestingly, previous analysis of the DC-SCRIPT promoter demonstrated putative 
binding sites for DC specific TFs PU.1, Spi-B, c-Rel, Ikaros 2 and Gfi. In addition, also 
other TFs with an important function in DC biology suggestively bind the DC-SCRIPT 
promoter, including GATA-1 and the TF complexes NF-κB and AP-1.3 
 These findings suggest that DC-SCRIPT is an important factor in the development 
and function of different DC subsets. Its precise function in DC differentiation is, 
however, currently unknown. Analysis of the DC-SCRIPT promoter, knock-down 
studies with DC-SCRIPT targeting siRNAs, and the use of DC-SCRIPT knock-out mice 
are therefore important to reveal the significance of DC-SCRIPT in DC development. 
 
DC	maturation
DCs can mature into different states depending on the pathogen and environmental 
stimuli. This diversity allows DCs to differentially affect T-cell polarization thereby 
tailoring the immune response to the present pathogens. Generally, mature DCs 
can be immunostimulatory, or immunosuppressive. In chapter 3 and 4 of this thesis 
we have uncovered an important regulatory role for DC-SCRIPT in the expression 
of IL-105 and GILZ (S. Hontelez et al., submitted), two well known hallmarks of 
immunosuppressive, or tolerogenic DCs (tolDCs) (figure 2). In moDC, DC-SCRIPT 
was shown to repress the expression of both genes, and was therefore suggested to 
skew DC maturation towards immunity. In line with these results, DC-SCRIPT mRNA 
levels were significantly increased in immunostimulatory DC, albeit no differences 
at protein level could be discerned. Possibly, LPS stimulation increases turnover of 
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DC-SCRIPT protein during DC maturation. To compensate for lost protein expression 
DCs increase transcription of the DC-SCRIPT gene, thereby maintaining equal protein 
expression levels. DC-SCRIPT proteins levels in tolDCs were comparable to immature 
and mature DCs, therefore other mechanisms regulating DC-SCRIPT function upon 
GR activation must be in place, such as PTM or binding of chaperone proteins. 
 When DCs mature in the absence of danger signals, or in the presence of 
immunosuppressive stimuli, they turn into tolDCs. These DCs express low levels of 
co-stimulatory molecules, and therefore suppress T-cell proliferation. In addition, 
secretion of the anti-inflammatory cytokine IL-10 is enhanced, which could trigger 
Treg polarization.22 DC-SCRIPT knock down in moDCs increased IL-10 secretion which 
subsequently impaired production of the pro-inflammatory cytokine IL-12 (figure 
2). Other pro-inflammatory molecules such as cytokines IL-6 and TNF, and receptors 
CD80, -83- and -86 (CD86 data not shown), however, were not affected. This suggests 
that generation of tolDCs requires more than just the repression of DC-SCRIPT 
signaling. 
 Alternatively, DC-SCRIPT down-regulation may also be important for the 
maturation of Th17-polarizing DCs. Besides IL-23, IL-6 and TNF, generation of Th17 
responses also requires inhibition of Th1 and Th2 responses.23 Th1 responses inhibit 
Th17 differentiation, therefore an environment with high IL-10 and limited IL-12 
secretion will restrain Th1 differentiation and favor Th17 skewing. Th17 cells have 
been shown to function in anti-fungal responses, and recognition of C.	 albicans, 
skews DC maturation towards Th17-polarizing DCs.24 In chapter 2 we describe the 
crosstalk between PRRs mediating the detection of fungal antigens.25 Interestingly, 
collaboration between Dectin-1, TLR2/6 and Galectin-3 receptors results in cytokine 
secretion profiles similar to those seen upon DC-SCRIPT knock-down. 
 One way of enhanced and prolonged IL-10 transcription in DCs is NF-κB 
acetylation.26 In DCs, IL-10 expression greatly depends on NF-κB activation.27 
Interestingly, we have recently obtained preliminary data that suggest a potential 
effect of DC-SCRIPT on NF-κB dependent transcription. Transcription assays with 
inducible NF-κB actelylation, as well as the use of specific signaling pathway blockers 
in DC-SCRIPT knock-down experiments would provide important information on the 
putative role of DC-SCRIPT on NF-κB transcription regulation.
In chapter 4 we show that DC-SCRIPT also inhibits the expression of another 
important molecule in tolDCs, GILZ (glucocorticoid induced leucine zipper) (S. 
Hontelez et al., submitted). TolDCs can be generated through stimulation with 
glucocorticoids (GCs) prior to DC maturation.28 GCs activate GR, a Type I NR with 
profound immunosuppressive properties.29 Within DCs, GR activation impairs STAT, 
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NF-κB, AP-1, 14-3-3, Raf-1 and Ras signaling, thereby preventing up-regulation of 
co-stimulatory molecules upon DC maturation. Expression of the GR target gene 
GILZ is induced upon GC stimulation, and serves an important role in mediating the 
immunosuppressive effects by GR. In fact, expression of GILZ in the absence of GR 
activation was demonstrated to be sufficient for the generation of tolDCs, whereas 
silencing GILZ expression prevented tolerance.30 In DCs, silencing of DC-SCRIPT 
resulted in elevated, GR dependent, GILZ expression, suggesting DC-SCRIPT inhibits 
GR transcriptional activity on the GILZ promoter (figure 2). In the absence of GCs, 
also slight expression of GILZ was detected in DC-SCRIPT knock-down DCs, but not in 
control DCs. This could be an effect of the increased IL-10 expression in these cells, 
as IL-10 also induces the expression of GILZ in DCs.31 
Together, these data imply an important role for DC-SCRIPT during DC maturation, 
favoring immunity over tolerance by repressing both IL-10 and GILZ expression. 
Figure 2. DC-SCRIPT regulates IL-10 and GILZ expression in DCs.	 In	 the	 presence	 of	 DC-SCRIPT,	 the	
anti-inflammatory	 cytokine	 IL-10	 is	 expressed	 at	 low	 levels,	while	 the	 pro-inflammatory	 cytokine	 IL-12	
is	abundantly	produced.	Knock-down	of	DC-SCRIPT	results	 in	high	 IL-10	secretion	upon	TLR	stimulation,	
which	consequently	inhibits	IL-12	secretion	by	these	cells.	In	addition,	DC-SCRIPT	in	DCs	represses	ligand	
depended	 and	 GR	 mediated	 transcription	 of	 GILZ,	 possibly	 preventing	 oversensitivity	 of	 DCs	 to	 the	
tolerogenic	effects	of	glucocorticoids.	Knock-down	of	DC-SCRIPT	relieves	repression	on	GR,	resulting	in	an	
significant	increase	in	GILZ	expression	levels,	which	has	been	shown	to	mediate	the	generation	of	tolDCs.
DC-SCRIPT in tumor cells
Next to DCs, also breast epithelial cells were found positive for DC-SCRIPT expression. 
Malignant transformation of these cells leads to breast cancer, and is accompanied 
by decreased, or complete loss of DC-SCRIPT expression. NR signaling plays an 
important role in the development and malignancy of this cancer.32 In chapter 5 we 
have demonstrated DC-SCRIPT to be involved in regulation of NR activity in these 
cells, balancing the activity of proliferative and anti-proliferative actions of both Type 
I and Type II NRs.6 Indeed, this balance is important for proper NR crosstalk, and the 
maintenance of a healthy cell phenotype, which we further discussed in chapter 6.33 
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Prognostic	marker
Despite the major improvements in detection and treatment, breast cancer is still 
one of the main causes of cancer death in women.34 Different prognostic markers 
are currently used in the clinic to predict treatment efficacy, tumor recurrence 
and patient survival. Classically, these include pathological features, such as tumor 
size, histological subtype and grade and lymph node metastases. Molecular- and 
genetic markers have also been identified, with a central role for NR and their co-
regulators.35 In particular the Type I NRs ER and PR are well established markers, and 
their expression is positively correlated with a good prognosis.36 Additionally, also 
the Type II NRs RAR/RXR and PPAR, as well as various NR co-regulators, have been 
described as important biomarkers for breast carcinoma.32 
In chapter 5 we have characterized DC-SCRIPT as a prognostic marker in breast 
carcinoma, concomitant with its function as NR co-regulator.6 DC-SCRIPT was found 
to be a strong and independent prognostic marker for disease-free survival of breast 
cancer patients with ER- and/or PR-positive tumors. These results were based on 3 
relatively small cohorts from Nijmegen, and were recently confirmed by a validation 
study on a independent cohort of 1505 primary breast cancers from Rotterdam. 
The latter showed DC-SCRIPT to be a predictive factor for the occurrence of distant 
metastasis in patients that did not receive adjuvant therapy, independent of other 
currently used prognostic markers.37 In another recent study, DC-SCRIPT was also 
implicated in prostate cancer. This hormone responsive carcinoma develops from 
the cells that align the ducts of the prostate glands.38 DC-SCRIPT expression was 
observed in morphologically normal prostate glands and infiltrating immune cells 
with IHC staining. As with breast epithelial cells, DC-SCRIPT expression in the prostate 
was lost in malignant prostate epithelial tissue and prostate carcinoma cell lines.10
 Collectively, these data suggest an important role for DC-SCRIPT in preventing 
development and malignant transformation of hormone responsive tumors. Since DC-
SCRIPT has been shown to regulate multiple NRs, it is likely to affect other epithelial 
derived NR dependent carcinomas. Hence screening of other adenocarcinomas, 
e.g. from the colon, endometrium or pancreas, would be an interesting next step. 
However, caution must be taken when addressing the prognostic value of a single 
marker, or a set of markers (gene expression signatures). Venet et al. (2011) recently 
demonstrated that most random signatures are significantly (p<.05 for 77%, and 
p<10-5 for 30% of the tested signatures) associated with breast cancer outcome, 
without having a biological relation to cancer.39 This is most likely caused by the 
fact that most genes of the breast carcinoma transcriptome are related to one 
variable, the proliferating cell nuclear antigen (PCNA). The PCNA gene encodes a 
protein that importantly regulates several processes leading to DNA replication. As 
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a consequence, correcting for this variable abrogates most significant associations. 
Hence, the evaluation of markers against the outcome association of comparable 
negative control markers is highly important. Cell proliferation is an important factor 
in tumor biology, therefore deducing whether a change in the expression of a marker 
is a cause, or a consequence of increased cell proliferation, is crucial. Nonetheless, 
an accurate, but biological irrelevant marker may still be valuable in the clinic. The 
early loss of DC-SCRIPT expression in both breast- and prostate tumor cells makes it 
an interesting prognostic marker, however, it remains to be determined whether this 
is initiating, or following malignant transformation.
NR	balance	and	cell	cycle	regulation
Whether DC-SCRIPT is a causative- or consequential marker, loss of expression very 
likely aids tumor growth and malignancy. In chapter 5 we demonstrate DC-SCRIPT 
to co-repress the Type I NR ERα and PR-B, and enhance transcriptional activities of 
the Type II NR RARα/RXR and PPARγ.6 In breast cancer cells, the activity of the NR 
plays an important role, as these NR affect both cell growth and apoptosis. Estrogens 
exert proliferative and pro-apoptotic effects in these cells, and are often seen as 
causative agents in breast cancer development.33,40 In contrast, RARα/RXR and PPARγ 
are typically referred to as tumor suppressive, and counteract the effects of ERα in 
cell cycle control and apoptosis pathways.41-43 In chapter 6 we describe the opposing 
roles of ERα and RAR in the apoptosis pathway, cell cycle regulation and growth 
factor signalling.33 Importantly, by regulating the activity of both NR types, DC-
SCRIPT may balance their function in breast epithelial cells, preventing uncontrolled 
proliferation. A similar role for DC-SCRIPT is recognized in prostate carcinoma cells. 
Here, androgens drive cancer development, growth and survival, whereas VDR 
activation triggers anti-proliferative and differentiating effects.44,45 DC-SCRIPT was 
shown to co-repress AR while enhancing VDR function, and may thereby function to 
restrict cell proliferation.10 
Interestingly, the tumor-suppressive effect of DC-SCRIPT could also be 
demonstrated in	 vitro. In chapter 5 DC-SCRIPT overexpression in MCF-7 breast 
carcinoma cells was shown to inhibit cell growth.6 Recent studies with breast cancer 
cell lines Cama-1 and MDA-MB-231 (M. Ansems, personal communication) and the 
prostate carcinoma cell line 22Rv110 confirmed these results. In addition, expression 
profiling of ER-positive breast cancer tissue uncovered a negative association between 
high DC-SCRIPT and many cell cycle proteins. This is in-line with the transcriptional 
control of ERα on cell cycle-related genes, however, to date no direct effect of DC-
SCRIPT expression on these ER-controlled cell cycle proteins could be discerned in 
vitro. In contrast, inducible expression of DC-SCRIPT in MCF-7 cells did observably 
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affect cell cycle progression, with increased number of cells in the G1-phase, and 
less in the S-phase (M. Ansems, personal communication). Since ERα is known to 
induce G1- to S-phase transition, DC-SCRIPT possibly hampers ERα-mediated cell 
proliferation.40,46,47 
 These findings thus demonstrate an important role for DC-SCRIPT in both 
prostate and mammary adenocarcinomas, possibly as a tumor-suppressor gene. In 
the presence of functional NRs, DC-SCRIPT expression can control cell proliferation, 
hence the reduced or lost expression early in cancer development favors tumor 
growth. How DC-SCRIPT expression is regulated is currently unknown, and requires 
further research. One possible mechanisms is DNA methylation, however, studies 
with demethylation agents did not induce DC-SCRIPT expression. Other regulatory 
processes include histone modifications and transcription regulation via other TFs. 
Promoter studies and ChIP experiments for histone modifications and TF binding 
could increase insight into these issues. Data provided by the ENCODE (Encyclopedia 
of DNA Elements, http://genome.ucsc.edu/ENCODE/) consortium, which aims to 
identify all functional elements in the human genome, could be used to analyze 
the genomic site of DC-SCRIPT. This could provide detailed information regarding 
regulatory elements, epigenetic modifications and TF binding sites that regulate DC-
SCRIPT expression. Ultimately, more detailed insight into the regulation of DC-SCRIPT 
expression and function may lead to more specific treatment strategies of these 
carcinomas.
CONCLUSIONS
In this thesis DC-SCRIPT was demonstrated to have important regulatory roles on 
gene transcription in both DCs and epithelial cells. Although both cell types differ 
greatly in function and phenotype, overlapping roles of DC-SCRIPT on NR dependent 
transcription were detected. Cell specific effects were also recognized, such as 
regulation of IL-10 secretion in DC maturation and control of cell cycle progression 
in breast cancer cells. Future research is essential to provide a more detailed and 
more complete view on the function and regulation of DC-SCRIPT in both cell types. 
This can importantly aid understanding of DC- and tumor biology, and provide new 
insights for DC vaccinations and treatment strategies. It is, however, important to 
realize that transcription regulators such as DC-SCRIPT function in concert with other 
TFs and regulatory proteins, and that their activity therefore depends on the present 
molecular environment. DC-SCRIPT, and other TFs, should therefore not be seen 
as an individual acting proteins, but more as a members of a community, in which 
proteins tightly interact and influence each other’s activity and function. 
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SAMENVATTING VAN DIT PROEFSCHRIFT
Dendritische cellen zijn de centrale cellen van ons immuunsysteem die de afweer 
tegen infecties en tumoren regisseren. Het eiwit DC-SCRIPT komt voor in dendritische 
cellen en tumorcellen, en is essentieel voor het goed functioneren van de dendritische 
cel, terwijl DC-SCRIPT in de tumorcel de groei van de cel en van de tumor remt. In 
beide gevallen reguleert DC-SCRIPT de activiteit van belangrijke genen in deze cellen. 
Bovendien bepaald DC-SCRIPT de invloed van hormonen en vitaminen op de cellen, 
waarvan bekend is dat ze de groei en functie van de cel kunnen beïnvloeden. 
HET IMMUUNSYSTEEM
Het immuunsysteem, ook wel afweersysteem genoemd, beschermd ons, het 
menselijk lichaam, tegen bedreigingen van buitenaf (e.g. bacteriën en virussen), en 
van binnenuit (tumoren). Een belangrijke rol hierbij is weggelegd voor de dendritische 
cel, welke zowel de rol van verkenner, rechter en generaal vertolkt. Deze cellen vinden 
we overal in ons lichaam, waar ze met hun ‘dendrieten’ de omgeving afspeuren naar 
ongewenste indringers. Op deze manier worden ziekteverwekkers herkend, maar 
worden ook lichaamseigen cellen die tot tumorcel getransformeerd zijn opgespoord. 
Deze verdachte objecten worden door de dendritische cel opgenomen in een proces 
dat fagocytose wordt genoemd. Vanaf dit moment fungeert de dendritische cel als 
rechter, en beoordeeld of de opgenomen stoffen/cellen een gevaar vormen voor 
het lichaam. Is dat het geval, dan ondergaat de dendritische cel de transformatie 
naar generaal, en activeert het immuunsysteem. De dendritische cel presenteert 
delen van de opgenomen ziekteverwekker aan de effector cellen (soldaten) van het 
immuunsysteem, de T- en B-cellen. Ook bepaald de dendritische cel de strategie 
voor de aanval, door de T- en B-cellen te laten specialiseren in het opruimen van 
bacteriën, schimmels, virussen of tumoren. Op deze manier wordt de aanwezige 
ziekteverwekker op een zo efficiënt mogelijke manier bestreden. 
In het zojuist beschreven proces past het immuunsysteem de afweerreactie aan op 
de ziekteverwekker. Deze vorm van afweer wordt daarom ook wel het adaptieve- of 
verworven immuunsysteem genoemd. Echter, naast de adaptieve immuniteit wordt 
ons lichaam ook beschermd door het aangeboren immuunsysteem. Dit systeem gaat, 
na herkenning van de ziekteverwekker, direct over in het ter plekke bestrijden van 
de infectie. Het is in feite de eerste verdedigingslinie van ons lichaam tegen externe 
ziekteverwekkers en tumoren, en kan de infectie bestrijden of controleren voordat 
het adaptieve immuunsysteem geactiveerd is.
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Het aangeboren systeem bestaat uit een variëteit aan cellen (granulocyten, 
macrofagen, dendritisch cellen en monocyten) die door middel van speciale 
receptoren een groot scala aan ziekteverwekkers kunnen herkennen. Deze receptoren 
worden in het Engels ook wel Pattern Recognition Receptors (PRRs) genoemd, wat 
in feite betekend dat ze specifieke moleculaire patronen van bacteriën, virussen of 
schimmels kunnen herkennen. Recente ontwikkelingen in de wetenschap hebben 
aangetoond dat vooral de combinatie van verschillende PRRs belangrijk is voor de 
herkenning van een specifiek micro-organisme. Hoofdstuk 2 beschrijft hoe deze 
receptoren door de cellen van het aangeboren immuunsysteem gecombineerd 
kunnen worden op moleculair niveau, en zo elkaars functie en activiteit beïnvloeden. 
Op deze manier kunnen de cellen van het aangeboren systeem niet alleen onderscheid 
kunnen maken tussen de verschillende klassen van micro-organismen, maar ook 
tussen verschillende soorten binnen dezelfde klasse. 
DC-SCRIPT EN DE DENDRITISCHE CEL
De verbindende factor tussen de twee afweersystemen is de dendritische cel. Deze 
cel behoord tot het aangeboren immuunsysteem, herkend ziekteverwekkers via zijn 
brede scala aan PRRs en activeert het adaptieve immuunsysteem. De dendritische cel 
presenteert delen van de ziekteverwekker aan het immuunsysteem, en produceert 
verschillende signaalstoffen, cytokinen genoemd. Deze cytokinen beinvloeden de 
activatie en specialisatie van T- en B cellen, zodat de immuunrespons aangepast 
wordt aan de aanwezige infectie. Zo is de productie van IL-12 belangrijk voor een 
optimale respons tegen virussen en tumoren, IL-4 tegen bacteriën en IL-23, TNF en 
IL-6 voor de bestrijding van schimmels. Tot slot kan de dendritische cel ook IL-10 
uitscheiden, wat de cellen van het immuunsysteem remt, en zo voorkomt dat een 
immuunreactie wordt opgewekt tegen een ongevaarlijke stof of micro-organisme. 
In het laatste geval spreken we van tolerogene dendritische cellen, aangezien ze het 
immuunsysteem tolerant maken voor de aanwezigheid van een bepaalde stof of 
micro-organisme. 
 Het eiwit DC-SCRIPT speelt een belangrijke rol in deze processen, wat nader 
beschreven wordt in hoofdstuk 3 en 4 van dit proefschrift. In hoofdstuk 3 laten we 
zien dat DC-SCRIPT al vroeg in de ontwikkeling van de dendritische cel aanwezig is, 
en voornamelijk voorkomt in de kern van de cel, waar de genregulatie plaatsvindt. 
Als we de hoeveelheid DC-SCRIPT in de cel experimenteel verlagen, zien we dat de 
dendritische cel meer IL-10 en minder IL-12 gaan produceren, waardoor de activatie 
van T-cellen geremt wordt. De dendritische cel wordt dus meer tolerogeen in de 
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afwezigheid van DC-SCRIPT.
 Eenzelfde effect kan worden bewerkstelligd door de toevoeging van 
corticosteroïden. Dit stress-gerelateerde hormoon remt het immuunsysteem, en 
maakt dendritische cellen tolerant. Corticosteroiden worden om deze reden vaak 
toegepast in situaties waarbij het immuunsysteem geremd moet worden, zoals bij 
transplantaties, allergieën en auto-immuunziekten. Corticosteroïden activeren een 
receptor in de cel, de Glucocorticoid Receptor (GR), welke de activiteit van belangrijke 
genen reguleert. In hoofdstuk 4 laten we zien dat DC-SCRIPT een remmende werking 
heeft op GR, en daarmee het effect dat het hormoon op de cel heeft reduceert. 
In de dendritische cel leidt de verlaging van DC-SCRIPT dan ook tot een verhoogde 
gevoeligheid voor corticosteroïden. Dit wijst erop dat DC-SCRIPT een belangrijke 
rol speelt in de transformatie die de dendritische cel ondergaat na detectie van 
ziekteverwekkers.
DC-SCRIPT IN TUMORCELLEN
Behalve dendritische cellen hebben we ook aangetoond dat DC-SCRIPT een 
belangrijke rol speelt in de cellen van borsttumoren. Borsttumoren ontstaan uit de 
epitheel cellen die de klieren in de borst bekleden, en zijn vaak gevoelig voor het 
hormoon oestrogeen. Dit activeert de oestrogeen receptor (ER), die de activiteit van 
genen in de tumorcel reguleert, en de groei van de cellen en de tumor bevorderd. 
Patiënten worden om die reden vaak behandeld met anti-oestrogenen, die de 
werking van de oestrogeen receptor blokkeren. Echter, in sommige patiënten is de 
oestrogeen receptor niet meer aanwezig in de tumor, waardoor deze onafhankelijk 
geworden is van de effecten van oestrogeen. Behandeling met anti-oestrogenen is 
dan niet meer mogelijk. 
  Hoofdstuk 5 laat zien dat DC-SCRIPT aanwezig is in gezonde epitheel cellen 
van het borstklierweefsel, maar afneemt zodra deze cellen transformeren naar 
tumorcellen. Deze afname gaat gepaard met een verhoogd risico op terugkeer van de 
tumor na de operatieve verwijdering. Patiënten waarbij weinig tot geen DC-SCRIPT 
in de borsttumor aanwezig was hadden een hogere kans op terugkeer van de ziekte 
vergeleken met patiënten waar relatief hoge hoeveelheden DC-SCRIPT in de tumor 
gevonden werden. Echter, dit effect is alleen aantoonbaar bij oestrogeen gevoelige 
tumoren. In patiënten met een oestrogeen ongevoelige tumor had de aanwezigheid 
van DC-SCRIPT geen voorspellende waarde.
 Om dit effect nader te verklaren hebben we de effecten van DC-SCRIPT op de 
werking van de oestrogeen receptor onderzocht. Hoofdstuk 5 laat zien dat de 
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aanwezigheid van DC-SCRIPT in een cel de activiteit van de oestrogeen receptor remt. 
Bovendien blijkt dat DC-SCRIPT een stimulerende werking heeft op de effecten van 
o.a. vitamine A. In tegenstelling tot oestogeen, is vitamine A voornamelijk bekend om 
zijn remmende effect op de groei van borsttumoren. Doordat DC-SCRIPT de werking 
van vitamine A versterkt, terwijl het de effecten van oestrogeen remt, kan het een 
belangrijke factor zijn in het voorkomen borstkanker. 
 
Van de werking van de oestrogeen- en vitamine A receptoren in borsttumoren is veel 
bekent. Onderzoek heeft aangetoond dat deze receptoren onafhankelijk van elkaar 
verschillende genen reguleren, maar ook samenwerken, of elkaar tegenwerken bij 
de regulatie van andere genen. Deze zogenaamde ‘crosstalk’, en de rol hiervan in 
tumorcellen, wordt besproken in hoofdstuk 6. Aangezien vaak meerdere hormonen 
en vitaminen in de omgeving van de tumor aanwezig zijn, is het interessant om 
onderzoeken wat de effecten van deze crosstalk op de cellen zijn, en hoe DC-SCRIPT 
daarbij betrokken is. 
TOEKOMSTPERSPECTIEVEN
In dit proefschrift hebben we laten zien dat DC-SCRIPT een belangrijke rol speelt 
in zowel dendritische cellen als tumorcellen. In beide gevallen reguleert DC-SCRIPT 
de activiteit van belangrijke genen, en beïnvloed het de effecten die hormonen en 
vitaminen op deze cellen hebben. Echter, hoe dit op moleculair niveau gebeurt is 
nog grotendeels onbekend. Er ligt daarom een grote uitdaging om de onderliggende 
mechanismen te ontdekken. Details over de precieze werking en regulatie van DC-
SCRIPT in deze cellen kan potentieel nieuwe inzichten in de biologie van dendritische 
cellen en tumorcellen verschaffen. Bovendien zou deze kennis in de toekomst 
waardevol kunnen zijn voor het ontwikkelen van op dendritische cel gebaseerde 
immuun therapieën en kankerbestrijding. 
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DANKWOORD
Natuurlijk moet ik ook een hoop mensen bedankten voor hun bijdrage en steun bij 
het tot stand komen van dit proefschrift. Als eerste natuurlijk Gosse, aan wie ik dit 
onderzoek te danken heb. Het leukste aan werken onder jouw leiding was de vrijheid 
die ik had in het onderzoek. Dat betekende natuurlijk wel dat ik de focus moest 
bepalen, wat als beginnende onderzoeker niet altijd even makkelijk is! Maar gelukkig 
kon ik altijd bij je binnenlopen voor advies. Bedankt voor al je goede raad die ik van 
je gekregen heb de afgelopen jaren!
Daarnaast zijn natuurlijk de SCRIPT-girls heel belangrijk geweest voor het tot stand 
komen van dit boekje, en het plezier dat ik had op het werk! Wat een fantastisch 
groepje hadden wij zeg! 
 Als eerste Maaike, een van mijn twee paranimphjes. Maaike, jij hebt me wegwijs 
gemaakt in het lab en me alle fijne kneepjes geleerd die me nu nog steeds goed van 
pas komen! Je doorzettingsvermogen is aanstekelijk, en je vond het nooit erg als het 
wat later werd (al waren onze Bas-en daar vaak minder blij mee…). Het was heel fijn 
en gezellig om samen met jou aan dit project te werken, vooral omdat we altijd iets 
hadden om over te kletsen! Ik hoop dat we elkaar nog regelmatig zullen zien!
 Dan Nina, mijn andere paranimpfje. Je begon bij ons als student, en bent nooit 
meer vertokken… Hartstikke leuk dat je bent gebleven, want het is heel gezellig met 
jou in het lab! En natuurlijk daarbuiten, want je was er altijd bij als er weer een borrel 
of een kroegavond was. Nu ben je zelf in je laatste jaar van je promotie beland en heb 
je (net als ik) minder tijd voor uitgaan. Gelukkig kunnen we zo nu en dan nog samen 
een biertje drinken bij een van de vele TIL promotiefeestjes. Ik wens je het allerbeste 
toe, en vooral heel veel succes met de laatste loodjes!
 En tot slot het laatste, maar zeker niet minst belangrijke SCRIPT-meisje, Marleen. 
Of eigenlijk moet ik zeggen MA… Het was super gezellig om naast jou in het aquarium 
te zitten, in kon me geen betere buurvrouw wensen! Je staat op bijna alle artikelen 
in dit boekje, en het was fijn dat we elkaar altijd even snel om advies konden vragen. 
Maar natuurlijk is het allerbelangrijkste dat het ook altijd gezellig was. De grootste 
zin en onzin hebben we besproken, tijdens en na het werk. Mijn vrijdagavonden 
zijn een stuk stiller nu je naar de VS verhuist bent, maar ik weet zeker dat we onze 
filmavondjes in Nijmegen gewoon weer oppakken als je terugkomt! Ik kijk er nu al 
naar uit dat jij en Koen over twee jaar ook gezellig in Lent komen wonen! Eucalypta 
staat op jullie te wachten ;). 
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Dear Anna, my ‘overbuurvrouw’ in our aquarium, it was great sitting opposite of 
you and it got very empty when you left… But luckily we still saw each other outside 
work, on wine-tasting evenings, girls-nights-out or the poker parties that you and 
Patrick organized. Now that you and Patrick are living in London we don’t see each 
other so often anymore, although that is just a good excuse to go to London more 
often. Thanks for the great weekend we had last September!
 En natuurlijk kan ik ook Malou niet vergeten. Jouw patent op de term de “Saartje-
wiggle” staat nog steeds, en ik heb er zelfs mijn werk van gemaakt! En komende 
zomer Graspop he… ;)
 Tot slot wil ik ook alle TIL-ers bedanken voor de fantastische tijd die ik heb gehad 
in het lab. Het was altijd gezellig in het lab en aan de koffietafel! En natuurlijk maakten 
jullie de vele dagjes uit, kroegentochten en kerstdiners extra bijzonder…
 
Natuurlijk moet ik hier ook mijn vrienden bedanken… Frank, a.k.a. Popi, als er iemand 
is waar ik op kan rekenen dan ben jij het wel. Je bent er altijd bij en staat altijd voor 
iedereen klaar. Bedankt voor al onze leuke gesprekken over van alles en nog wat, en 
wetenschap in het bijzonder! Robert(ooooo) mijn Bergfreund en kroegmaatje. Jij 
weet als geen ander hoe lastig het kan zijn als je en in de kroeg wil staan, en het hele 
weekend wil sporten… Gelukkig zijn we nog jong genoeg om het te combineren ;) En 
deze zomer gaan we voor de C2! Casper(ge), technisch gezien ken ik jou langer dan 
Bas, al scheelt het maar een half uurtje… Sindsdien is het altijd gezellig met jou, waar 
we ook zijn! En natuurlijk ook Barry & Simone, Dennis, Ronald & Loes, Eelke & Els 
en alle anderen (jullie zijn met teveel om iedereen te noemen!) die Nijmegen voor 
mij de mooiste stad van Nederland hebben gemaakt. Met jullie is het altijd feest, in 
de kroeg, bij de 4-daagse, op festivals, op vakantie of gewoon thuis aan de koffie, het 
maakt niet uit, alles wat we doen is toch wel leuk ;). Bij jullie kan ik altijd mezelf zijn.
 
Hettie, ook jou wil ik hierbij bedanken. We zien we zien elkaar niet vaak, maar je bent 
familie, mijn enige echte schoonmoeder. Bedankt voor alle gezellig avondjes met jou 
en Karel, en voor de interesse die jullie altijd hebben getoond voor mijn werk.
 En dan natuurlijk mijn tweede familie, Hugo, Barbara, Linda, en Borg. Bedankt 
voor al jullie steun en interesse tijdens de afgelopen jaren, ik weet dat ik altijd op 
jullie kan rekenen. Bij jullie heb ik een tweede thuis gevonden.
 
Tot slot mijn eigen familie… Pap en Mam, bedankt voor alles! Dankzij jullie ben ik hier, 
aan het einde van mijn proefschrift. Het is fijn dat jullie mij en Jan altijd de vrijheid 
hebben gegeven om onze eigen keuzes te maken, ook al hadden jullie zelf soms je 
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twijfels. Bedankt voor al jullie steun en goedbedoelde zorgen en bemoeienissen! Jan, 
het leek er even op dat je me ging inhalen, maar gelukkig ben ik alsnog als eerste 
klaar met mijn boekje ;) Het is leuk dat jij en Hanneke ook in Nijmegen wonen, ook 
al zien we elkaar door promotiedrukte de laatste tijd niet veel. Maar het is altijd fijn 
om jullie te zien en even bij te praten, en tegen elkaar te kunnen klagen over werk/
ouders/etc. 
 
Lieve Bas, natuurlijk wil ik jou ook bedanken. We zijn al bijna een dozijnjaar samen, 
en ik kan me niet meer voorstellen hoe mijn leven zonder jou zou zijn. Bedankt dat 
je er altijd bent, en me afremt of aanspoort als dat nodig is. Niemand kent me zoals 
jij. Met jou ben ik gelukkig.
Saartje
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CURRICULUM VITEA
Saartje	 Hontelez werd geboren op 31 mei 1983 te Wageningen. Na het behalen 
van haar VWO diploma aan het Pantarijn te Wageningen, begon zij in september 
2001 aan de studie Biologie aan de Wageningen Universiteit. In 2005 behaalde ze 
hiervoor haar Bachelors diploma. Tijdens de daaropvolgende Masterfase heeft zij, 
bij dezelfde universiteit, een tweetal onderzoeksstages van 6 maanden voltooid. 
De eerste stage betrof een onderzoek naar de moleculaire achtergrond van het 
leergedrag van sluipwespen, en werd uitgevoerd bij de vakgroep Entomologie, onder 
begeleiding van Dr. Hans M. Smid. De tweede stage was gericht op de fenotypische 
karakterisering van een Arabidopsis	 thaliana mutant, welke deficiënt is voor een 
eiwit van het exocytose complex, en werd, onder begeleiding van Dr. Tijs Ketelaar, 
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LIST OF ACRONYMS
AF-1  Activation Function 1
Ag  Antigen
AIB  Amplified in Breast Cancer
AP-1  Acivator Protein 1
APC  Antigen Presenting Cells
AR  Androgen Receptor
AtRA  All trans Retinoic Acid
B-cell  B lymphocytes
Bcl  B-cell Cll/lymphoma
BCR  B-cell receptor
BDCA  Blood Dendritic Cell Antigen
CARD  Caspase Recruitment Domain family
CCN  Cell Cyclin
CCR  chemokine (C-C motif) receptor 
CD  Cluster of Differentiation
CDP  Common DC Precursor
ChIP  Chromatin Immunoprecipitation
ChIP-seq  ChIP-sequencing
CI  Confidence Interval
CLR  C-type Lectin Receptor
CLSM  Confocal Laser Scanning Microscopy
Co-IP  Co- Immunoprecipitation
CR  Complement Receptor
CRD  Carbohydrate Recognition Domain
CREB  cAMP Responsive Element Binding protein
CtBP  C-terminal Binding Protein
CTL  Cytotoxic T-cell
DAMP  Danger Associated Molecular Pattern
DBD  DNA Binding Domain
DC  Dendritic Cell
DCIR  Dendritic Cell Immunoreceptor
DC-SCRIPT  Dendritic Cell-specific tranSCRIPT
DC-SIGN  Dendritic Cell-Specific Intracellular adhesion molecules-3 Grabbing Non-integrin
Dex  Dexamethasone
DUSP  Dual Specific Phosphatase 
ECM  Extracellular Matrix 
EGFR  Epidermal Growth Factor Receptor
ELISA  Enzyme-linked immunosorbent assay
ER  Estrogen Receptor
ERE  ER Responsive Element
ERK  Extracellular signal-Regulated Kinase
ERR  Estrogen Related Receptor
FcR  Fc Receptor
FDC  Follicular DC
FKBP5  FK506 Binding Protein
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FoxA1  Forkhead box P3
GC  Glucocorticoid
Gfi  Growth factor independence
GFP  Green Fluorescent Protein
GILZ  GC Inducible Leucine Zipper
GM-CSF  Granulocyte Macrophage Colony Stimulating Factor 
GR  Glucocorticoid Receptor
GRE  GR Responsive Element
HAT  Histone Acetyl Transferase
HDAC  Histone Deacetylase
HEK293  Human Embryonic Kidney 293
HEP3B  Human hepatocellular carcinoma 3B
HR  Hazard Ratio
HRE  Hormone Responsive Element
iDC  immature DC
IFN  Interferon
IGF  Insuline-like Growth Factor
IGF-1R  Insuline-like Growth Factor 1 Receptor
Ig  Immunoglobulin
IHC  Immunohistochemistry
IL  Interleukin
IL-1R  Interleukin-1 Receptor
IP  Immunoprecipitation
IRF  Interferon Regulatory Factor
ITAM  Immunoreceptor Tyrosine-based Activation Motif
JNK  JUN N-terminal kinase
LBD  Ligand Binding Domain
LC  Langerhans Cells
LP  Lymphoid Precursors
LPS  Lipopolysaccharide
LRR  Leucine Rich Region
LXR  Liver X Receptor
MAPK  mitogen-activated protein kinase
MCF-7  Michigan Cancer Foundation - 7, human breast cancer cell line
mDC   mature DC
MDC  Myeloid DC 
MHC  Major Histocompatibility Complex
MKP  Mitogen-activated protein Kinase Phosphatase
MLR  Mixed Leukocyte Reaction
MMTV  Mouse Mammary Tumor Virus
moDC  monocyte derived DC
MP  Myeloid Precursor
MR  Mannose Receptor (chapter 2) or Mineralcorticoid Receptor (chapter 7)
MyD88  Myeloid Differentiation primary response gene (88)
N/C ratio  Nuclear/Cytoplasmic ratio 
NCOA  Nuclear receptor Coactivator
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NCoR  Nuclear receptor Corepressor
NF1  Nuclear Factor 1
NFAT  Nuclear Factor of Activated T-cells
NF-κB  Nuclear Factor-κB
nGRE  negative GRE
NK cell  Natural Killer cell
NLR  NOD-like Receptor
NLRP  NLR family, pyrin domain containing
NLS  Nuclear Localization Signal
NR  Nuclear Receptor
Oct1  Octamer Transcription Factor 1
ORF  Open Reading Frame
PAMP  Pathogen Associated Molecular Patterns
PBGD  Porphobilinogen Deaminase
PBL  Peripheral blood lymphocyte
PBMC  Peripheral blood mononuclear cell
PCNA  Proliferating Cell Nuclear Antigen
PCR  Polymerase Chain Reaction
PDC/pDC  Plasmacytoid DC
poly(I:C)  Polyinosinic:polycytidylic acid
PPAR  Peroxisome Proliferator-Activated receptor
PR  Progesterone Receptor
Pred  Prednisolone
preDC  precursor DC
PRR  Pattern Recognition Receptor
PTM  Post Translational Modification
PTX3  Pentraxin 3
R848  Resiquimod
RA  Retinoic Acid
RAR  Retinoic Acid Receptor
RARE  RAR Responsive Element
rh-DC-SCRIPT recombinant human DC-SCRIPT
RIP140  Receptor Interacting Protein 140
RLR  Retinoic acid-inducible gene (RIG)-I like receptors
ROR  Retinoid acid-related receptor
ROS  Reactive Oxygen Species
RU-486  Mifepristone
RXR  Retinoic X Receptor
siIL-10  IL-10 targeting siRNA
siRNA  small interfering RNA
siSC  DC-SCRIPT targeting siRNA
SL2  Schneider Drosophila Line 2
SMRT  Silencing Mediator for Retinoid and Thyroid hormone receptors
SRC  Steroid Receptor Coactivator
STAT  Signal Transducer and Activator of Transcription
SWI/SNF  Switch/Sucrose Nonfermentable
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T-cell  T lymphocyte
TCR  T-cell Receptor
TF  Transcription Factor
TFF  Trefoil Factor
TGF  Transforming Growth Factor
Th-cell  T helper cell
THP-1  Human acute monocytic leukemia cell line 
TLR  Toll-Like Receptor
TNF  Tumor Necrosis Factor
tolDC  tolerogenic DC
TR  Thyroid hormone Receptor
Treg  regulatory T-cell
VDR  Vitamin D3 Receptor
YFP  Yellow Fluorescent Protein
ZNF366  Zincfinger protein 366
  

